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Abstract 
Less than 50% of all patients with major depressive disorder (MDD) treated with currently available 
antidepressants (ADs) show full remission. Moreover, about one third of the patients suffering from 
MDD does not respond to conventional ADs and develop treatment-resistant depression (TRD). 
In 2000 Berman and his colleagues demonstrated for the first time a rapid antidepressant effect of a 
low dose of ketamine, acting within 2 hours (h) and 4h and lasting up to 10 days. Ketamine, a non-
competitive, voltage-dependent N-Methyl-D-aspartate receptor (NMDAR) antagonist, is a drug that is 
usually used for anaesthesia. An antidepressant effect of ketamine can be observed in patients 
suffering from TRD. Moreover, ketamine diminished suicidal ideation. These clinical findings provide 
a promising basis for novel therapeutic targets and development in MDD. Previous studies showed 
that pharmacological treatment with ketamine results in a glutamate burst, increased brain-derived 
neurotrophic factor (BDNF) levels, Tropomyosin receptor kinase B (TrkB) receptor and mammalian 
target of rapamycin complex 1 (mTORC1) activation, elevated synaptic protein synthesis and 
integration of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) into the 
synaptic membrane. These processes strengthen glutamatergic synapses resulting in synaptogenesis. 
The overall aim of this thesis is to identify biosignatures and biomolecular pathways affected by 
ketamine treatment. Results from my research in mice can aid in the development of novel fast 
acting ADs with a similar mode of action as ketamine, however, with fewer side-effects.  
Taken together, the results of the present study implicate the mitochondrial energy metabolism as a 
downstream effector of ketamine treatment in the hippocampus (HPC), which includes processes 
such as glycolysis, citrate cycle and oxidative phosphorylation (OXPHOS). Ketamine significantly alters 
protein levels of the electron transport chain (ETC) as well as the energy status measured by ATP, 
ADP, NADH, NAD, GTP and GDP metabolite levels and the respective ratios. Furthermore, ketamine 
affects the antioxidant capacity by changing enzymes and molecules; thereby finally leading to 
decreased carbonlyated (damaged) protein levels. 
In addition, ketamine impacts the gamma-aminobutyric acid (GABA)ergic and glutamatergic system 
by altering GABA, glutamate and glutamine metabolite levels and ratios as well as changing GABAR 
and AMPAR protein levels. My proposed novel model describes an elevation of synaptic Ca2+ upon 
neuronal activation that leads to mitochondrial enrichment in the synaptic compartment. 
Furthermore, activated mTORC1 induces mitochondrial metabolism and promotes adenosine 
triphosphate (ATP) production to cope with the elevated energy demand in activated synapses.  
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1.0 Introduction 
Mood disorders, in particular major depressive disorder (MDD) are the 4th leading cause of disability 
worldwide and might become the 2nd only to cardiovascular diseases in the next two decades1, 2. The 
prevalence for mood disorders has been estimated at 21 million people across 28 European countries 
at an annual cost of 106 billion Euro3, 4. Globally, approximately 350 million people suffer from MDD, 
where women are more likely to be affected than men with a ratio of approximately 2:1. However, 
men are frequently suffering from more severe forms of depression. The average age of onset is 32 
years5, 6. The currently available medications are antidepressants (ADs) which require a chronic long-
term treatment of several, but at least two weeks, until a therapeutic effect is achieved7, 8. Less than 
50% of all patients treated with current antidepressants show full remission9. Moreover, about one 
third of the patients suffering from MDD does not respond to conventional ADs and therefore suffer 
from treatment-resistant depression (TRD)10. At its worst, 15% of severely depressed individuals 
commit suicide and overall 800 000 people die by suicide every year. Therefore, suicide is the second 
leading cause of death in the ages of 15 to 29-years6. MDD is a highly heterogeneous disorder and 
results from a complex interaction of social, environmental, psychological, and biological factors; 
however, the underlying cause remains elusive11, 12. Epidemiology studies revealed that genetic as 
well as environmental factors contribute to the development of depression. Family, monozygotic and 
dizygotic twin studies lead to heritability estimates for the genetic component of approximately 50%. 
An increased susceptibility was observed for environmental factors like stressful and adverse life-
events13-15.  
 
 
1.1 Major depressive disorder: Clinical characteristics and classification systems 
MDD is diagnosed based on the patient's self-reported experiences and symptoms and/or 
descriptions of a person’s behavior by relatives or friends as well as a mental status examination16. 
To date, there is no laboratory or biomarker test for MDD17. MDD, also known as unipolar 
depression, stays in contrast to bipolar depression, which includes manic episodes in addition to the 
depressive symptoms. Manic episodes are characterized by increased or irritable mood, over-activity, 
pressure to speak, inflated self-esteem, and a decreased need for sleep. Depression can be long-
lasting or recurrent, but it always and substantially impairs the person’s ability to function at 
work/school or cope with daily life16, 18-20.  
The most widely used criteria for diagnosing MDD are the American Psychiatric Association's revised 
fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), and the World 
Health Organization's International Statistical Classification of Diseases and Related Health Problems 
(ICD-10), distinguishes between depressive episode (a single episode) and recurrent depressive 
disorder (for repeated episodes)18, 19. The ICD-10 is generally used in European countries, whereas 
DSM-IV is used in the USA and many other non-European nations. However, the authors of both 
catalogues have worked towards conforming one another. Diagnostic criteria for MDD are essentially 
descriptions of symptoms that fall into one of four categories:  
 affective or mood symptoms including depressed mood, feelings of worthlessness, or guilt 
 behavioral symptoms including social withdrawal and agitation 
 cognitive symptoms, or problems in thinking including difficulty with concentration or making 
decisions 
 somatic or physical symptoms including sleep alterations like insomnia or hypersomnia18, 20  
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1.1.1 Diagnostic and Statistical Manual of Mental Disorders (DSM) 
The first DSM was published 1952 by the American Psychiatric Association and has gone through 
several revisions until DSM-IV, the fourth edition, was published in 2000. It lists over 200 mental 
health conditions and the criteria required for each in order to make an appropriate diagnosis. 
DSM-IV describes MDD as a disorder that impairs an individual’s function: socially, occupationally 
and educationally. According to DSM-IV a patient needs to meet the criteria of at least 5 of 9 specific 
symptoms for a diagnosis of MDD—present nearly every day and at least for two weeks. The two 
main symptoms of MDD are:  
 depressed mood indicated by either a patients self-report or observations made by others  
 anhedonia which describes a decreased interest or pleasure in most activities that the 
patient had enjoyed before  
 
One of these main symptoms must be present to meet the criteria for a diagnosis for MDD. Further 
symptoms can be:  
 significant weight change (5%) or a change in appetite 
 sleep alterations like Insomnia or hypersomnia  
 fatigue or loss of energy  
 change in activity like psychomotor agitation or retardation  
 feelings of worthlessness or excessive or inappropriate guilt  
 diminished ability to think, concentrate or being more indecisive 
 suicidality with thoughts of death, suicide attempts, and suicide plans  
 
Furthermore, the described symptoms must be present without being the direct physiological effects 
of a substance (e.g. a drug of abuse, a medication) or a general medical condition (e.g. 
hypothyroidism). MDD can further be divided into a single major depressive episode or recurrent, 
which describes the intermediate relief of depressive symptoms for at least two consecutive 
months20. 
 
 
1.1.2 International Statistical Classification of Diseases and Related Health Problems (ICD) 
In the early 1960s, a programme with the Mental Health Programme of the World Health 
Organization started with the aim to improve the diagnosis and classification of mental disorders. In 
contrast to the DSM-IV, ICD-10 does not use the term MDD, however, it describes very similar criteria 
for the diagnosis and defines three typical depressive symptoms: 
 depressed mood  
 anhedonia 
 reduced energy  
 
Two of these three symptoms should be present in order to meet the criteria for depressive disorder 
diagnosis. Further symptoms include:  
 change in appetite  
 sleep alterations  
 feelings of worthlessness and decreased self-confidence  
 feelings of guilt  
14 
 
 diminished ability to think, concentrate  
 lack of interest 
 suicidality 
 further somatic symptoms 
 
Depending on the number and severity of symptoms a depressive episode can be mild, moderate, or 
severe and the term recurrent describes multiple depressive episodes without mania. In general, 
mild depression includes a minimum of 2 to 3 symptoms which describe a patient as generally 
impaired, but able to do most activities. In order to meet the criteria for moderate depression, an 
individual typically has to suffer from 3 or more symptoms. A diagnosis of moderate depression 
mostly involves great difficulties to do the daily activities. Severe depression includes even more 
symptoms than described for mild and moderate depression. Typically the patient loses his or her 
self-worth and has feelings of guilt. Suicidal ideation and suicidal attempts are often recognized and 
usually there are also somatic symptoms. Unlike DSM-IV, ICD-10 includes psychotic symptoms and, 
therefore, is differentiated in severe depression with or without psychotic symptoms18. 
 
 
1.1.3 Research domain criteria (RDoC) 
MDD is a highly heterogeneous brain disorder and neuroscientists, psychologists, and medical 
doctors in the field of psychiatry could therefore conclude that not only a single MDD exists rather 
that there are different subtypes of MDD. The symptoms described in DSM-IV and ICD-10 can vary 
from patient to patient, but would still meet the criteria for a diagnosis of MDD, however, patients 
might show a different set and amount of symptoms and co-morbidities. Another promoting aspect 
for subtypes of MDD comes from the fact that different patients respond to different AD treatments 
(personal communication, Thomas Kirmeier and Ulrike Schmidt, Max Planck institute of psychiatry, 
Munich). At present, MDD is categorized by diagnostic systems that does not incorporate 
neuroscience research information, and thus is suboptimal.  
Another way of classification system involves the deconstruction of complex behaviors into so-called 
research domains or constructs to attempt the linkage of these to an underlying neurobiological 
system. RDoC was initiated in 2008 and developed by the National Institute of Mental Health. In 
contrast to DSM-IV and ICD-10, RDoC aims at understanding and categorizing the neurobiology of 
certain biological processes, subsequently looking to a range of the behavioral outcome, also 
described as domains or constructs. RDoC attempts “to create a new kind of taxonomy for mental 
disorders by bringing the power of modern research approaches in genetics, neuroscience, and 
behavioral science to the problem of mental illness.”  
RDoC is based on four assumptions:  
 a diagnostic approach based on the biology as well as the symptoms must not be constrained 
by the current DSM categories 
 mental disorders are biological disorders involving brain circuits that implicate specific 
domains of cognition, emotion, or behavior  
 each level of analysis needs to be understood across a dimension of function 
 mapping the cognitive, circuit, and genetic aspects of mental disorders will yield new and 
better targets for treatment 
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The major preliminary RDoC research domains or constructs include a:  
 negative valence systems (fear, anxiety, loss)  
 positive valence systems (reward learning, reward valuation)  
 cognitive systems (attention, perception, working memory, cognitive control),  
 systems for social processes (attachment formation, social communication, perception of 
self, perception of others)  
 arousal and modulatory systems (arousal, circadian rhythm, sleep, and wakefulness) 
 
At the moment these domains or constructs can be studied in 8 different classes:  
 genes  
 molecules 
 cells 
 neural circuits 
 physiology  
 behaviors  
 self-reports 
 paradigms21 
 
In contrast to DSM-IV and ICD-10, RDoC considers dimensions of behaviors that range from normal to 
abnormal and focuses on behavior-brain relationships and links them to clinical characteristics. 
 
 
1.2 The functional neuroanatomy of depression  
MDD involves different brain regions and neuronal connectivity networks. Clinical imaging and post-
mortem studies of brains from depressed patients have revealed functional and structural alterations 
in several limbic and cortical brain regions, e.g. the prefrontal cortex (PFC), hippocampus (HPC), 
cingulate cortex, amygdala, and basal ganglia22-25.  
The PFC is the cerebral cortex that covers the front part of the frontal lobe, which has been 
implicated in planning complex cognitive behaviors, personality expression, decision-making, and 
moderating social behavior. The basic function of the PFC is to orchestrate thoughts and actions in 
accordance with internal goals24, 25. The HPC, cingulate cortex and the amygdala belong to the limbic 
system, a complex set of brain structures that supports a variety of functions including adrenaline 
flow, emotions, behaviors, motivation, long-term memory and olfaction. The HPC plays an important 
role in memory, learning, and spatial navigation26. The cingulate cortex is a part of the limbic system 
that receives inputs from the thalamus and the neocortex and projects to the entorhinal cortex via 
the cingulum. It is involved in emotion formation and processing, learning and memory, which makes 
it highly influential in linking behavioral outcomes to motivation27-29. The amygdala regulates 
emotional reactions including fear responses, processing of memory, decision-making30. The basal 
ganglia comprise multiple subcortical nuclei, which are strongly interconnected with the cerebral 
cortex, thalamus, and brainstem as well as several other brain areas. Their functions include the 
control of voluntary motor movements, procedural learning, as well as automatic behaviors such as 
bruxism, eye movements, cognition, and emotions. Further, they are implicated in action selection—
deciding which of several possible behaviors should be executed31-34.  
MDD patients show neuronal atrophy and reduced volumes culminating in a decreased neuronal 
function of the HPC and the PFC. In contrast, the amygdala of MDD patients shows elevated activity 
and altered morphology35-46. The decreased volume of the HPC and PFC might therefore lead to 
several symptoms typically observed for MDD e.g. feelings of worthlessness or 
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excessive/inappropriate guilt, diminished ability to think and concentrate, or being more indecisive. 
An increased function of the amygdala may lead to a loss of control of emotions and mood, increased 
fear, anxiety, and hypothalamic pituitary adrenal (HPA)-axis dysregulation (also see section 1.3.2)35. 
The altered connectivity of these regions might therefore underlie depressive symptoms.  
 
 
1.3 Treatment options for MDD: Monoamines and beyond 
The most common treatments for MDD are psychological treatments such as behavioral activation, 
cognitive behavioral therapy, and interpersonal psychotherapy. In addition, AD medication is used, 
such as tricyclic ADs (TCAs) and selective serotonin reuptake inhibitors (SSRIs)6. The first medications, 
therefore also called first generation of ADs, became available in the 1960s including monoamine 
oxidase inhibitors (MAOI) and TCAs47, 48. Further research elucidating the mechanism of MAOIs and 
TCAs represented the main evidence for the monoamine hypothesis of depression and drove the 
pharmacological research for over 4 decades. In the 1980s and 1990s, several different classes of 
ADs, the so-called second generation of ADs were developed. These ADs include SSRIs, selective 
noradrenaline reuptake inhibitors (SNRIs), noradrenergic and specific serotonergic ADs (NaSSAs), and 
5-hydroxytryptamine (5-HT) receptor antagonists/reuptake inhibitors (SARIs) 49, 50. They are based on 
the monoaminergic hypothesis of depression with a primary mechanism of monoamine reuptake 
inhibition and/or antagonism of selected monoamine receptors. Drugs acting on the monoaminergic 
system usually need at least 2 to 8 weeks before a therapeutic effect can be observed and each drug 
is only efficient in around 60–70% of patients8. Furthermore, the observed discrepancy between 
pharmacological and biochemical function of ADs (a few minutes) and their clinical mood altering 
responses (10–15 days) remains elusive51. A third generation of ADs is based on peptidergic, 
glutamatergic, or circadian rhythm-related mechanisms including corticotropin-releasing factor (CRF) 
1 receptor antagonists, glutamatergic agents (N-Methyl-D-aspartate receptor (NMDAR) modulators, 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)kines, metabotropic Glutamate 
receptor (mGluR) modulators), and melatonergic agonist/5-HT2c receptor antagonist9, 52-57.  
Over the past 50 years different theories were developed trying to explain the pathobiology of MDD. 
These theories included alterations in the monoaminergic, glutamatergic, gamma-aminobutyric acid 
(GABA)ergic, or neurotrophin system, as well as changes in the regulation of the HPA axis and 
neuronal plasticity. The following sections will explain each hypothesis and the known or 
hypothesized underlying biomolecular mechanisms. 
 
 
1.3.1 Monoaminergic hypothesis of depression 
Monoamines are neurotransmitters like serotonin, noradrenaline, and dopamine, which are derived 
from aromatic amino acids like phenylalanine, tyrosine, tryptophan, and the thyroid hormones. The 
monoaminergic system is involved in the regulation of cognitive processes such as emotion, arousal, 
and certain types of memory58, 59. Serotonin, also called 5-hydroxytryptamine (5-HT), 
regulates mood, appetite, sleep, but also influences some cognitive functions, including memory and 
learning60-62. On the other hand, the general function of noradrenaline is to mobilize the brain and 
body for an action. Therefore, noradrenaline release is low during sleep and increases during 
wakefulness. Noradrenaline increases arousal and alertness and therefore rise during situations of 
stress 63, 64.  
17 
 
The basic version of the monoaminergic hypothesis of depression was developed after the discovery 
of TCAs and MAOIs in the 1960s47, 48. MDD was recognized as a disorder with reduced availability of 
monoamines, in particular serotonin and noradrenaline and that ADs would simply act through an 
increase of extracellular synaptic monoamines65. Afterwards, the sensitization status of monoamine 
receptors rather than monoamine availability was discussed to be more the reason for AD action and 
might therefore also play a role in the development of depression. The hypothesis was criticized after 
the discovery that inhibition of monoamine reuptake leads to a quick increase in synaptic 
monoamine availability within hours, but a delayed therapeutic effect of several weeks51, 66, 67. It was 
proposed that slow adaptive changes in post-receptor signaling cascades and downstream mediators 
might be the key in explaining the delayed onset. The updated version of the hypothesis then 
integrated post-receptor signaling cascades with mechanism of gene expression including epigenetic 
mechanisms and several other processes including synaptic mechanisms, neurotrophic mechanisms 
and neurogenesis68, 69.   
In detail, the functional deficiency of serotonergic and noradrenergic neurotransmission in 
depression was inferred from the effects of TCAs and MAOIs at the monoamine metabolism. Both 
drug types increase synaptic monoamine levels. The first MAOI was recognized in the early 1950s 
when the antitubecular drug iproniazid showed mood-elevating properties70. The action of MAOIs 
and TCAs are mediated either through inhibiting monoamine metabolism or reuptake, stimulating 
their release directly or indirectly through blocking presynaptic inhibitory autoreceptors70. MAOIs are 
irreversible inhibitors of the main metabolic enzymes of the neurotransmitters noradrenaline, 
serotonin and dopamine. TCAs inhibit more or less selectively a number of membrane transporters of 
monoamines resulting in an increase of extracellular monoamines. Afterwards more selective ADs 
were developed, the so-called SSRIs, which resulted in the current mainstay of the treatment with 
drugs like paroxetine, which is the most commonly prescribed AD at the moment, fluoxetine, 
fluvoxamine, sertraline and citalopram70. However, SSRIs seem to be less effective than TCAs in the 
treatment of severe depression71. For this reason SNRIs with lack of binding to monoamine receptors 
were developed, e.g., venlaflaxine and milnacipran70. By a screening in experimental animals, drugs 
with no or only weak monoamine reuptake inhibitory effect, but antagonistic effect at α2-adrenergic 
and 5-HT2 receptors were discovered. Afterwards more specific ones were developed, but were not 
clinically demonstrated unambiguously. Overall, these drugs have the same effect in facilitating 
noradrenergic or serotonergic neurotransmission or both70.  
A subset of depressed patients showed lowered levels of noradrenaline72. Therefore, monoamine 
concentrations might be altered through disrupted synthesis, storage or release or postsynaptic 
receptors or messenger activity alterations. 
Monoamine receptors account for approximately 5% of synapses in the brain51. Noradrenergic 
neurons have their cell bodies in the locus coeruleus in the brainstem and innervate the limbic 
system and neocortex70. There are different subtypes of adrenergic receptors, which are all G-protein 
coupled receptors and mediate their underlying mechanism through a second messenger 
intercellular process. Noradrenaline seems to act on two types of receptors; postsynaptic excitatory 
α1 receptors and inhibitory presynaptic α2 autoreceptors on terminals of noradrenergic projection 
targets70. Autoreceptor activation leads to an inhibition of noradrenaline release, thereby serving as 
a negative feedback loop to limit extracellular noradrenaline concentrations in the synaptic cleft. A 
second negative feedback loop lies within the locus coeruleus, where noradrenaline can also be 
released by local collaterals and dendrites of projection neurons70, 73-75. Inhibition of α2 autoreceptors 
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on noradrenergic cell bodies controls the whole noradrenergic system70, 73-75. Moreover, synaptic 
noradrenaline concentrations in the locus coeruleus and the forebrain are controlled by reuptake of 
noradrenaline by membrane transporters, which is a target for ADs. The combination of a reuptake 
inhibitor and the simultaneous blockade of α2 autoreceptors block both control mechanisms70, 76, 77. 
However, a chronic treatment might desensitize α2 autoreceptors78-80. 
Serotonergic neurons have a very similar neurophysiology compared to the noradrenergic system. 
The cell bodies localize in the raphé nucleus of the midbrain and literally project to every brain 
region, but also to the same forebrain areas as noradrenergic neurons70. The neurocircuitry of the 
limbic system is involved in the regulation of mood and behavior and is rich in serotonergic 
projections26, 81. There are different kinds of 5-HT receptors, all of which are G-protein-coupled, 
except the 5-HT3 receptor, which is an ion channel. The antidepressant effect targeting the 
serotonergic system is mainly mediated by enhancing serotonergic neurotransmission at 
postsynaptic 5-HT receptors. The regulatory mechanisms of this system are very similar to that 
observed for the noradrenergic system. However, in contrast to the noradrenergic system the 
autoreceptors of the cell bodies in the raphé nucleus and forebrain are different. At the cell body 5-
HT autoreceptors control cell firing and at the terminals 5-HT autoreceptors regulate 
neurotransmitter release49, 70, 82-86.  
The lag-time of SSRIs and SSNIs therapeutic effect might be due to the activation of inhibitory 
autoreceptors at serotonergic and noradrenergic neurons to initially attenuate the effects of ADs, 
which upregulate the amount of serotonin and noradrenaline in the synaptic cleft70. As a 
consequence, the noradrenaline and serotonin levels first decrease, however, increase again after 
approximately 4 weeks. This effect might be mediated by desensitization of these autoreceptors over 
time70, 87, 88.  
In the later and unified hypothesis the increase of synaptic noradrenaline and serotonin levels still 
seems to be critical for AD action. However, some downstream pathways like the increase of 
postsynaptic receptors in the cortex are probably responsible for AD drug action triggered by the 
elevated monoamine concentrations70, 89, 90. 
From the original study of neurotransmitter serotonin and noradrenaline concentrations and 
membrane receptor activity and sensitivity, neuroscientists started focusing more on mediated 
downstream signaling pathways, but also on stress regulatory system of an organism. 
Monoaminergic neurotransmitters, especially dopamine, serotonin, and noradrenaline regulate the 
HPA-axis. The latter is responsible for an individual’s appropriate response to stressful situations, and 
regulates many body processes, including digestion, the immune system, mood and emotions, 
sexuality, and energy storage and expenditure91, 92. 
 
 
1.3.2 The corticosteroid receptor hypothesis of depression 
An individual is (Human beings are) repeatedly exposed to stressful situations throughout their life 
and the organism reacts in order to maintain homeostasis on a biochemical, neurobiological, 
circadian, hormonal, and behavioral way. Disruptions in this homeostatic system can lead to 
depressive symptoms14, 15, 93-95.  
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The HPA-axis integrates physical and psychosocial stimuli in order for an individual to react 
effectively to its environment14, 15. It consists of a chain of neuronal and endocrine organs: the 
hypothalamus, the pituitary gland and adrenal gland. There are further anatomical connections 
between different brain areas such as the amygdala, HPC, and PFC which facilitate the activation of 
the HPA-axis96. Sensory information arrives at the amygdala and is processed and conveyed to 
several brain regions involved in responses to fear. Fear-signaling inputs at the hypothalamus 
activate the sympathetic nervous system and the modulating systems of the HPA-axis. It is governed 
by secretion of CRF and arginine-vasopressin (AVP) from the hypothalamus which then activates the 
secretion of adrenocorticotropic hormone (ACTH) into circulation from the pituitary gland94, 97.  
 
Figure 1: Schematic overview of the HPA-axis regulation in response to stress. Environmental stress is processed by the 
amygdala, which positively influences the paraventricular nucleus of the hypothalamus. The latter is negatively regulated by 
the HPC. The amygdala response to a stressful situation leads to CRF release of the hypothalamus thus activating the 
pituitary gland to secrete ACTH. The enhanced activity of the pituitary gland then results in cortisol secretion by the adrenal 
gland. Together, CRF, ACTH and cortisol regulate the organism’s stress response. Furthermore, cortisol also inhibits the 
pituitary gland and the hypothalamus, whereas it activates the HPC. 
 
CRF binds to CRF-receptor type 1 and type 2 with distinct functions, tissue specificity, and binding 
affinity98, 99. ACTH activates the secretion of cortisol (cortisol in human and corticosterone in 
rodents), a glucocorticoid, which belongs to the class of corticosteroids. Cortisol is released from the 
adrenal gland and together with CRF and ACTH facilitates the stress response. Furthermore, cortisol 
inhibits the pituitary gland and the hypothalamus thereby forming a negative feedback loop that 
limits cortisol secretion, but enhances hippocampal activity (figure 1). After its release, cortisol 
interacts with glucocorticoid receptor (GR) and mineralcorticoid receptor (MR) throughout the 
body97.  
However, during chronic and sustained stress situations, continuously elevated levels of cortisol lead 
to neuronal atrophy and volume decline of the HPC and PFC35, 36, 43, 46. The majority of depressed 
patients, mostly suffering from severe depression with/ or without psychotic symptoms, have a 
dysfunctional hyperactive HPA-axis regulation100-102. Hyperactivity results from a deficit in the 
negative feedback, caused by an insufficient GR activation, which under normal conditions serves to 
decrease cortisol concentrations in the blood103. Plasma cortisol levels following a higher release of 
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ACTH are elevated in a majority of MDD patients. Cortisol levels remain elevated in the afternoon 
and evening instead of the prominent cortisol peak during the morning as observed in healthy 
controls104, 105. Furthermore, a reduced GR expression in post-mortem human brain of depressed 
patients was observed and a non-suppression of cortisol secretion following the administration of 
dexamethasone103, 106-110.  
Another study showed a correlation of stressful life events with increased vulnerability for affective 
and anxiety disorders. Stressful life-events also often precede the onset of depression and correlate 
with the severity of depression. Stressful life-events in childhood also predispose to the development 
of mood and anxiety disorders in adulthood14, 15.    
The HPC is a highly plastic brain region and is therefore especially sensitive to the effects of stress. 
Corticosterone-treated animals showed neuronal atrophy with reduction in cell body size but no 
differences in cell number in the HPC and PFC. Chronic stress and glucocorticoids have a negative 
effect on cell proliferation leading to a rapid and prolonged decrease in neurogenesis in the HPC43, 46. 
The number of spine/synapse connections in HPC and PFC are decreased upon chronic stress. A loss 
of these connections might lead to a functional disconnection, so that a normal control of emotions 
and mood is not given. The medial PFC controls and regulates mood and emotions by input from 
other brain regions, mostly from the amygdala. Therefore, stress or rather the resulting neuronal 
atrophy and volume decline of the HPC and PFC could result in cognitive deficits and labile mood as 
well as emotions35, 36, 38, 111. The morphological and functional effects of chronic stress can often be 
reversed by chronic, but not acute AD treatment111-116.  
Chronic stress and glucocorticoid treatment also reduce brain-derived neurotrophic factor (BDNF) 
mRNA and protein levels117-119. BDNF is a member of the nerve growth factor family and the most 
abundant neurotrophic factor in the brain. It has an important role during embryonic development in 
the guidance, function, and survival of neurons. But it is also expressed at high levels in adult brain 
and plays an important role in brain function, plasticity, and survival117. This knowledge links the 
glucocorticoid receptor hypothesis of depression to the neuronal plasticity hypothesis of depression.  
 
 
1.3.3 The neuronal plasticity hypothesis of depression 
Neuronal plasticity is the overall term to describe many processes where the brain senses, adapts 
and responds to external and internal stimuli9. It consists of major cellular and molecular 
manifestations in the adult brain like modifications of gene expression and synaptic plasticity. 
Modifications of gene expression include the activation of signaling cascades, activation of 
transcription factors, epigenetic changes, and activation/repression of different genes120-125. 
Modifications of synaptic plasticity are often referred to activity-dependent modifications at 
glutamatergic receptors. The most common long-lasting changes are long-term potentiation (LTP) 
and long-term depression (LTD) to selectively strengthen or weaken a synapse, respectively. LTD is an 
activity-dependent reduction in synaptic efficacy whereas LTP is an activity dependent increase and 
strengthening in of synaptic efficacy. LTD probably serves to specifically clear old memory traces in 
the HPC. LTD results from persistent weak synaptic activity and leads to a decrease of postsynaptic 
receptor density as well as probably presynaptic decrease of neurotransmitter release. In contrast to 
LTD, LTP is stimulated by higher persistent activity and strengthen synapses. Plasticity occurring at 
glutamatergic synapses allows the encoding of new information and thus, LTD and LTP play a role in 
learning and memory. These processes are mediated through glutamatergic excitatory and 
GABAergic inhibitory neurons126-129.  
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Synaptic plasticity leads to alterations in synaptogenesis, alterations in dendritic function, neurite 
extension, synaptic remodeling, and modification of synaptic neurotransmissions. Maladaptive 
plasticity to a pathological state can at least partly be reversed through AD treatment by inducing 
neuronal plasticity112-116. Upon modulation of receptors for serotonin and noradrenaline through AD 
treatment, different downstream pathways get activated that have a common function which is the 
regulation of gene expression, e.g. BDNF9, 130, 131. The neuronal plasticity hypothesis of depression 
therefore combines different models: the neurotrophin hypothesis of depression, the glutamatergic 
hypothesis of depression and the GABAergic hypothesis of depression. I will describe each model and 
the underlying biomolecular mechanism in the following section.  
 
  
1.3.3.1 The glutamatergic system  
In the human brain, glutamatergic neurons project from the cortex to the subcortical regions like 
locus coeruleus, raphé nucleus, and substantia nigra where monoaminergic pathways are 
modulated132. The glutamatergic system controls learning, memory, cognition, emotion, neurotoxic 
actions, and induction of neuronal plasticity126, 127, 132. In a pathological state glutamate becomes a 
potent excitotoxin triggering rapid or delayed neurotoxicity. Furthermore, glutamate plays a role in 
several neurodegenerative and neuropsychiatric diseases like Huntington’s chorea, epilepsy, 
Alzheimer’s disease, schizophrenia, anxiety disorders, and MDD132, 133.  
Glutamate is the major mediator of excitatory neurotransmission in mammalian brain which can be 
found in approximately 80% of all neurons132, 134. It is synthesized by transamination of alpha-
Ketoglutarate in the citrate cycle or recycled through the glutamate/glutamine cycle134. Glutamate is 
transported to synaptic vesicles by vesicular glutamate transporters and is released into the synaptic 
cleft in a Ca2+-dependent manner. There, it can bind to two classes of glutamate receptors: 
ionotropic (iGluRs) and metabotropic (mGluRs) glutamate receptors. iGluRs consists of NMDARs, α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), and kainate receptors. 
NMDARs comprise a tetrameric complex of two NR1 and NR2 subunits. There are 8 splice variants for 
NR1, 4 for NR2 and two for NR3. AMPARs comprise a homomeric or hetereomeric complex of 4 
subunits (Gria1-4). Kainate receptors have three low-affinity subunits (GluR5-7) and two high affinity 
subunits (KA1 and KA2). mGluRs are classified into three groups according to their second messenger 
coupling system, molecular structure, sequence homology and their pharmacology. Group I mGluRs 
(mGluR 1 and 5 and their splice variants) are positively linked to phospholipase C and their activation 
is linked to increased phosphoinositide turnover and enhances glutamate excitation. Group II mGluRs 
(mGluR2 and mGluR3) and Group III mGluRs (mGluR4, 6, 7, 8 and their splice variants) are Gi-coupled, 
coupled to adenylate cyclase and upon activation inhibit cyclic adenosine monophosphate (cAMP) 
production and glutamate release presynaptically135-139.  
High-affinity excitatory amino acid transporters (EAAT) in neighbouring glial cells clear the synaptic 
cleft from glutamate. In glial cells, glutamate is transformed into glutamine by glutamine synthetase 
and is transported back to the neurons where it is metabolized back to glutamate by glutaminase140.  
AMPARs are important for synapse maturation and the number of AMPARs and their activity is a 
determinant for the synaptic strength. NMDAR and AMPAR often co-localize in dendritic spines123. 
Spines can be subdivided into three most common subtypes according to their size and relative 
proportion of the spine head and neck: stubby, thin, and mushroom spines. Spines are primary sites 
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for structural plasticity of excitatory neurotransmission. They undergo activity-dependent 
enlargement and stabilization and, conversely, inactive spines get eliminated. The major mechanism 
for expression of LTP at the hippocampal CA1 region requires NMDAR activation and therefore Ca2+-
influx into the postsynaptic terminal and activation of downstream signaling cascades123. In detail, 
the presynaptically released glutamate binds to NMDARs and AMPARs. The latter gets activated first 
which leads to depolarization of the postsynaptic membrane. NMDARs are usually blocked by Mg2+, 
however, a certain threshold of depolarization then causes conformational changes, eventually 
resulting in NMDAR opening. This in turn leads to recruitment of AMPARs to the postsynaptic 
membrane which is believed to mediate LTP123. One extensively studied downstream cascade upon 
LTP is the transcription factor cAMP-response element binding protein (CREB). Generally all kinds of 
ADs stimulate CREB function141. The mechanisms that are influenced by CREB include learning and 
memory, outgrowth of neuronal processes, regulation of circadian rhythms, neurogenesis, 
pathophysiology of neuropsychiatric and neurodegenerative disorders and mechanisms of 
psychotropic drugs. CREB is regulated by multiple kinases of which the activation by the Ras-mitogen 
activated protein kinase (MAPK) and the calcium/calmodulin-dependent cascades might be the most 
important studied for MDD. Chronic AD treatment activates ERK-MAPK and cAMP-dependent 
Proteinkinase A (PKA) that subsequently induce CREB phosphorylation and activation. There are 
more than 100 genes regulated by CREB, e.g., Gria1, the presynaptic protein Synapsin1, CRF, and 
BDNF9, 69, 142-155. Therefore, BDNF is transcribed in a neuronal activity-dependent manner.  
 
 
1.3.3.2 The neurotrophin hypothesis of depression 
The neurotrophin hypothesis of depression arose in 2006 and postulates that a decrease in BDNF 
levels plays a major role in the pathobiology of MDD and possibly other neuropsychiatric diseases 
and the restoration of these levels may be critical for AD drug action117, 156-159. 
The BDNF gene can be transcribed into at least 11 different transcripts. The functional difference is 
not studied extensively yet, but it seems that they regulate the availability of BDNF at different cell 
compartments, like cell soma, dendrites and axons according to the needs of plasticity160, 161. BDNF is 
secreted from postsynaptic spines or presynaptic terminals through a Ca2+-dependent influx at 
NMDARs or voltage-gated Ca2+-channels120, 121, 160, 162-164. The secreted BDNF binds to and activates the 
Tropomyosin receptor kinase B (TrkB) receptor, which is localized on glutamatergic post- and 
presynapses and co-localizes postsynaptically with NMDARs and postsynaptic density protein 95 
(PSD-95), a scaffolding protein that regulates activity-dependent incorporation of AMPARs into the 
synaptic spine membrane during experience-dependent synaptic strengthening165-171. The activated 
TrkB receptor interacts with different docking proteins that regulate downstream pathways like the 
MAPK cascade, but also indirectly activates the ubiquitous mammalian target of rapamycin complex 
1 (mTORC1)172. mTORC1 is a central regulatory nexus that integrates important physiological signals 
from different cellular signaling cascades, thereby modulating anabolic versus catabolic pathways in 
response to nutrients, growth factors, and the cellular energy status173-177. Among other functions, 
mTORC1 controls several metabolic pathways at the transcriptional, translational, and post-
translational level176. This includes regulation of glycolysis, the pentose phosphate pathway175, and 
oxidative phosphorylation (OXPHOS) by positively modulating mitochondrial biogenesis and 
activity173, 177. mTORC1 positively regulates protein synthesis in an activity-dependent manner and, 
therefore, is required for synaptic plasticity. BDNF’s effect at the mTORC1 pathway was well studied 
with regard to stress and synaptic plasticity125, 178-180. Chronic mild stress (CMS, cf. section 1.4) in mice 
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leads to decreased protein levels of mTORC1 pathway components in the PFC including 
phosphorylated and activated mTORC1 and p70S6 Kinase, a serine/threonine kinase which, when 
phosphorylated, induces protein synthesis at the ribosome. Moreover, CMS results in decreased 
synaptic protein levels and the number and function of spines181. Acute and chronic stress decreases 
BDNF levels in the dentate gyrus and pyramidal cell layer of the HPC in rodents. Virtually all kinds of 
ADs increase BDNF levels in limbic brain regions, mainly the HPC and PFC and can prevent stress-
induced decline of BDNF in the HPC117, 118, 182. In order to further study the effects of BDNF different 
transgenic BDNF mouse-lines were generated. A homozygous deletion of BDNF is lethal, whereas 
heterozygous BDNF +/– mice showed reduced length and branching of apical dendrites at the CA3 
region of pyramidal neurons in the HPC similar to what is observed during stress183. The knock-in 
BDNF Val66Met transgenic mouse line expresses a single-nucleotide polymorphism (SNP), which is 
found in approximately 25% of humans. The mutation has been associated with hippocampal volume 
decline and an increased vulnerability to develop MDD in patients with traumatic or early life stress 
events. In rodents, the SNP mutant reduces the processing of pro-BDNF to BDNF, reduces BDNF 
transport to synaptic terminals and thereby blocks the activity-dependent release of BDNF into the 
synaptic cleft. BDNF Val66Met mice have decreased dendrite length, branch points of neurons and 
number and function of spines in the HPC and medial PFC. The observed changes are associated with 
increased anxiety and depression-like behaviors184.  
A viral-mediated mesolimbic dopamine pathway-specific knockdown of BDNF showed that BDNF is 
not needed for the development of depression-like behavior induced by CMS185. In line with this 
study, knockdown of BDNF in hippocampal dentate gyrus, but not the CA1 region, attenuates the AD 
drug response without inducing depression-like behavior186. Furthermore, the application of BDNF 
into the brain of rats showed synaptic plasticity as well as antidepressant-like effects in two animal 
stress paradigms: the forced swim test (FST) and learned helplessness (LH, cf. section 1.4) 187-189. 
Furthermore, BDNF is required for LTP establishment and is involved in memory acquisition and also 
long-term memory storage. Therefore, BDNF ultimately results in cell survival during hippocampal 
development, increased synaptic protein levels, presynaptic neurotransmitter release, and synapse 
formation149, 178, 183, 190-193. BDNF also influences the monoaminergic system, thereby also connecting 
the neurotrophin hypothesis to the monoaminergic hypothesis of depression.  
However, some findings suggest a more complex system for BDNF mediated mechanisms. Different 
kinds of stress paradigms increase BDNF expression or show a more complex pattern of regulation. 
Many inconsistent findings were produced and a partial knockout of BDNF in mice does not produce 
a depression-like behavior in rodents, however, it reduces AD treatment effects158, 186. Furthermore, 
BDNF has opposing roles in the HPC and PFC versus the nucleus accumbens and ventral tegmental 
area117. 
 
 
1.3.3.3 The glutamatergic hypothesis of depression 
The neurotrophin hypothesis of depression is obviously linked to the glutamatergic hypothesis of 
depression as described in the previous section that already concentrated on the glutamatergic 
system. In this section, I will focus on several lines of evidence that promote a glutamatergic 
hypothesis of depression and explain the biomolecular mechanisms.  
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Neuroimaging and post-mortem brain studies of depressed patients showed ventricular 
enlargement, HPC and PFC volume reductions, and reduced neuron and glia density. The 
hippocampal volume reduction in depressed patients also correlates with length and recurrence of 
depressive episodes. AD treatment stimulates neurogenesis in the HPC and preclinical studies 
demonstrated that chronic AD treatment increases glial cell birth in the PFC35-43, 46, 111, 194-196. 
Different paradigms of stress or administration of corticosterone in rats induce a rapid and transient 
increase of extracellular glutamate in PFC, HPC, and amygdala197-200. Moreover, different types of 
environmental stress in animals enhance glutamate release, reduce glial mediated glutamate cycling, 
and alter synaptic transmission in limbic and cortical areas. Chronic stress induces neuronal atrophy 
of apical dendrites in CA3 hippocampal area, increases the amplitude while reducing a decay of 
NMDAR currents, impairs LTP, and facilitates LTD112, 201-207.  
However, stress initially induces LTP in the HPC, but followed by a longer period where LTP is 
inhibited by increasing the threshold for LTP, probably to rather preserve the stressful memory than 
other information. Chronic stress may therefore decrease the volume of the HPC35, 43, 208. On the 
other hand, the amygdala shows hypertrophy—an increased neuronal growth and number of 
spines—upon stress can be observed, probably thereby enhancing the emotional and anxious 
reaction to stress44, 45. The neuronal atrophy at the PFC might also result from the increased 
inhibitory function of the amygdala projecting to the PFC.  
Different studies on the plasma and brain of patients with mood disorders found altered levels of 
glutamate, however these findings were inconsistent. On the one hand, glutamate levels were 
increased in the plasma and brain of patients with mood disorders209-213. AD treatment reduces 
plasma glutamate levels of depressed patients209, 214, 215. In contrast, glutamate levels were decreased 
in the CSF of depressed individuals. Neuroimaging brain studies revealed elevated 
glutamate/glutamine levels in the frontal lobe, basal ganglia, and occipital cortex of depressed 
patients212, 216, 217. Another study showed reduced glutamate/glutamine levels in anterior cingulate 
cortex218-221. Individuals suffering from depression showed abnormal elevation of glutamate 
neurotransmission and levels in cortical and limbic brain areas. Chronic, but not acute treatment with 
ADs markedly and significantly reduces the depolarization-evoked release of glutamate, but not the 
release of GABA in hippocampal synaptosomes affecting the readily releasable pool of vesicles—the 
physiological relevant pool of neurotransmitters222. Treatment with conventional ADs acutely 
increases whereas and chronically administered reduces presynaptic glutamate release222, 223. 
Therefore, the reduction of glutamate observed with chronic AD treatment might be an adaptive 
mechanism. 
Patients suffering from MDD showed down-regulated glutamine synthetase transcripts in anterior 
cingulate cortex, dorsolateral PFC, and amygdala224. Vesicular glutamate transporters, that transport 
glutamate into synaptic vesicles were unchanged, however, repeated AD treatment increases 
vesicular glutamate transporters mRNA in the cortex and HPC in rats225, 226. Reduced EAAT1 and 
EAAT2 protein levels, that are expressed in astroglia, were found in two post-mortem frontal brain 
tissues in patients suffering from MDD224. EAAT3 and EAAT4 are mainly localized at neurons and their 
mRNA levels were decreased in the striatum in mood disorders227.  
A decreased NMDAR binding and NR1 subunit expression was reported in the HPC and superior 
temporal cortex in MDD patients228-231. In preclinical studies, monoaminergic ADs per se have no 
effect on spine number, however, these drugs are capable of blocking the effects of chronic stress. 
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Chronic treatment with an SSRI (fluoxetine) resulted in up-regulation of NR2A and AMPAR subunit 
Gria1 and Gria2 in the forebrain. Chronic fluoxetine treatment increases the protein levels of 
phosphorylated Synapsin1, PSD-95, and synaptic Gria1 in a rat model of reduced synapse density. 
Acute AD treatment rescues LTP after acute stress232-234. Tianeptine also reverses stress induced 
down-regulation of MEK/ERK-MAPK signaling cascades and phosphorylation of Gria1 subunit of 
AMPARs235. Furthermore, chronic AD treatment increases the membrane insertion and synaptic 
expression of Gria1 and up-regulates Gria2/3. Therefore, an antidepressant effect might be mediated 
through AMPARs as activation of AMPARs increases BDNF expression and stimulation of synaptic 
plasticity. As a consequence AMPAkines, potentiators of AMPARS, were developed55, 56, 179, 236-240. 
Chronic AD treatment reduces NMDAR function or expression and various ADs like imipramine and 
citalopram also bind to and inactivate NMDARs. Furthermore, various NMDAR antagonists showed 
antidepressant-like effects in animal screening tests179, 213, 241-243.  
 
 
Ketamine – a fast acting antidepressant 
In 2000 Berman et al. demonstrated for the first time a rapid antidepressant effect of a low dose of 
ketamine, within 2h and 4h that last up to 7 and 10 days244. Ketamine, a drug usually used for 
anaesthesia, is a non-competitive, voltage-dependent NMDAR antagonist which blocks the NR2B- 
and NR2A-containing receptors equally in the presence of Mg2+ 245-250. An antidepressant effect of 
ketamine can be observed in patients suffering from TRD251, 252. Moreover, ketamine diminished 
suicidal ideation.253 These clinical findings provide a promising basis in studying the glutamatergic 
system of the brain—receptors, modulators and affected pathways—for novel therapeutic targets 
and development in MDD. Unfortunately, ketamine cannot be used as a first-line drug due to its 
psychomimetic side-effects. However, it is therefore also suitable in order to study the neurobiology 
of schizophrenia, but also misused as a drug254-258.  
A number of studies in animal models were published in the last years revealing an antidepressant-
like effect and insights into the molecular mechanism of ketamine drug action. Several behavioral 
testing like LH, FST, chronic mild stress (CMS) and novelty suppressed feeding (NSF) could 
demonstrate the antidepressant-like effect of a single injection of ketamine in mice and rats179, 240, 243, 
259-261. A low dose of 10 mg kg-1 ketamine seems to act through the activation of mTORC1 causing an 
increase of synaptic proteins as well as an elevated number of spines and their activity in the medial 
PFC of rats179. In this study, the key regulators of protein translation and members of the mTORC1-
signalling pathway eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), p70S6K and mTORC1 
show increased phosphorylation and therefore activation already 30 minutes after a single injection 
of a low dose of ketamine179. Although, most recently, a study revealed that 1h after a 10 mg kg-1 
ketamine treatment does not increase pmTORC1 protein levels in the HPC and PFC in mice262. An 
even lower concentration of ketamine (3 mg kg-1) does not phosphorylate mTORC1 and p70S6K in 
the frontal cortex of mice243. Moreover, the antidepressant-like effects observed in the FST 30 
minutes after ketamine administration were blocked by rapamycin, an mTORC1 inhibitor, with a 
ketamine concentration of 10 mg kg-1 in rats, but not with 3 mg kg-1 in mice179, 243. Furthermore, 
increased levels of postsynaptic proteins required for formation, maturation, and function of new 
spine synapses like PSD-95, Gria1 as well as Synapsin1 were observed 2h after ketamine treatment 
(10 mg kg-1) and lasting up to 72h in the medial PFC in rats179. However, 3 mg kg-1 of ketamine 
administration does not change Gria1 protein levels in the frontal cortex of mice243. Whereas in 
another study 10 mg kg-1 showed an increase of Gria1 and Gria2 protein levels in the HPC, but not 
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the PFC of mice262. Nevertheless, ketamine’s (3 mg kg-1 and 10 mg kg-1) antidepressant-like effects 
are dependent on AMPARs. Receptor blockage by 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo-
chinoxaline-2,3-dione (NBQX) reverses the antidepressant-like behavioral effects in mice and rats179, 
243. Exposing rats to stress in the LH paradigm decreased the number of spines and protein levels of 
synaptic Gria1, PSD-95, and Synapsin1 protein levels. This could be reversed by a single injection of 
ketamine. Furthermore, also these effects could be blocked by rapamycin179.  
A single ketamine injection of 3 mg kg-1 as well as 10 mg kg-1 also seems to deactivate the eukaryotic 
elongation factor 2 (eEF2) kinase which phosphorylates eEF2 in the HPC of mice. Thus, eEF2 
phosphorylation in the HPC, but not in the frontal cortex and PFC, is decreased already 30 min, 1h 
and 24h after ketamine administration resulting in an increased translation of BDNF in the HPC243, 262. 
Moreover, translation, but not transcription of BDNF is necessary for ketamine drug action as 
indicated by unaltered BNDF mRNA levels, but increased BDNF and pro-BDNF protein levels after a 
single injection of ketamine. Furthermore, knock-out of BDNF and/or the TrkB receptor blocked the 
antidepressant-like effect of ketamine in mice243.  
Inhibition of MAPK, a regulator of protein translation during neural activity, does not have an effect 
on FST behavior upon ketamine treatment, however, a reduction of MAPK phosphorylation in 
hippocampal tissue could be observed. Ketamine requires the phosphorylation and inhibition of 
glycogen synthase-kinase-3β (GSK-3β), which has a role in regulating the insertion of glutamate 
receptors into the postsynaptic membrane and regulation of transcription38, 243, 263, 264. These findings 
suggest a rapid transformation of the synaptic structure and function in the PFC of rats and HPC of 
mice through a single injection of ketamine thereby enhancing synaptic plasticity leading to the rapid 
antidepressant-like effect of ketamine. Moreover, ketamine drug action is dependent on AMPAR 
activity, BDNF translation as well as most probably the mTORC1-signalling pathway.  
There are two major hypotheses for ketamine’s antidepressant effects: one postulates the direct 
inhibition and the other an indirect inhibition or disinhibition of inhibition of excitatory pyramidal 
neurons38, 243, 265, 266.  
The disinhibition of inhibition hypothesis is most widely discussed and suggests a selective 
antagonism at PFC inhibitory neurons resulting in a disinhibition of inhibition and activation of 
excitatory pyramidal neurons. NMDARs mediate excitatory postsynaptic potentials throughout the 
brain. Paradoxically, NMDAR antagonism predominately decreases the activity of putative inhibitory 
GABAergic interneurons, thereby increasing the firing rate of the majority of excitatory pyramidal 
neurons. The fact that GABAergic inhibitory interneurons of the PFC are mostly activated by NMDARs 
implies a mechanism by which NMDAR inhibition causes excitation by disinhibition of pyramidal 
neurons of the PFC265, 266. Further supporting this hypothesis are results of a dose-response study in 
rats using microdialysis. Low doses of ketamine (10, 20, and 30 mg kg-1) increase glutamate outflow 
in the PFC and increased glutamatergic neurotransmission266. In contrast, intermediate (50 mg kg-1) 
or anaesthethetic (200 mg kg-1) doses of ketamine did not affect or decrease glutamate levels, 
respectively266. These effects were also blocked by intra-PFC application of the AMPA/kainate 
receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX)266. Furthermore, ketamine 
increased excitatory postsynaptic current (EPSC) frequency responses to serotonin in medial PFC 
pyramidal neurons which was blocked by rapamycin179. Ketamine decreases the average frequency of 
AMPAR EPSC recorded from rat hippocampal slices at CA1 stratum radiatum interneurons. Acute 
application of ketamine to hippocampal slices of mice potentiated the synaptic responses measured 
by field potentials. Furthermore, ketamine NMDAR-EPSCs were also decreased in rat primary 
hippocampal neurons (PHN) 243, 262.  
27 
 
The above model provides a mechanism for MDD. It implies that MDD results from a breakdown of 
synaptic homeostasis and destabilization of glutamatergic synapses. Synaptic terminals are 
maintained and controlled by circuit activity and function including the activity-dependent release of 
BDNF. In case of normal mood with synaptic homeostasis glutamate is released from presynaptic 
terminals in an activity-dependent manner and AMPARs and NMDARs are activated leading to BDNF 
secretion from the postsynaptic terminal. Upon stress and during MDD glutamatergic synapses 
destabilize leading to neuronal atrophy and decreased synaptic connections in the PFC and HPC and 
reduced BDNF release and mTORC1 activity. Importantly, these processes are dependent on 
GABAergic inhibitory interneurons which during stress and MDD further the decline of neuronal 
activity of excitatory glutamatergic neurons by increased release of GABA—a process that can be 
described as LTD-like. Ketamine mainly blocks NMDARs at GABAergic inhibitory neurons, thereby 
decreasing the GABA release and its inhibitory effects on glutamatergic excitatory neurons. As a 
consequence, glutamate release increases, which then binds and activates AMPARs and NMDARs. 
The postsynaptic membrane is depolarized, which promotes BDNF secretion from glutamatergic 
excitatory neurons and synthesis of synaptic proteins involved in spine remodeling—an LTP-like 
process (figure 2)38. 
 
Figure 2: Model of MDD development and ketamine’s antidepressant effect on excitatory glutamatergic and inhibitory 
GABAergic interneurons. In the case of regular mood and synaptic homeostasis pre- and postsynapses regulate their activity 
by presynaptic release of glutamate which binds to AMPARs and NMDARs postsynaptically. In the case of stress leading to 
MDD homeostasis is destabilized by increasing interference from GABAergic interneurons and inhibition of glutamatergic 
neuron activity. This process leads to an internalization of AMPARs into the cytoplasm and decreased BDNF levels and 
mTORC1 activity ultimately weakening glutamatergic synapses (LTD-like). Stress coping or exercise can reverse this effect. 
However, pharmacological treatment with ketamine results in a glutamate burst, increased BDNF levels, TrkB receptor and 
mTORC1 activation, elevated protein synthesis of synaptic proteins and integration of AMPARs into the synaptic membrane. 
These processes strengthen glutamatergic synapses resulting in synaptogenesis. Over time the antidepressant effect might 
weaken, causing a depression relapse and loss of synaptic homeostasis38.   
 
The direct model proposes a mechanism of NMDAR inhibition at excitatory pyramidal neurons. 
According to this model, NMDAR blockade would be in line with a homeostatic synaptic plasticity 
mechanism with a rapid compensatory effect and increase in mTORC1 activity as well as synaptic 
protein synthesis267. There is also evidence that ketamine mainly acts through blockade of NR2B-
containing NMDARs as selective antagonists are also effective in patients and decrease the 
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immobility time in FST and tail suspension test (TST) in preclinical models179, 268, 269. Furthermore, 
NR2B-, but not NR2A-containing NMDARs, when activated restrict mTORC1 activity and synaptic 
protein synthesis and regulate excitatory homeostatic synaptic plasticity. NR2B-containing NMDARs 
are more sensitive to glutamate and therefore would also be more sensitive towards ketamine 
blockade268, 270-272. Higher concentrations of ketamine would block all NMDARs leading to 
psychomimetic side-effects and anaesthesia267. Furthermore, with higher doses ketamine might bind 
to other proteins like the opioid receptors267. The indirect hypothesis describes the different effects 
of ketamine by binding to NMDARs on different cell types. An anaesthetic effect is observed when 
ketamine also binds to NMDARs present on excitatory neurons and other receptors255.  
Recently, Zanos et al. discovered that the fast antidepressant-like effects of ketamine seems to be 
dependent on a ketamine’s metabolism. Deuterated ketamine at the C6 position (6,6-
dideuteroketamine) is unable to metabolize, however without changing its pharmacological 
properties. 6,6-dideuteroketamine also decreases the immobility time in the FST, but no 
antidepressant-like effects in the LH paradigm.  
Mice treated with the ketamine metabolite (2R, 6R)-hydroxynorketamine exhibit an antidepressant-
like effect similar to ketamine, however, most probably independent of NMDAR binding, but also 
dependent on AMPAR activity. Pretreatment of NBQX also prevented an antidepressant-like effect of 
(2R, 6R)-hydroxynorketamine. Furthermore, (2R, 6R)-hydroxynorketamine also decreases peEF2 1h 
and 24h as well as increases BDNF protein levels 24h after the treatment in HPC, but not the PFC in 
mice262.  
 
 
1.3.3.4 The GABAergic system, alterations and treatment options of MDD 
Several lines of evidence already pointed to an involvement of GABAergic neurotransmission and 
receptors in MDD and AD drug action. GABA is the most widely expressed inhibitory 
neurotransmitter in the mammalian brain and modulates neuronal function and behavioral 
processes like sleep, feeding, aggression, sexual behavior, pain, cardiovascular behavior, 
thermoregulation, locomotor activity, and mood195, 247, 273-278. GABA represents approximately one 
third of the synapses in cerebral cortex, HPC, thalamus, basal ganglia, cerebellum, and the brain 
stem273, 279-282. GABA neurotransmission is present in GABAergic inhibitory interneurons and 
modulates local neuronal circuitry such as glutamatergic, noradrenergic, dopaminergic, and 
serotonergic neurons283. Furthermore, the GABAergic and glutamatergic neurotransmission are 
interconnected with the HPA-axis. Glutamatergic and GABAergic synaptic inputs are identified in 
hypothalamic CRF-containing neurons284, 285. The HPC, PFC, lateral septum, and amygdala regulate 
the HPA-axis by affecting the hypothalamic paraventricular nucleus (PVN). However, none of these 
regions directly innervate to the PVN, they project to PVN-projecting neurons which in turn regulate 
the PVN. HPC and PFC release glutamate which activate PVN-projecting neurons. On the other hand, 
the lateral septum and medial amygdala inhibit PVN-projecting neurons by GABA. The PVN-
projecting neurons inhibit or activate the PVN by either GABA or glutamate, respectively. The 
activated PVN releases CRF and therefore activates the pituitary gland that releases ACTH which in 
turn activates the adrenal gland. The HPC, PFC, pituitary gland, and PVN are then inhibited in a 
feedback loop by released cortisol91, 286. The regulatory roles of glutamatergic and GABAergic systems 
in the activity of the HPA-axis are intriguing regarding how they interact and are involved in 
depression.  
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Glutamate decarboxylase synthesizes GABA from glutamate which then is stored in synaptic vesicles 
and released into the synaptic cleft in a Ca2+-dependent manner273, 287-290. GABA binds to two classes 
of receptors: The ionotropic GABAA and the metabotropic GABAB receptors. GABAA receptors are 
composed of 5 subunits belonging to several different classes. Its activation leads to Cl–-influx into 
the postsynaptic cell causing a fast inhibitory postsynaptic potential (IPSP). GABAB receptors are 
metabotropic autoreceptors, expressed as heterodimers with GABAB1 and GABAB2 subunits and 
different splice variants. Therefore, GABAB receptors are G-protein-coupled inhibiting synaptic 
neurotransmission presynaptically and mediating a slow IPSP275, 291-297. After release, GABA is quickly 
cleared from the synaptic cleft in a sodium-dependent uptake process of GABA transporters in 
presynaptic terminals or glia cells. Glial GABA is transformed to succinate semialdehyde by 
mitochondrial GABA transaminase. Succinate semialdehyde is metabolized to succinate and re-enters 
the citrate cycle to regenerate glutamate by alpha-Ketoglutarate. Glutamate is transferred to 
glutamine, which is then transported to neurons, in which it is transformed to GABA—a process also 
described as GABA/glutamine cycle282, 289, 298, 299.  
Preclinical and clinical evidence strongly associates the GABAergic system with depression. Preclinical 
mouse studies showed, that the knockout of the major GABA transporter 1 (GAT1) led to a reduced 
depression- and anxiety-like behavior in comparison to wild-type mice300. GABAB receptor knockout 
mice exhibit an antidepressant-like effect as observed through a reduced immobility time in the FST. 
In contrast, chronic treatment with drugs which are known to have antidepressant properties like 
lithium, valproate, carbamazepine, fengabide, and probagide, increase GABAB receptor, but not 
GABAA receptor protein levels in the rat HPC and frontal cortex301-303. In contrast, traditional ADs 
reduce GABAA receptor protein levels in the rat HPC, cortex, and hypothalamus, albeit, not in all 
studies304-311. Further analyses on rats could demonstrate increased receptor binding sites for GABAB 
receptors in the HPC of rats treated with conventional ADs, again, not in all studies312-317. LH, as a 
stress paradigm decreases GABAB receptor protein levels and AD treatment reverses this effect in the 
frontal cortex of rats318-321.  
Clinical studies on GABA have so far yielded conflicting results. GABA levels at the plasma and CSF of 
depressed patients were reduced, whereas in two other studies no alterations of GABA levels in CSF 
could be observed. Another study demonstrated decreased GABA levels in plasma, surprisingly, even 
persisting after successful AD treatment for at least 4 years whereas another study could not find any 
differences before and after AD administration283, 322-337. Neuroimaging brain studies with depressed 
patients showed reduced GABA levels at the occipital cortex, anterior cingulate cortex, and medial 
and dorsal anterior PFC212, 338-340. Furthermore, there were no correlations of GABA levels and the 
severity of MDD symptoms. The protein levels of glutamate decarboxylase, the enzyme transforming 
glutamine to GABA, were reduced in the cerebral cortex and cerebellum in MDD patients. However, 
higher glutamate decarboxylase protein levels were found in the dorsolateral PFC, superior temporal 
cortex, and HPC341-343. The density of GABAA receptors in PFC was elevated and GABAA receptor 
subunit A1 and GABAA receptor subunit B3 were up-regulated in the anterior cingulate cortex of 
MDD suicide victims. In contrast, GABAA receptor subunit A mRNA levels were reduced in the frontal 
cortex of suicide victims224, 344-346.  
Modulations of GABAergic neurotransmission have proven effective in sustaining a positive response 
of AD treatment like progabide (an analogue and prodrug of GABA), tiagabine (a GABA reuptake 
inhibitor), and fengabine. The latter showed an antidepressant effect, but its biomolecular 
mechanism remains unknown. The effects were reversed by GABAA receptor antagonists. In clinical 
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trials, fengabine's efficacy was comparable to that of the TCAs, however with a more rapid onset of 
action and much less side effects347, 348.    
  
 
1.4 Animal models of depression 
A model is defined as an organism (non-human) or a particular biological state of an organism that 
reproduces aspects of human pathology, therefore, providing a certain degree of predictive 
validity349. Typical symptoms of MDD like depressed mood, guilt, and suicidality are difficult to model 
as it is either uncertain if such emotions are distinct for humans or not clear if there are present in 
rodents (cf. section 1.1). In general, we do not know if a mouse is depressed or can feel depressed. 
Other symptoms, also common in MDD, can be modelled like anhedonia, behavioral despair, and 
neurovegetative changes like appetite or sleep. Depression models are often evaluated by three 
main criteria: 1) face validity (requires a reasonable level of symptom consistency), 2) construct 
validity (requires causative factors and a comparable etiology) and 3) pharmacological validity 
(requires reversal of depressant-like symptoms by available ADs)350-353. The major problem in MDD 
research is the restricted availability of validated animal models as no “depression gene” was 
discovered yet354. An ideal model would lead to an understanding of the underlying biomolecular 
mechanisms involved in MDD and its development. 
 
  
1.4.1 Models of acute stress 
Forced swim test (FST) and tail suspension test (TST) 
The FST is the most widely used test for AD drug action and in general more often applied as a 
screening test for substances with potential antidepressant-like properties. Moreover, depression-
like behavior can also be tested. The FST was developed in 1977 and is also called Porsolt test. A 
mouse or rat is placed in a cylinder filled with water. Following an initial phase, the time the mouse 
or rat struggles, swims, and floats, the latter also referred to as immobility time, are measured. The 
immobility time is then mostly applied to describe depression-like (higher immobility time) or 
antidepressant-like (reduced immobility time) behavior (figure 3). The test is highly reliable in 
predicting the therapeutic potential of a tested compound. In general, tested substances should 
always also been tested for locomotion as changes in such activities might therefore have an 
influence on the FST. Disadvantages of the FST are the low face and construct validity. The TST was 
first introduced in 1985, in which mice are suspended by their tail and the time the animal stays 
immobile is measured (figure 3). The two different tests are interpreted as behavioral despair and 
the behavior is reversed by acute administration of almost all ADs354-364. 
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Figure 3: Simplified illustration of the forced swim test (FST) and tail suspension test (TST). In the FST, a mouse or rat that is 
placed in a cylinder filled with water shows three different behaviors: struggling, swimming, or floating. The latter is a 
measure for depressant-like behavior. In the TST, a mouse is suspended by its tail and the immobility time is a measure for 
depressant-like behavior365.   
 
   
The learned helplessness (LH) Model 
As described in the previous sections, individuals that have suffered from trauma or other stressful 
life-events are more vulnerable to develop MDD. In this context, unpredictable, uncontrollable and 
inescapable stress-like exposure to electric shocks might cause a state of helplessness in animals. Re-
exposed to the same stress, however, with an easy escape route, will lead to either increased escape 
latency or a completely failure to escape. The model was first developed in the 1960s while studying 
classical Pavlovian conditioning. Animals develop persistent changes like weight loss, diminished 
sexual behavior, alterations in sleep pattern and HPA-axis activity with elevated levels of CRF and 
corticosterone and loss of spines in the HPC. The LH stress paradigm is short-lived in mice only 
persisting 2 to 3 days. The results are largely compatible with the ones gained by the FST. Only 10–
80% of animals fail to develop escape deficits. These results let to breeding of helpless and non-
helpless animals to create different LH-strains. Repeated AD treatment and electroconvulsive seizure 
therapy reduces latency to escape and decreases the number of animals that showed LH. Most 
strikingly, no currently available AD in clinical use, failed when testing for LH. LH seems to be a good 
model for AD drug action as it has excellent face validity and a high predictive value349, 353, 354, 359, 366-
373. 
 
 
1.4.2 Hormones of the HPA-axis 
The forebrain GR knockout mice display enhanced basal serum glucocorticoid levels, dexamethasone 
non-suppression, increased immobility in FST and TST, and the changes are reversible by AD 
treatment. However, overexpression of GR in forebrain of mice shows similar effects, suggesting that 
mood altering properties are more complex than simply changing the hormone levels. Another 
model is based on the fact that chronic glucocorticoid administration leads to depression. Chronic 
administration of corticosterone for 20 days into their drinking water leads to anhedonia, increased 
TST immobility which is reversible by chronic amitriptyline administration (a TCA) in mice. Increases 
in serum cortisol levels in MDD might be secondary to CRF synthesis and secretion. CRF’s behavioral 
effects might be independent to adrenal function as they are not reversed by adrenalectomy. To 
deepen the knowledge of CRF’s behavioral effects, numerous transgenic and knockout mouse lines 
were developed. Overexpression of CRF during mouse development leads to increased anxiety, 
elevated FST and TST immobility time during adulthood and, in line with this study, conditional 
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CRFR1 knockout mice display anxiolysis. This research led to the development of CRFR1 antagonists 
used in depression and anxiety disorders by pharmaceutical companies374-380. 
 
 
1.4.3 Models of chronic stress 
Models of chronic stress were developed based on clinical evidence that chronic stressful life-events 
in humans lead to an increased risk for a depressive episode. The main strength of these models lies 
in the ability to characterize neuroplasticity in association with chronic stress and/or AD treatment. 
The tests are composed of chronic uncontrollable and unpredictable stress that is coupled with a 
method measuring depression- and antidepressant-like behavior. However, low throughput rates 
makes them poorly suited for pharmacological validation of new compounds118, 365.  
 
 
Chronic mild stress (CMS) 
CMS applies a variety of intermittent physical stresses like food and water deprivation, small 
temperature alterations, changes of cage mates over a relatively prolonged time period (1 to 7 
weeks). Anhedonia can be analyzed by a sucrose preference test. Moreover, mouse behavior like 
grooming deficits or changes in aggressive and sexual behavior can be measured. CMS creates 
subtypes for anhedonia as only about 60 % of mice develop anhedonia associated with increased FST 
immobility. However, all mice showed alterations in locomotor activity and reduced exploration. 
Many developed phenotypes are reversible by chronic AD treatment either during the stress or 
afterwards. Rats develop an AD-sensitive and AD-resistant phenotype upon CMS which makes these 
animals a perfect model of TRD. However, there are problems to reproduce the results in different 
laboratories. CMS shows a good predictive value, face validity, and construct validity351, 381-388. 
 
 
Psychosocial stress model 
CMS mostly consists of physical stressors not considering that these forms of stress are unlikely to 
happen to mice and rats in the wild. Moreover, to make an animal model more comparable to the 
human situation where stress mostly develops from social interactions, the psychosocial stress 
paradigm was introduced which is also called the social defeat stress. In this stress paradigm, two or 
more rodents are “forced” to interact socially and physically. Thus, one resident mouse and to a later 
time point another intruder mouse are interacting in one cage. The intruder mouse is investigated 
and they start fighting; subsequently they get divided after some minutes. The resident mouse 
reaches a dominant status whereas the intruder is defeated. Some groups use age- and strain-
matched mice whereas others use another more aggressive or larger mouse strain for defeating. In 
addition to physical stress, some research groups add another psychological stress where they 
prolong the sensory contact for usually 24h. Therefore, the experimental mouse is exposed to 
different aggressors for several days by holding them in the same cage without being able to physical 
interact. Afterwards, these mice display a reduced social interaction, exploration, locomotor activity, 
and anhedonia, increased FST/TST immobility time and alterations in HPA-axis activity and autonomic 
functions. Many symptoms can be reversed by chronic, but not acute AD treatment. The social 
defeat stress model should be applied for at least 20 days in order to develop depression-like 
symptoms. An even shorter defeat stress might rather lead to an anxiety phenotype185, 389-400. 
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Other forms of social stress  
In order to more accurately model human stressful situations, several different kinds of stress 
paradigm were developed. A prolonged social isolation during adulthood results in reduced sucrose 
drinking and alterations in sexual behavior. Early life stress induced by maternal separation during 
postnatal developmental periods, results in cognitive and “emotional” changes that persist into 
adulthood. The novelty-suppressed feeding (NSF) test elicits competing motivations: drive to eat and 
fear to be in the center of a bright lit arena. NSF more likely measures anxiety, however, the stress 
paradigm is also sensitive to chronic AD treatment401-404.  
1.5 Biomarkers in MDD research 
The National Institutes of Health defines a biomarker as being “a characteristic objectively measured 
and evaluated as an indicator of normal biological and pathogenic processes, or biological responses 
to a therapeutic intervention”405. This characteristic can be physiological, pathological and 
anatomical and includes genes, mRNAs, proteins, metabolites, images, electroencephalography 
patterns, electrophysiological traces, physiological, and cognitive signals35, 43, 106, 107, 118, 406-414. 
Biomarkers can be used to differentiate between health and disease states and help classify disease 
subtypes (diagnostic biomarker) as well as treatment outcome (treatment biomarker). Moreover, 
biomarkers are useful in drug development efforts by providing information of a biological state or 
drug effect. In psychiatric research biomarkers can help to stratify patient sub-populations. Drug 
development would benefit from biomarkers or a biosignature to predict a treatment effect for 
newly developed ADs. Currently, mood disorders are symptomatically determined by a patient’s self-
report or by information from others. As described in section 1.1, to date symptoms are assessed 
based on DSM-IV or ICD-10 without any biological parameters16, 17. Biomarkers for MDD still remain 
elusive and are of urgent need. The development and validation of biomarkers predictive for MDD 
subtypes would greatly help not only in the development of novel ADs, but also in clinical trials to 
stratify MDD patients. 
The literature describes several biomarkers that might be suitable for translation into the clinic:  
 Growth factors like BDNF (cf. section 1.3)118, 407-409, 413 
 Pro-inflammatory markers like cytokines including tumor necrosis factor-α and interleukin-6 
have altered levels in MDD410, 411, 414, 415 
 Endocrine markers reflecting an altered HPA-axis regulation (cf. section 1.3.2) and the 
dexamethasone suppression test106, 107, 412. Dexamethasone is a synthetic glucocorticoid and 
the test is a measure for the integrity of feedback inhibition of the HPA-axis. A positive test 
result is reflected by elevated plasma cortisol levels. This test might reflect an MDD subtype 
as well as differentiate between healthy and MDD subjects   
 ADs and MDD affect electroencephalography profiles which might serve as a biomarker406 
 HPC volume decline in individuals suffering from MDD and reversal after AD treatment (cf. 
section 1.3)35, 43 
 Markers like neurotransmitters and (mRNA) as described in previous sections 
 
None of these potential biomarkers are currently used in the clinic. In all likelihood a set of 
biomarkers will ultimately be required.   
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2.0 Thesis project aims and objectives 
MDD is a devastating neuropsychological disorder with a high co-morbidity and risk for mortality 
accompanied by a dysfunctional brain circuitry involving the HPC and PFC. Conventional ADs need at 
least 2 to 8 weeks before a therapeutic effect results and approximately one third of the patients do 
not respond to traditional treatment and therefore suffer from TRD8. In 2000, Berman et al. 
discovered the fast antidepressant effect of ketamine with symptom reduction already within 2h and 
4h, lasting up to 7 to 10 days and being especially effective for patients suffering from TRD. 
Unfortunately, ketamine’s psychomimetic side-effects prevented its routine use in the clinic so far179, 
243, 244, 251, 416.  
Ketamine is a non-competitive antagonist of the NMDAR with profound downstream effects. To 
date, studies on ketamine’s biomolecular mechanism mainly focuses on the BDNF and mTORC1 
mediated neurotrophic effects on synaptic plasticity—a process with high energy demand in form of 
adenosine triphosphate (ATP)179, 243, 262. However, the exact mechanism and brain circuitry still 
remains elusive. So far, no alternative cellular targets besides and downstream of the NMDAR are 
known that could aid the development of alternative faster acting ADs with a similar mode of action 
as ketamine, but with fewer side-effects. Furthermore, no treatment biomarkers for ketamine’s 
mode of action, especially for its antidepressant effects are known.  
 
The fast antidepressant action of ketamine was previously reported in patients suffering from TRD. 
However, the actions of ketamine are afflicted with psychomimetic side effects and have prevented 
its clinical routine use as antidepressant drug to date. Hence, the examination of ketamine’s cellular 
targets (other than NMDAR) and its exact mechanism of action might provide new contact points for 
future antidepressant drug development and biomarker research. Therefore, the overall aim of this 
thesis is to identify biosignatures and biomolecular pathways affected by ketamine treatment. 
Results from my research in mice can aid in the development of novel fast acting ADs with a similar 
mode of action as ketamine, however, with fewer side-effects. The specific objectives of my thesis 
project are: 
 To investigate the time-dependent antidepressant-like effect of a low ketamine dose in mice 
using the FST 
 To compare metabolite profiles of defined brain regions, liver, and blood from ketamine- and 
vehicle-treated mice as well as mouse primary hippocampal neurons (PHN) subjected to 
ketamine and vehicle treatment 
 To determine hippocampal ketamine treatment response biomarkers, especially for the 
drugs’ antidepressant effect 
 To compare hippocampal protein expression profiles between ketamine- and vehicle-treated 
mice based on molecular pathways identified by metabolomic analyses 
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3.0 Materials and Methods 
3.1 Chemicals and consumables 
Table 1: Chemicals and consumables used in the present study. 
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3.2 Buffers and solutions 
Table 2: Buffers and solutions used in the present study. 
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3.3 Software and equipment 
Table 3: Software and equipment used in the present study. 
 
 
 
3.4 Animals and ketamine treatment  
Eight-week-old male C57BL/6 mice (Charles River Laboratories, Maastricht, the Netherlands) were 
first singly housed for 2 weeks under standard conditions (12h) light/dark cycle, lights on at 06.00 
am, room temperature 23 ± 2 °C, humidity 60%, tap water and food ad libitum) in the facilities of the 
Max Planck Institute of Psychiatry. After habituation, the mice were treated intraperitoneally with S-
ketamine (3 mg kg-1, Pfizer, Karlsruhe, Germany) or vehicle (0.9% saline solution). 2h, 14h, 24h and 
72h after ketamine treatment, an FST was performed measuring the antidepressant-like behavior 
and afterwards animals were killed by an overdose of isoflurane (Forene, Abbott, Wiesbaden, 
Germany). Blood was taken cardiac puncture and the animals were subsequently perfused with 0.9% 
ice-cold saline solution. Mice were decapitated, their livers and brains were harvested and dissected. 
Tissues and blood were shock-frozen in liquid nitrogen and stored at -80 °C until further analysis. The 
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experiments were performed in accordance with the European Communities Council Directive 
86/609/EEC. The protocols were approved by the committee for the Care and Use of Laboratory 
Animals of the Government of Upper Bavaria, Germany. 
 
 
3.5 Forced swim test (FST) 
Each mouse was put into a 2 liter glass beaker (diameter: 13 cm, height: 24 cm) filled with tap water 
(21 ± 1 °C) to a height of 15 cm, so that the mouse could not touch the bottom with its hind paws or 
tail. Testing duration was 6 min and at the end of the test the animals were immediately dried with a 
towel and returned to their home cage. The floating time was scored 2h (ketamine-treated animals: 
n=33, vehicle-treated animals: n=33), 14h (ketamine-treated animals: n=31, vehicle-treated animals: 
n=29), 24h (ketamine-treated animals: n=33, vehicle-treated animals: n=33) and 72h (ketamine-
treated animals: n=31, vehicle-treated animals: n=29) after ketamine treatment by an experienced 
observer, blind to the condition of the animals. 
 
 
3.6 Isolation of blood plasma  
The animals’ blood was taken by cardiac puncture and plasma was obtained by centrifuging the 
blood in a phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich, Munich, Germany), EDTA and 
protease inhibitor cocktail Tablets ‘cOmplete’ (Roche Diagnostics, Mannheim, Germany) containing 
pre-added tube at 1 300g for 10 min. The blood plasma (supernatant) was stored in -20 °C and the 
pellet containing the blood cells was discarded.   
 
 
3.7 Isolation of cytoplasmic (CF) and membrane-associated (MF) proteins  
CF and MF were prepared by repeated tissue homogenization and extraction of non-membrane-
associated proteins and solubilization of MF proteins with sodium dodecyl sulfate (SDS). In detail, 
tissues were homogenized for 30s in 1ml of 2 M NaCl, 10 mM Hepes/NaOH, pH 7.4, containing 1mM 
EDTA, phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich, Munich, Germany), protease inhibitor 
cocktail Tablets ‘cOmplete’ (Roche Diagnostics, Mannheim, Germany), then incubated for 10 min and 
homogenized again for 30 s and further with a ultrasonicator for 3 × 10 s on ice. The homogenates 
were centrifuged at 16 100 g at 4 °C for 20min. The supernatant contained the CF proteins. The 
pellets were rehomogenized in 1 ml of 0.1 M Na2CO3 and 1 mM EDTA containing 1 mM EDTA, 
phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich, Munich, Germany), protease inhibitor cocktail 
Tablets ‘cOmplete’ (Roche Diagnostics, Mannheim, Germany), pH 11.3, mixed at 4 °C for 30 min and 
collected by centrifugation (16 100g at 4 °C for 20min). Subsequently, the pellets were extracted with 
5 M urea, 100 mM NaCl, 10 mM Hepes, pH 7.4 and 1 mM EDTA containing 1 mM EDTA, phosphatase 
inhibitor cocktail 2 and 3 (Sigma-Aldrich, Munich, Germany), protease inhibitor cocktail Tablets 
‘cOmplete’ (Roche Diagnostics, Mannheim, Germany) and then washed twice with 0.1 M Tris/HCl, 
containing 1 mM EDTA, phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich, Munich, Germany), 
protease inhibitor cocktail Tablets ‘cOmplete’ (Roche Diagnostics, Mannheim, Germany) pH 7.6. The 
pellets were solubilized in 20-50 µl of 2% SDS, 50 mM dithiothreitol and 0.1 M Tris/HCl, containing 1 
mM EDTA, phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich, Munich, Germany), protease 
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inhibitor cocktail Tablets ‘cOmplete’ (Roche Diagnostics, Mannheim, Germany) pH 7.6, at 90 °C for 1 
min and stored at -20 °C until further analysis. 
 
 
3.8 Protein concentration determination with the Bradford assay 
CF protein concentrations were determined by a Bradford protein assay (Bio-Rad, Hercules, USA) 
based on the principles of Bradford according to the manufactures descriptions417. 
 
 
3.9 Protein concentration determination with the Lowry assay 
MF protein concentrations were determined by a Lowry protein assay (Bio-Rad, Hercules, USA) based 
on the manufactures descriptions418. 
 
 
3.10 Western Blot  
Hippocampal MF and CF proteins from 8-week-old male C57BL/6 mice treated with ketamine for 2h, 
14h, 24h and 72h were fractionated by SDS-polyacrylamide gel electrophoresis and Western Blot was 
performed based on standard protocols. After electrophoresis, proteins were transferred to PVDF 
membranes (Immobilon-P, Millipore, Billerica, USA). Primary antibodies were against complex II 
subunit A of the succinate dehydrogenase complex (SDHA, sc98253, Santa Cruz Biotechnology, 
Dallas, USA), protein kinase C γ (PKC γ, Acris antibodies, Herford, Germany), Ca2+/calmodulin-
dependent protein kinase II α (CaMKII α, Abcam, Cambridge, UK), subunit 1 of gamma-aminobutyric 
acid type A receptor (GABAAR1, Abcam, Cambridge, UK), subunit 1 of N-Methyl-D-aspartate receptor 
1 (NMDAR1, Abcam, Cambridge, UK), Peroxisome proliferator-activated receptor gamma coactivator 
1-α (PGC1α, Novus Biologicals, Littleton, USA), mitochondrial transcription factor A (Tfam, Abcam, 
Cambridge, UK), adenosinmonophosphate-activated proteinkinase (AMPK, Abcam, Cambridge, UK), 
phosphorylated AMPK (pAMPK, Cell Signaling, Merck, Darmstadt, Germany), peroxiredoxin 1 (Prdx1, 
Abcam, Cambridge, UK), Peroxiredoxin 3 (Prdx3, Abcam, Cambridge, UK), translocase of inner 
membrane (Tim23, BD Biosciences, Heidelberg, Germany), β-Actin (Sigma, Munich, Germany), Porin 
(Abcam, Cambridge, UK), myelin basic protein (MBP, Abcam, Cambridge, UK), myelin 
oligodendrocyte glycoprotein (MOG, Abcam, Cambridge, UK) and oxidative phosphorylation 
(OXPHOS) protein complexes by a premixed antibody cocktail (‘MitoProfile’, Abcam, Cambridge, UK) 
against complex I subunit NADH:ubiquinone oxidoreductase subunit B8 (NDUFB8), complex II SDHB, 
complex III mitochondrial cytochrome C oxidase subunit I (MTCOI), complex IV (Ubiquinol-
cytochrome C reductase core protein II (UQCRC2) and complex V ATP synthase subunit alpha 
(ATP5a). Anti-rabbit, anti-mouse and anti-goat ECL horseradish peroxidase-linked secondary 
antibodies (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK) were used. The 
densitometric analyses were performed with the Image Lab software (Bio-Rad, Munich, Germany). 
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3.11 OxyBlotTM Protein oxidation detection 
Oxidative modification of proteins by oxygen free radicals and other reactive species (ROS) occurs in 
physiologic and pathologic processes. As a consequence of the modification, carbonyl groups are 
introduced into protein side chains by a site-specific mechanism. The OxyBlotTM Kit (Merck Millipore, 
Darmstadt, Germany) provides reagents for simple and sensitive immunodetection of these carbonyl 
groups, which is a hallmark of the oxidation status of proteins. The carbonyl groups in the protein 
side chains are derivatized to 2,4-Dinitrophenylhydrazone (DNP-hydrazone) by reaction with 2,4-
Dinitrophenylhydrazine (DNPH). The DNP-derivatized protein samples are separated by SDS-gel 
electrophoresis followed by Western Blot. Afterwards, the membrane is incubated with primary 
antibody (Anti-DNP), specific to the DNP moiety of the proteins. This step is followed by incubation 
with a horseradish peroxidase-antibody conjugate directed against the primary antibody (secondary 
antibody: goat anti-rabbit immunoglobulin). 
5μL containing 10µg of CF hippocampal protein sample is transferred into an eppendorf tube and 5μL 
12% SDS is added for a final concentration of 6% SDS. The sample is derivatized by adding 10μL of 1x 
DNPH Solution. The mixture is incubated at room temperature for 15 min in the dark. 7.5μL of 
Neutralization Solution is added to stop the reaction. 1µl of 2-Mercaptoethanol is added to the 
sample mixture to avoid further protein oxidation. The protein mixture was then separated in an 
SDS-gel and Western Blot was performed based on standard protocols. After electrophoresis, 
proteins were transferred to PVDF membranes (Immobilon-P, Millipore, Billerica, MA, USA). 
 
 
3.12 Total antioxidant capacity (TAC) 
The TAC Assay Kit (BioVision, Milpitas, USA) measures antioxidant molecules and proteins by 
reducing Cu2+ to Cu+. Cu+ chelates with a colorimetric probe giving a broad absorbance peak around 
570 nm, proportional to the total antioxidant capacity. The lyophilized Trolox standard is dissolved in 
20µl of DMSO by vertxing, then 980µl of water is added and mixed well, generating a final 1 mM 
solution. Antioxidants are measured by adjusting 0.25µl CF protein sample to 100µl total volume, 
filling the sample with water. One part of the Cu2+ reagent is diluted with 49 parts of the Assay 
diluent. 100µl of Cu2+ working solution is added to all standard and samples. The mixture is 
transferred to a 96 well plate, covered and incubated at room temperature for 1.5h. Afterwards, the 
signal is measured at an absorbance of 570 nm using the plate reader. 
 
 
3.13 Isolation of mitochondria 
Mitochondria were isolated by repeated brain tissue homogenization and centrifugation. Therefore, 
brain tissue of approximately 30mg were incubated in 180µl of 250-STM buffer for 15 min on ice and 
then homogenized, incubated for 10 min on ice and homogenized a second time. The homogenate 
was then centrifuged at 800g for 15 min at 4°C. The supernatant contains already mitochondria. The 
pellet also containing mitochondria is resuspended with 640µl 250-STM buffer and centrifuged at 
800g for 15 min at 4 °C. This supernatant is combined with the first one and centrifuged at 6 000g for 
15 min at 4°C. The mitochondria enriched pellet is resuspended with 100µl of 250-STM buffer and 
centrifuged a 6 000g for 15 min at 4°C. The pellet is resuspended with 250µl 10 mM Hepes, 
incubated on ice for 30 min and subsequently loaded on a sucrose gradient containing 1.75ml of 
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50%, 1.75ml of 36% and 0.75ml of 20% sucrose and centrifuged at 25 000rpm at 4°C for 60 min. 
Afterwards the third fraction between the 20% and 36% sucrose contain the mitochondria and are 
washed twice with 1.5ml 10mM Hepes and centrifuged at 17 200g for 20 min at 4 °C. The pellet is 
resuspended with 50µl 10mM Hepes and the protein concentration determined with Bradford assay.  
Mitochondrial membrane protein complexes are solubilized with 1ml solubilization buffer without 
digitonin, Dodecylmaltoside (DDM) or Triton-x100 and centrifuged twice at 17 500g for 10 min at 4 
°C. 50µl solubilization buffer with 2µl of a 20% Digitonin stock solution (8g Digitonin/g protein) or 
0.75µl of a 20% DDM stock solution (3g DDM/g protein) or 0.75µl of a 20% Triton-x100 stock solution 
(3g Triton-x100/g protein) is added to the pellet and incubated for 30 min at 4 °C while gently mixing. 
Subsequent centrifugation at 17 500g for 10 min at 4 °C results in a supernatant containing 
mitochondrial membrane protein complexes. Afterwards 1x BN-loading buffer is added to the 
mitochondrial membrane protein complexes for the blue native-polyacrylamide gel electrophoresis 
(BN-PAGE). 
 
 
3.14 Blue native-polyacrylamide gel electrophoresis (BN-PAGE) 
Native protein complexes can be separated by BN-PAGE. Therefore, also mitochondrial membrane 
protein complexes are separated in a 4% to 16% gradient gel without SDS as a detergent. Coomassie 
contains a negative anionic charge and can binds to hyrdrophobic membrane proteins. Therefore, 
the proteins can be electrophoretic separated. BN-cathode buffer with 0.02% Coomassie is filled into 
the inner chamber and the BN-anode buffer into the outer chamber. Gel electrophoresis starts with 
100V and is subsequently increased up to 200V. After approximately one third of the SDS-gel-
electrophoresis, the BN-cathode buffer with 0.02% Coomassie is exchanged with BN-cathode buffer 
containing 0.002% Coomassie. Mitochondrial OXPHOS ETC protein complexes were then identified by 
LC-ESI-MS/MS with the LTQ Orbitrap XLTM (Thermo Fisher Scientific, Bremen, Germany).    
 
 
3.15 Sample preparation for LC-ESI-MS/MS analyses 
3.15.1 Protein sample preparation for the identification of OXPHOS ETC protein complexes 
Identification of mitochondrial OXPHOS protein complexes requires the separation of the complexes 
by BN-PAGE. Separated protein complexes were then stained with Coomassie staining solution for 20 
min and destained over night with Coomassie destaining solution. Each gel band of interest was cut 
into an approximately 2.5 mm gel slice and then further cut into smaller gel pieces. 
 
 
3.15.2 Protein sample preparation for quantitative proteomics analyses 
Hippocampal CF and MF proteins were mixed 1:1 with CF and MF 15N-labeled internal standard. 
In vivo 15N-labeled hippocampal proteins were derived from C57BL/6 mice mice that were raised with 
a 15N mouse diet (Silantes, Munich, Germany) for 12 weeks. 50 μg of the 14N/15N protein mixture 
were separated by SDS gel electrophoresis. Separated proteins were stained with Coomassie staining 
solution for 20 min and destained over night with Coomassie destaining solution. Each gel lane was 
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cut into 16 approximately 2.5 mm slices per biological replicate and these further cut into smaller gel 
pieces. 
 
 
3.15.3 In-gel-trypsin digestion and peptide extraction 
The gel pieces were covered with 100µl of 25 mM Na4HCO3/50% ACN in order to destain the gel 
pieces completely and mixed for 10 min at room temperature. The supernatant was discarded and 
this step repeated twice. Proteins inside the gel pieces are reduced with 75L 1x DTT/25 mM 
NH4HCO3 mixed at 56 C for 30 min in the dark. The supernatant is discarded and for alkylation 100µl 
IAM are added to the gel pieces and mixed for 30 min at room temperature. The supernatant was 
discarded and the gel pieces washed twice with 100µl 25 mM Na4HCO3/50% ACN and mixed for 10 
min at room temperature. The supernatant is discarded and gel pieces are dried for approximately 
20 min at room temperature. Proteins are digested with 50 µl trypsin solution (5ng/µl trypsin/25 mM 
NH4HCO3) over night at 37 °C. Peptides were extracted from the gel pieces by mixing them in 50µl of 
2% FA/50% ACN for 20 min at 37 °C and subsequently sonicating them for 5 min. The supernatant 
contains the peptides. This step is repeated twice with 50 µL of 1% FA/50% ACN. The supernatants 
are then combined and the solution removed by centrifugal vacuum concentrator (Speed Vac Plus, 
SC 210 A, Savant) and the pellet is stored at -20 °C.  
 
 
3.16 Protein identification with LTQ Orbitrap XLTM 
The LTQ Orbitrap XLTM is a hybrid fourier transform (FT) mass spectrometer combining a linear ion 
trap MS and the Orbitrap mass analyzer. Peptide ions are generated by electrospray ionization (ESI) 
and collected in the LTQ XL and afterwards ejected into the C-shaped storage trap. The C-trap is used 
to store and for collision before injecting them to the Orbitrap Mass Analyzer. Signals are amplified 
and transformed into a frequency spectrum by fast Fourier transformation which is finally converted 
into a mass spectrum. Ions can be selected in the linear ion trap and fragmented either in the ion 
trap (CID) or in the collision cell (HCD). For HCD (Higher Energy Collisional Dissociation) ions are 
passed through the C-trap into the gas-filled collision cell (figure 4)419.  
 
 
Figure 4: Schematic of the LTQ OrbitrapTM. The LTQ Orbitrap XLTM consists of an ESI Ion Source, an LTQ XL Linear Ion Trap, 
a C-Trap, an HCD Collision Cell and an Orbitrap Mass Analyzer419. 
 
The mitochondrial membrane protein samples for MS-measurements are filtered beforehand with 
Costar SpinX filter tubes. They are first activated with 5µl of 0.1% HCOOH, centrifuged at 1 000g for 1 
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min at 4 °C and the flow-through was discarded. The protein samples are dissolved in 20µl 0.1% 
HCOOH, vortexed for 30 sec and sonicated for 10 min. 7µl of the protein samples are transferred to 
Costar SpinX filter tubes and centrifuged for 3 min at 1000g at 4 °C and 5µl of the filtered protein 
sample filled into a vial for MS-measurements. Tryptic peptides were then dissolved in 0.1% FA and 
analyzed with a nanoflow HPLC-2D system (Eksigent, Dublin, CA, USA) coupled online to an LTQ-
Orbitrap XLTM mass spectrometer. Samples were on-line desalted for 10 min with 0.1% FA at 3 μl/min 
(Zorbax-C18 (5 μm) guard column, 300 μm × 5 mm, Agilent Technologies, Santa Clara, CA, USA) and 
separated via RP-C18 (3 μm) chromatography (in-house packed Pico-frit column, 75 μm × 15  cm, 
New Objective, Woburn, MA, USA). Peptides were eluted with a gradient of 95% ACN/0.1% HCOOH 
from 10% to 45% over 93 min at a flow rate of 200 nl/min. Column effluents were directly infused 
into the mass spectrometer via a nanoelectrospray ion source (Thermo Fisher Scientific). The mass 
spectrometer was operated in positive mode applying a data-dependent scan switch between MS 
and MS/MS acquisition. Full scans were recorded in the Orbitrap mass analyzer (profile mode, m/z 
380–1600, resolution R = 60000 at m/z 400). The MS/MS analyses of the five most intense peptide 
ions for each scan were recorded in the LTQ mass analyzer in centroid mode. The mitochondrial 
OXPHOS ETC protein complexes were then identified with Mascot Daemon (Matrix Sciences London, 
http://www.matrixscience.com/daemon.html). Proteins were considered with a score ≥ 50 and ≥ 2 
peptide matches and searched within the Swiss-Prot database FDR≤0.052. 
 
  
3.17 Quantitative proteomics analyses with Q ExactiveTM Hybrid Quadrupole-OrbitrapTM 
Mass Spectrometer 
The Q ExactiveTM Quadrupole-OrbitrapTM mass spectrometer combines high-performance quadrupole 
precursor selection with high-resolution and accurate mass Orbitrap detection (figure 5)420.  
 
Figure 5: Schematic representation of the Q ExactiveTM Quadrupole-OrbitrapTM. The mass spectrometer consists of an ESI 
ion source, a quadrupole mass filter, a C-Trap, an HCD Collision Cell and an Orbitrap Mass Analyzer420.  
Hippocampal MF and CF proteins were identified and quantified by a Dionex Ultimate 3000 RSLC  
nanoUPLC (Thermo Fisher Scientific, Waltham, USA) system and a Q ExactiveTM OrbitrapTM mass 
spectrometer (figure 5, Thermo Fisher Scientific, Waltham, USA). Separation of peptides was 
performed by reverse-phase chromatography at a flow rate of 300 nl/min and a Thermo Scientific 
reverse-phase nano easy-spray column (Thermo Scientific PepMap C18, 2 µm particle size, 100A pore 
size, 75 µm x 50 cm length). Peptides were loaded onto a pre-column (Thermo Scientific PepMap 100 
C18. 5 µm particle size, 100A pore size, 300 µm x 5mm length) from the Ultimate 3000 autosampler 
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with 0.1% FA for 3 min at a flow rate of 10 µl/min. After this period, the column valve was switched 
to allow elution of peptides from the pre-column onto the analytical column. Solvent A was water + 
0.1% FA and solvent B was 80% ACN, 20% water + 0.1% FA. The linear gradient employed was 2-40% 
B in 30 min. The LC eluant was sprayed into the MS by means of an easy-spray source (Thermo Fisher 
Scientific). All m/z values of eluting ions were measured in an Orbitrap mass analyzer, set at a 
resolution of 70 000. Data dependent scans (Top 20) were employed to automatically isolate and 
generate fragment ions by higher energy collisional dissociation (HCD) in the quadrupole mass 
analyzer and measurement of the resulting fragment ions was performed in the Orbitrap analyser, 
set at a resolution of 17 500.  Peptide ions with charge states of 2+ to 4+ and above were selected for 
fragmentation. 
OrbitrapTM raw files were converted to mzXML files using MSConvert software. The in-house 
software package iSPY, which was adapted from an earlier version of a peptide quantitation program 
known as iTracker, was used to identify and quantify peptides. The software was used to convert 
mzXML to mgf files that were then finally imported into Mascot and searched against the SwissProt 
Mouse database and a decoy database. The databases were searched using the following settings: 
variable modifications of carbamidomethyl (cys), oxidation (met); 20 ppm peptide tolerance, 0.1 Da 
MS/MS tolerance, 2 missed cleavages and peptide charge state of +2, +3, or +4. In iSPY, Mascot dat 
output files were run through Percolator for improved identification. Non-unique peptides were 
discarded. Only peptides with a protein type 1 error of less than 0.01 were kept in the final dataset. 
The heavy and light peak intensities for each peptide were calculated in iSPY using retention time 
and sequence information from the MS1 spectra and Mascot search, respectively. Briefly, the 
intensities for a pre-specified number of isotopomeric peaks were calculated by scanning through a 
retention window spanning a set distance either side of the maximum intensity value. The 14N and 
15N peptide isotopic peaks from the MS1 dataset were used to compare the theoretical mass 
difference between the heavy and light peptides, and the typical isotopic distribution patterns. Only 
quantifiable peptides (those for which both a heavy and a light peak intensity were identified in five 
replicates) were included in the dataset. 
 
 
3.18 OXPHOS protein complex in-gel-enzymatic activity measurement 
The enzymatic activity of the mitochondrial membrane OXPHOS protein complexes were measured 
in the gel by histochemical staining through redox reactions of the OXPHOS protein complexes 
enzymatic activity. The gel bands of interest were cut out of the gel and for a minimum of 30 min 
incubated in a pre-incubation buffer. Afterwards the gel bands were incubated in activity solution 
different time points depending on the ETC protein complex (complex I: 3.5 min; complex II: 30 min; 
complex III: 50-60 min; complex IV: 40 min; complex V: 80 min). The reaction was then stopped with 
a stopping solution for complex I-IV containing 50% methanol/10% HCOOH and for complex V 50% 
methanol.      
 
  
3.19 Ketamine treated mouse primary hippocampal neurons 
PHN were a gift from Dr. D. Refojo and S. A. Giusti (Max Planck Institute of Psychiatry, Munich, 
Germany). Briefly, the PHN were prepared from CD1 mouse embryos (E17.5–E19.5) and maintained 
in Neurobasal-A medium with 2% B-27 and 0.5 mM GlutaMAX-I (Gibco) at 37 °C and 5% CO2421. After 
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3 weeks PHN maturation, cells were treated with different concentrations of ketamine for 24h (00.5 
M, 0.001 M, 0.0009 M, 0.0008 M, 0.0007 M, 0.0006 M, 0.0005 M, 0.0004 M, 0.0003 M, 0.0002 M, 
0.0001 M, 0.00009 M, 0.00008 M, 0.00007 M, 0.00006 M, 0.00005 M, 0.00004 M, 0.00003 M, 
0.00002 M, 0.00001 M, 0.000005 M, 0.000001 M) and tested for cell viability with the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. Further, mature 3 week-old PHN were 
treated with 0.0001 M of ketamine for 24h and metabolites were isolated for further metabolomics 
analyses.  
 
 
3.20 Cytotoxicity measurement through the MTT assay 
Cytotoxicity was measured by the MTT calorimetric assay that determines cell metabolic rate. Viable, 
metabolically active cells produce reduction equivalents that reduce the MTT to its insoluble 
formazan that shows an absorbance maximum at 570 nm. The quantity of formazan is directly 
proportional to the number of viable cells. PHN were grown in a 96 well plate with 150 µl of medium. 
75 µl of the medium was removed and 25 µl of MTT (2mg/ml in PBS) was added and covered with 
the 75 µl of the remaining medium subsequently incubated for 6h at 37 °C. The formazan was 
solubilized by incubation of 100 µl 40 % dimethylformamide/ 10 % SDS, pH 4 over night in the dark at 
room temperature. The formazan dependent absorbance was then measured at 570 nm.    
 
  
3.21 Isolation of polar metabolites 
3.21.1 Isolation of polar metabolites from mouse tissue 
Mouse tissues were homogenized (2 min × 1 200 min-1, homogenizer PotterS, Sartorius, Göttingen, 
Germany) in 30-fold ice-cold 80% methanol. Samples were centrifuged (14 000 g, 10 min, 4 °C) and 
the supernatants were incubated on dry ice. Afterwards, the pellets were incubated in 6-fold ice-cold 
80% methanol and then combined with the previous supernatants. The metabolite extracts were 
vortexed, centrifuged (14 000 g, 10 min, 4 °C), and the solution was removed by centrifugal vacuum 
concentrator (Speed Vac Plus, SC 210 A, Savant) and the samples stored at -80 °C.  
 
 
3.21.2 Isolation of polar metabolites from mouse blood plasma 
400µl of cold (stored at -80 °C) 100% methanol was added to 100µl of mouse blood plasma and 
vortexed for 2 min and afterwards incubated on dry ice for 2h. The mixture was then centrifuged at 2 
053 g for 10 min at 4 °C. The supernatant was transferred to a new tube and subsequently 
centrifuged at 1 105 g for 2 min at 4 °C. The solution was removed by centrifugal vacuum 
concentrator (Speed Vac Plus, SC 210 A, Savant) and the samples stored at -80 °C.  
 
 
3.21.3 Isolation of polar metabolites from PHN 
The metabolism of the cells are slowed down by incubating the cell culture plates on ice for 10 min. 
Afterwards the cell were washed twice with Dulbecco’s phosphate-buffered saline and incubated on 
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dry ice until the cells are completely frozen. Twice, 500µl of ice-cold 80% methanol (stored at -80 °C) 
was added, the plates are transferred to ice, scraped and the fluid collected and subsequently frozen 
in liquid nitrogen. The samples were then melt on ice, subsequently vortexed for 30s and centrifuged 
for 10 min at 800 g at 4 °C. The supernatant was then stored at dry ice and the pellet resolved with 
500µl of ice-cold 80% methanol (stored at -80 °C) and the sample frozen in liquid nitrogen. The 
mixture was then melt again on ice, vortexed for 30s and centrifuged for 10 min at 800 g at 4 °C. The 
supernatants are combined, centrifuged at 15 000 rpm for 1 min subsequently transferred to a new 
tube and the solution was removed by centrifugal vacuum concentrator (Speed Vac Plus, SC 210 A, 
Savant) and the samples stored at -80 °C. 
 
 
3.22 Targeted metabolomics analysis through selected reaction monitoring (SRM) with 
5500 QTRAP triple quadrupole 
Samples were resuspended using 20μl liquid chromatography-mass spectrometry grade water. 10µl 
were injected and analyzed using a 5500 QTRAP triple quadrupole mass spectrometer (AB/SCIEX, 
Framingham, USA) coupled to a Prominence UFLC high-performance liquid chromatography system 
(Shimadzu, Columbia, USA) via SRM of a total of 293 endogenous water-soluble metabolites for 
steady-state analyses of samples (figure 6). 
 
Figure 6: Schematic representation of the 5500 QTRAP triple quadrupole. The mass spectrometer consists of an ESI ion 
source, three quadrupoles. In targeted metabolomics research the first quadrupole Q1 selects specific ions (metabolites), 
the second Q2 fragment these ions and the third Q3 select the fragment ions422.  
Samples were delivered to the mass spectrometer via normal phase chromatography using a 4.6-mm 
× 10 cm Amide Xbridge HILIC column (Waters, Milford, USA) at 350μl min-1. Gradients were run 
starting from 85% buffer B (high-performance liquid chromatography grade ACN) to 42% B from 0 to 
5 min; 42% B to 0% B from 5 to 16 min; 0% B was held from 16 to 24 min; 0% B to 85% B from 24 to 
25 min; 85% B was held for 7 min to re-equilibrate the column. Buffer A comprised 20 mM 
ammonium hydroxide/20 mM ammonium acetate (pH 9.0) in 95:5 water:ACN. Some metabolites 
were targeted in both positive and negative ion modes for selected reaction monitoring transitions 
using positive/negative polarity switching. Electrospray ionization voltage was +4 900 V in positive 
ion mode and - 4500 V in negative ion mode. The dwell time was 4 ms per selected reaction 
monitoring transition and the total cycle time was 1.89 s. Approximately 9–12 data points were 
acquired per detected metabolite. Peak areas from the total ion current for each metabolite-selected 
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reaction monitoring transition were integrated using the MultiQuant v2.0 software (AB/SCIEX)423. 
Animals from the same cohort were used for all metabolomics analyses. 
 
3.23 Statistics and data analyses  
3.23.1 Identification of significant metabolite and protein level alterations  
Metabolite intensities as well as protein ratios were median-normalized and auto-scaled for 
statistical analysis. Significant metabolite and protein level changes 2h, 14h, 24h and 72h upon 
ketamine treatment were identified by multivariate partial least squares-discriminant analyses (PLS-
DA) and high-dimensional feature selection significance analysis of microarrays (SAM) using 
MetaboAnalyst424-426. The quality of the PLS-DA models were assessed for R2, Q2 and accuracy values 
with variable influence of projection (VIP)-score≥1.0 and for SAM with q≤0.1 and false discovery rate 
(FDR)≤0.10427. We improved robustness of our data analyses and increased confidence in 
significantly altered metabolites and proteins as well as in the subsequent analyses of 
overrepresented KEGG pathways by only considering the overlap between the two different 
statistical methods.  
 
 
3.23.2 Identification of significantly enriched pathways  
Metabolomics pathway analyses were performed using MetaboAnalyst424, 425 applying a 
hypergeometric algorithm for overrepresentation analysis and relative-betweeness centrality for 
pathway topology analysis. Pathways were considered affected if they were significantly enriched for 
KEGG pathways (PHolm-corrected≤0.05) for all significantly altered metabolites. Proteomic pathway 
enrichment for KEGG pathways was assessed by String with an FDR≤0.10428, 429.  
 
 
3.23.3 Calculation of metabolite pair ratios  
The median-normalized metabolite intensities before auto-scaling of selected pairs of metabolites 
were used to calculate metabolite ratios. For statistical analyses, Student’s t-test was performed by 
using the metabolite ratio of interest for each ketamine- and vehicle-treated animal (for example, 
metabolite x/metabolite y of one ketamine-treated animal) calculated by dividing the metabolite 
intensity of metabolite x by the intensity of metabolite y for each time point. The final metabolite 
ratio of interest (for example, metabolite x/metabolite y for all ketamine- and vehicle-treated 
animals) was then calculated by dividing the average metabolite intensities of all ketamine-treated 
animals by the average metabolite intensities of all vehicle-treated animals.  
 
 
3.23.4 Identification of metabolite biomarker candidates 
AD treatment hippocampal metabolite biomarker candidates were detected by applying multivariate 
PLS-DA models taking the VIP-scores (VIP-score≥1.0) and SAM with q≤0.10 and FDR≤ 0.10 into 
account. The quality of the PLS-DA models was assessed in terms of R2, Q2 and accuracy values. 
Metabolites qualified as biomarker candidates if they had a consistent VIP-score≥1.0 for the 2h, 14h 
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and 24h time points for which good and robust PLS-DA models had been determined. In addition, 
they required q≤0.1 for at least one of the time points. 
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4.0 Results 
The overall goal of the present study was to identify biosignatures and molecular pathways affected 
by ketamine treatment. My results aid in the development of novel fast acting ADs with a similar 
mode of action as ketamine, but with fewer side effects.  
First, I investigated the fast antidepressant-like effects of a low dose of ketamine with the help of a 
behavioral test, FST. Next, I compared metabolite profiles of defined brain regions, the liver, and 
blood from drug- and vehicle-treated mice as well as mouse primary hippocampal neurons (PHN). In 
addition, the metabolomics results obtained from the HPC revealed biomarkers for ketamine’s 
antidepressant-like effects that aid in the development of fast acting ADs. I also investigated time-
dependent hippocampal proteome alterations between ketamine- and vehicle-treated mice and 
compared specific protein expression profiles based on the molecular pathways identified by 
metabolomics analyses. 
 
  
4.1 Investigating the antidepressant-like effect of ketamine through the FST 
To investigate ketamine’s fast antidepressant activity I chose the FST, the most widely used 
behavioral assay to study antidepressant-like effects in mice and rats. C57BL/6 wild-type mice were 
assessed at different time points with regard to the antidepressant-like FST floating behavior after 
receiving a single injection of a low dose of ketamine (3 mg kg−1; figure 7). In order to avoid any 
behavioral habituation, independent groups of mice were examined for their FST floating time. A 
two-way analysis of variance (ANOVA) showed no statistically significant interaction between the 
effects of treatment and different time points on the FST floating time.  
 
 
Figure 7: Antidepressant-like behavioral analysis of ketamine- (3 mg kg-1) and vehicle-treated wild-type mice. Passive 
floating behavior was measured using FST. Independent groups of mice were used for all time points to avoid behavioral 
habituation. The floating time was scored 2h (ketamine-treated animals: n=33, vehicle-treated animals: n=33), 14h 
(ketamine-treated animals: n=31, vehicle-treated animals: n=29), 24h (ketamine-treated animals: n=33, vehicle-treated 
animals: n=33) and 72h (ketamine-treated animals: n=31, vehicle-treated animals: n=29) after the respective treatment. 
Two-way analysis of variance (ANOVA) followed by Tukey’s honest significant difference (HSD) test, F(1,244)=58.75, p≤0.001 
for treatment groups; F(3,244)=7.59, p≤0.001 for duration of response; F(3,244)=1.77, p=0.15 for treatment-duration 
interaction. *: p≤0.05, **: p≤0.01, ***: p≤0.001. P-values were determined by two-way ANOVA and Tukey’s HSD test. Error 
bars represent s.e.m. 
 
The main effects analysis showed a significant reduction in FST floating time when comparing 
ketamine- with vehicle-treated animals and significant alterations for the different time points. 
Therefore, no treatment effects for the individual time points were examined. A Tukey’s honest 
significant difference (HSD) test revealed a statistically significant difference in FST floating time 
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between the 2h (ketamine-treated animals: n=33, vehicle-treated animals: n=33), 14h (ketamine-
treated animals: n=31, vehicle-treated animals: n=29) and 72h (ketamine-treated animals: n=31, 
vehicle-treated animals: n=29) time points, between the 14h and 24h (ketamine-treated animals: 
n=33, vehicle-treated animals: n=33) time points and between the 24h and 72h time points.  
Ketamine’s fast antidepressant-like effect is reflected on the behavioral level by the FST floating time. 
To determine the biomolecular effects of drug action I next analyzed time dependent metabolomics 
changes. 
 
 
4.2 Metabolomics profiling of ketamine treated mice and primary hippocampal neurons 
Alterations affecting the metabolome are a reflection of modified pathway activities in response to 
drug treatment430, 431. In the present study, C57BL/6 mice as well as PHN treated with a single low 
dose of ketamine (3mg kg-1 in mice and 100µM for PHN) were analyzed in order to identify affected 
biomolecular pathways and to assemble treatment biomarkers with the help of a sensitive 
metabolomics platform (for details, cf. chapter 3). Metabolomics profiling analyses of defined mouse 
brain regions, liver, blood, as well as mouse PHN were performed. The analyses are focused on the 
HPC and PFC as these brain regions are well known for their involvement in MDD pathobiology (for 
details, cf. chapter 1). Besides, the cerebellum (CRBL) was included as a brain region with no 
significant role in MDD pathobiology. I also acquired metabolomics data for blood plasma (BP) and 
the liver. On the basis of the obtained FST results (cf. section 4.1) 5 mice per group and time point 
were chosen for the metabolomics analyses. 
  
 
Figure 8: Cellular viability of mouse PHN treated with 22 different concentrations of ketamine measured with the MTT-
assay. The dotted line indicates cell viability without ketamine treatment. 
 
The ketamine concentration for PHN treatment was assessed with the MTT assay (figure 8). This 
colorimetric assay measures metabolic activity and thus indirectly cellular viability. PHN were treated 
with 22 different concentrations of ketamine for 24h and cellular viability was compared to 
control/non-treated PHN. Low doses of ketamine (≤80µM of ketamine) result in decreased cellular 
viability of ~60–70%. The cellular viability increases again with 80µM ketamine up to control levels. 
However, then the cellular viability decreases again with increased ketamine concentrations resulting 
in a very low metabolic rate and increased cell death (figure 8). Based on these results I treated PHN 
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with a low dose of 100µM of ketamine for 24h. Cell viability was still very high at ~80% and only 
slightly below that observed for control PHN.  
 
 
4.2.1 Comparative Metabolomics profiling of defined mouse brain regions, the liver, blood, 
and mouse primary hippocampal neurons 
A total of 228, 233, 243, 233, and twice 196 metabolites were quantified in the PHN 24h, CRBL 2h, 
liver 2h, PFC 2h, BP 2h and BP 24h, respectively (supplemental table 1). In comparison to univariate 
statistical analyses like the t-test, multivariate statistical analyses consider many dependent variables 
in contrast to a single one. Therefore, univariate statistical analyses are generally not recommended 
to be used when dealing with very large variable (here: metabolites) numbers since many 
metabolites would appear significant just by chance. Usually this issue can also be avoided in 
univariate statistical analyses with many dependent variables by multiple testing like Bonferroni 
correction. However, this method tends to be too conservative and therefore, I used multivariate 
statistical analyses taking all metabolites into account. I combined two different multivariate 
statistical methods in order to achieve robust metabolomics results.   
 
 
Figure 9: Multivariate partial least squares-discriminant analysis (PLS-DA) of (A) mouse primary hippocampal neurons 24h 
(PHN 24h), (B) cerebellum 2h (CRBL 2h), (C) liver 2h (Liver 2h), (D) prefrontal cortex 2h (PFC 2h), (E) blood plasma after 2h 
(BP 2h) and (F) 24h (BP 24h) after ketamine (3 mg kg-1 in animals and 100µM in mouse PHN) and vehicle treatment  or 
vehicle using all quantified metabolites. N=5 mice per group and time point. 
 
PHN 24h CRBL 2h Liver 2h 
PFC 2h BP 2h BP 24h 
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First, the metabolite profiles were analyzed by multivariate partial least squares-discriminant analysis 
(PLS-DA) and significance analysis of Microarrays and other –omics datasets (SAM). PLS-DA is a 
supervised statistical method suitable for analyzing and classifying metabolomics data. However, this 
method is prone to overfitting. To overcome this problem cross-validation is employed in order to 
assess the quality criteria of the PLS-DA. Therefore, especially the R2 and Q2 are calculated as they 
describe the goodness of fit or explained variation and the predicted variation or the quality of 
prediction, respectively. The values indicate how well the PLS-DA model is able to mathematically 
reproduce the data in the dataset. In general, a poorly and well fit model is described by R2 ~0.20-
0.30 and ~0.80-0.90, respectively. Furthermore, a good and outstanding model is defined by Q2 
values of ≥0.50 and ≥0.90, respectively. The quality criteria assessment by Q2 values only indicate 
good and robust PLS-DA models for PHN 24h (figure 9A and table 4) and the liver 2h (figure 9C and 
table 4). The metabolite profiles separated ketamine- from vehicle-treated mice and PHN using PLS-
DA (figure 9A-F). 
  
Table 4: Quality criteria assessment (R2, Q2, and accuracy values) of the multivariate data analyses using PLS-DA for mouse 
primary hippocampal neurons 24h (PHN 24h), cerebellum 2h (CRBL 2h), liver 2h, prefrontal cortex (PFC 2h), blood plasma 
2h and 24h (BP 2h and BP 24h) after ketamine (3 mg kg-1 in animals and 100µM in mouse PHN) and vehicle treatment. R2, 
Q2 and accuracy values indicate good (PHN 24h: R2=1.00, Q2=0.62, accuracy=1.00; Liver 2h: R2=0.84, Q2=0.55, 
accuracy=0.90) and weak models (CRBL 2h: R2=1.00, Q2=0.45, accuracy=0.80; PFC 2h: R2=1.00, Q2=0.49, accuracy=0.90; BP 
2h: R2=1.00, Q2=-0.29, accuracy=0.50; BP 24h: R2=0.95, Q2=0.20, accuracy=0.60). N=5 mice per group and time point. 
 
 
On the other hand the other models of CRBL 2h (figure 9B and table 4), PFC 2h (figure 9D and table 
4), BP 2h (figure 9E and table 4), and BP 24h (figure 9F and table 4) showed weak quality criteria 
which might therefore result in false-positives. Therefore, I restricted further statistical 
metabolomics profiling for PHN 24h and Liver 2h. For the identification of metabolite changes 
characteristic for group separation, the VIP-score was used. Metabolites with VIP-scores≥1.0 are 
considered important for group separation and were selected for subsequent data analysis. To 
further increase the robustness of the analyses, I combined the PLS-DA with results obtained from a 
SAM analysis, to determine a reliable list of metabolites that significantly contribute to ketamine 
drug action. SAM is a statistical method that was originally developed for mRNA expression analyses 
of microarrays. In the present study, 6 and 13 metabolites were statistically significant altered in PHN 
24h and liver 2h, respectively (table 5). In PHN 24h 3 metabolites were up- and downregulated 
whereas in the liver 2h all metabolites showed reduced levels.  
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Table 5: Metabolite alterations of (A) mouse primary hippocampal neurons (PHN) treated with ketamine (100µM) for 24h 
and (B) the liver from mice treated with ketamine (3 mg kg-1) 2h after treatment (PLS-DA VIP-score≥1.0, SAM FDR≤0.10 and 
SAM q≤0.10). N=5 mice per group and time point. 
 
 
Next, the statistically significant altered metabolites from PHN 24h and liver 2h were interrogated for 
overrepresented (enriched) molecular pathways. The alanine, aspartate, and glutamate metabolism 
was significantly enriched for PHN 24h (table 6A) whereas synthesis and degradation of ketone 
bodies was overrepresented for the liver 2h (table 6B).  
 
Table 6: Pathway enrichment analyses of significantly altered metabolites (PLS-DA VIP-score≥1.0, SAM FDR≤0.10, SAM 
q≤0.1) from (A) mouse primary hippocampal neurons treated with ketamine (100µM) for 24h (PHN 24h) and (B) the liver 2h 
after a single injection of ketamine (3 mg kg-1). N=5 mice per group and time point. 
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4.2.1 Time-dependent metabolomics profiling of the hippocampus 
The HPC plays a fundamental role in learning and memory which are affected in MDD. 
Antidepressant drug activity is dependent and mediated by synaptic plasticity mechanisms through 
the glutamatergic system, involving the NMDAR, BDNF, and the activation of synaptic protein 
synthesis mediated by mTORC1. The time-dependent hippocampal metabolite profiles 2h, 14h, 24h, 
and 72h after a single injection of a low dose of ketamine (3 mg kg-1) were analyzed. 
A total of 226, 218, 227, and 221 metabolites were quantified in the HPC for the 2h, 14h, 24h, and 
72h time points, respectively, after a single injection of ketamine (supplemental table 2). 
The metabolite profiles separated ketamine- from vehicle-treated mice using multivariate PLS-DA for 
all time points (figure 10A-D). The quality criteria (figure 10E) of PLS-DA models were assessed for R2, 
Q2 and accuracy values. The time-dependent metabolomics profiling analyses revealed good and 
robust models for the 2h, 14h, and 24h time points, respectively, but not at the 72h time point. The 
weak PLS-DA model of the 72h time point can result in false positives. Nevertheless, the results were 
included as they are an indication of ketamine’s fast antidepressant-like effect on the metabolome.  
 
 
    2h                  14h                         
    24h                      72h                  
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Figure 10: Multivariate partial least squares-discriminant analysis (PLS-DA) of (A) 2h, (B) 14h, (C) 24h and (D) 72h time 
points comparison after a single injection of a low dose of ketamine (3 mg kg-1) or vehicle using all quantified metabolites. 
E) Quality criteria assessment (R2, Q2 and accuracy values) of the multivariate data analyses using PLS-DA for the 2h, 14h, 
24h and 72h time points indicating good (2h: R2=0.99, Q2=0.60, accuracy=1.0; 14h: R2=1.0, Q2=0.63, accuracy=1.0) and 
robust (24h: R2=0.92, Q2=0.52, accuracy=0.8) models with the exception of the 72h time point (R2=1.0, Q2=0.29, 
accuracy=0.6). N=5 mice per group and time point.  
 
For the identification of metabolite changes characteristic for group separation, the VIP-score with 
values ≥ 1.0 was selected and used for further data analysis. To increase the robustness of the 
analyses, I again combined the PLS-DA with SAM analysis, to obtain a complete list of metabolites for 
each time point that significantly contribute to ketamine drug action (table 7).  
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Table 7: Hippocampal metabolite alterations (A) 2h, (B) 14h and (C) 24h after a single injection of a low dose of ketamine (3 
mg kg-1) (PLS-DA VIP-score≥1.0, SAM FDR≤0.10 and SAM q≤0.1). N=5 mice per group and time point. 
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Two hours after a single injection of ketamine 45 metabolite levels were significantly altered, with 21 
metabolites reduced and 24 metabolites upregulated when comparing ketamine- with vehicle-
treated mice (table 7A). For the 14h and 24h time points, 22 (table 7B) and 11 (table 7C) metabolites, 
respectively, were detected at lower levels. In agreement with the observation that the PLS-DA 
model of the 72h time point is not robust, no significant metabolite alterations were found 72h after 
ketamine treatment. 
 
Next, I examined the statistically significantly altered metabolites obtained by the time-dependent 
metabolomics analyses of the HPC and performed pathway enrichment analyses for KEGG pathways 
in order to delineate affected hippocampal biomolecular pathways that are affected by ketamine 
treatment. A single injection of ketamine significantly enriched the pyrimidine metabolism, the 
glycolysis/ gluconeogenesis, the alanine, aspartate and glutamate metabolism, the pentose 
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phosphate pathway, the citrate cycle, the glycine, serine and threonine metabolism and the pyruvate 
metabolism (table 8).  
 
Table 8: Pathway enrichment analysis for KEGG pathways of significantly altered hippocampal metabolites (PLS-DA VIP-
score≥1.0, SAM FDR≤0.10 and SAM q≤0.1) 2h, 14, and 24h after a single injection of ketamine. N=5 mice per group and time 
point. 
 
 
 
 
All 7 pathways that are statistically significantly enriched are interconnected by shared metabolites 
based on KEGG database information (figure 11). Several previous analyses by Turck’s research group 
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and others have also shown an involvement of the citrate cycle and glycolysis in psychiatric 
phenotypes and antidepressant drug action432-434.  
 
 
Figure 11: Metabolic KEGG pathways overview highlighting (blue) enriched pathways, calculated based on significantly 
altered hippocampal metabolites illustrated in either pink (increased fold change (FC) or black (decreased FC) dots  (PLS-DA 
VIP-score≥1.0, SAM FDR≤0.10, SAM q≤0.1) upon ketamine treatment (3 mg kg-1) at 2h, 14h, 24h and 72h time points (cf. 
table 7 and table 8). Citrate cycle, glycolysis/gluconeogenesis, pentose phosphate pathway, serine, glycine and threonine 
metabolism and pyrimidine metabolism are interconnected by a shared metabolite in the metabolic KEGG pathway 
network. Modified pathways are based on http://www.genome.jp/kegg/. N=5 mice per group and time point. 
The glycolysis and the citrate cycle take place in the cytoplasm and the mitochondria, respectively. 
These pathways consist of a series of biochemical reactions to generate high levels of energy in form 
of adenosine triphosphate (ATP) through the connected oxidative phosphorylation (OXPHOS) 
pathway. The citrate cycle is connected to the OXPHOS through SDHA, the enzyme metabolizing 
succinate to fumarate. This process is also known as mitochondrial respiration and consists of 5 
complexes. These are integrated into the mitochondrial inner membrane and transport electrons 
from NADH+H+ and succinate from the complexes I and II, respectively. The electron transport is 
driven by pumping H+ from the mitochondrial matrix into the intermembrane space of the 
mitochondria resulting in a mitochondrial membrane potential creating an electrochemical gradient. 
The energy is then used by complex V to produce ATP from adenosine diphosphate (ADP) by 
releasing H+ back into the mitochondrial matrix435.  
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Figure 12: Citrate cycle and glycolysis metabolite levels and metabolite ratios analyses upon ketamine treatment (3 mg kg-1) 
of 2h, 14h, 24h, and 72h time points. A) Citrate cycle and (B) glycolysis time course showing metabolite FC and metabolite 
ratios. Metabolite ratios are indicated by boxes. Each box represents a time point (from left to right 2h, 14h, 24h, and 72h). 
Significant metabolite ratio differences or trends are illustrated in pink (increased ratio) and black (decreased ratio). N=5 
mice per group and time point. #p≤0.10, *p≤0.05, **p≤0.01. P-values were determined by Student’s t-test and SAM.  
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Already 2h after a single injection of ketamine, the levels of the citrate cycle metabolites thiamine 
pyrophosphate, acetyl-CoA and succinate were significantly increased. Succinate-CoA showed a high, 
but not significant fold change (FC) 2h after ketamine treatment. Fumarate levels were significantly 
reduced 2h after ketamine injection as were malate levels for the 2h and 14h time points.  
Isocitrate tended to be downregulated and citrate levels were lower, albeit with no significant FC 2h 
after a single injection of ketamine. Oxaloacetate and alpha-ketoglutarate levels were unchanged 
(figure 12A and table 7 and table 8).  
The glycolysis/gluconeogenesis pathway was also enriched upon ketamine treatment. Almost all 
quantified metabolites were significantly altered 14h after a single injection of ketamine (figure 12B 
and table 4 and table 5). Glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-bisphosphate and 
dihydroxy-acetone-phosphate were significantly downregulated. In contrast, 3-phosphoglycerate 
was significantly upregulated at the 2h and 14h time points; phosphoenolpyruvate levels were found 
to be significantly upregulated 2h after ketamine treatment and pyruvate was unchanged.  
Selected pairs of metabolite concentrations (metabolite ratios) can indicate alterations in enzyme 
activity or expression rate436. Citrate cycle and glycolysis metabolite ratios (figure 12 and figure 13) 
are indicated by boxes, where each box represents a single time point (from left to right 2h, 14h, 24h, 
and 72h). Statistical significance or trends of metabolite ratio differences are illustrated in pink 
(increased ratio) and black (decreased ratio). The citrate/acetyl-CoA ratio is significantly decreased 
2h after ketamine treatment. The alpha-ketoglutarate/isocitrate metabolite ratio tended to be 
increased at the 2h and 24h time points and the fumarate/succinate ratio tended to be lower at 2h 
and was significantly decreased 14h after a single injection of ketamine (figure 12A and figure 13A). 
The fructose-6-phosphate/glucose-6-phosphate ratio tended to be elevated 14h after ketamine 
treatment. The fructose-1,6-phosphate/fructose-6-phosphate metabolite ratio showed a significant 
decrease at the 72h time point. However, as the PLS-DA only yielded a weak model for this time 
point, the decreased fructose-1,6-phosphate/fructose-6-phosphate metabolite ratio could be a false 
positive finding. The glyceraldehyde-3-phosphate/dihydroxy-acetone-phosphate and 
phosphoglycerate/glyceraldehyde-3-phosphate ratios were significantly increased 14h after a single 
injection of ketamine and tended to be upregulated at the 24h time point. The 3-
phosphoglycerate/phosphoenolpyruvate and pyruvate/phosphoenolpyruvate ratios were either 
significantly lower or tended to be lower, respectively (figure 12B and figure 13B). 
 
64 
 
 
 
Figure 13: Metabolite ratio analyses of (A) the citrate cycle and (B) the glycolytic pathway. Ratios for selected pairs of 
metabolites (metabolite ratios) were calculated indicating alterations of enzyme activity or protein expression. N=5 mice 
per group and time point. #p≤0.10, *p≤0.05, **p≤0.01. P-values were determined by Student’s t-test and SAM.  
 
The altered fumarate/succinate ratio is of particular interest as the enzymatic succinate 
dehydrogenase subunit A (SDHA) of the complex II metabolizes these metabolites and therefore also 
connects the citrate cycle with the OXPHOS. Furthermore, fumarate as well as the succinate 
metabolite intensities strongly correlated with the FST floating time at the 2h time point (figure 14A). 
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Thus, I hypothesized that the SDHA and most probably also the other complexes of the OXPHOS are 
involved in ketamine’s antidepressant effect. Time-dependent Western blots with an antibody 
against the SDHA were performed in order to validate that changes in the fumarate/succinate ratio is 
a result of protein level alterations. The Western blot analyses show that SDHA protein levels are 
indeed statistically significant increased 14h and 24h after a single injection of ketamine (figure 14B).   
 
    
Figure 14: Time-dependent hippocampal protein and metabolite level, metabolite ratio and correlation analyses after a 
single injection of a low dose of ketamine (3 mg kg-1). A) Correlation analyses of fumarate and succinate with the FST 
floating time 2h after a single injection of ketamine (p≤0.05). B) SDHA Western blot analyses of the 2h (ketamine-treated, 
n=4; vehicle-treated, n=5), 14h (ketamine-treated, n=5; vehicle-treated, n=4), 24h (ketamine-treated, n=5; vehicle-treated, 
n=5), and 72h (ketamine-treated, n=5; vehicle-treated, n=3) time points. C) ATP, GTP, and NADH levels after a single 
injection of ketamine. D) Correlation analyses of ATP (24h, p≤0.05), NADH (14h, not significant) and GTP (2h and 24h, 
p≤0.05) with the FST floating time after a single injection of ketamine. The results from ketamine-treated animals are 
normalized to the ones obtained from vehicle treatment (mean value = 1). N=5 mice per group and time point. #p≤0.10, 
*p≤0.05, **p≤0.01. P-values were determined by Student’s t-test. Error bars represent s.e.m. The correlation coefficient, r, 
was calculated by Pearson. The linear regression line is only shown for significant (p≤0.05) correlation coefficients. 
(2h) 
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GTP is metabolized through the transformation of succinate-CoA to succinate435. Therefore, the 
observed elevated complex II SDHA as well as succinate levels might also impact on the energy 
status. When comparing ketamine- to vehicle-treated mice, ATP levels decrease 24h after a single 
injection of ketamine, NADH levels tend to increase at the 14h time point and GTP levels first 
increase and then tend to decrease at the 2h and 24h time points (figure 14C). Moreover, GTP 
metabolite intensities significantly correlated with the FST floating time at the 2h time point and ATP 
and GTP also 24h after ketamine treatment. Whereas NADH metabolite intensities did not correlate 
with the antidepressant-like behavior (figure 14D). 
 
 
4.2.3 Biomarker discovery for ketamine’s antidepressant-like effects  
Biomarkers can be differentiated into diagnostic and treatment biomarkers; thus either 
distinguishing between a health and disease state/ subtype or a biosignature for a specific treatment 
effect. Moreover, biomarkers could aid in drug development, providing a specific biosignature of a 
drug effect.  
I attempted to identify metabolite biomarkers for a low dose ketamine treatment response. PLS-DA 
models can be used for biomarker discovery as they rate the metabolite's relevance via the VIP-
score. When PLS-DA for the 2h, 14h, 24h, and 72h time points were assessed for quality criteria 
(figure 10E) all R2, Q2, and accuracy values indicate good and robust models, with the exception of 
the 72h time point (cf. section 4.2.1). Based on these results we chose metabolites that are 
important and stable contributors to group separation with a consistent VIP-score≥1.0 for the 2h, 
14h, and 24h time points and with q≤0.10 for at least one of the time points. This resulted in 7 
potential metabolite biomarkers: 2-keto-isovalerate, glutathione, maleate, methylmalonate, 
sedoheptulose-7-phosphate, fumarate and cytosine – candidates for ketamine drug action (figure 
15).  
 
 
Figure 15: Identification of important metabolites and treatment biomarker candidates contributing to ketamine drug 
action. Quality criteria (R², Q², and accuracy) assessment of the multivariate data analyses using PLS-DA for the 2h, 14h, 
24h, and 72h time points of ketamine treatment (3 mg kg-1). R2, Q2, and accuracy values indicate good (2h: R2=0.99, 
Q2=0.60, accuracy=1.0; 14h: R2=1.0, Q2=0.63, accuracy=1.0) and robust (24h: R2=0.92, Q2=0.52, accuracy=0.8) models with 
the exception of the 72h time point (R2=1.0, Q2=0.29, accuracy=0.6). Important metabolites showed a VIP-score≥1.0 for the 
first three time points and q≤0.1 for at least one time point. N=5 mice per group and time point. 
 
In order to verify biomarker candidates for the antidepressant effect of ketamine, I compared these 
biomarker candidates to data from a previous metabolomics profiling study of mice treated with the 
SSRI Paroxetine by Webhofer et al. In this study the antidepressant-like effect measured by the FST 
became significantly apparent as expected after a chronic treatment for 24 days432. I re-analyzed the 
metabolomics data obtained from Paroxetine-treated animals and compared the FC, VIP-score, and 
q-values of the biomarker candidates from the present study for ketamine treatment.  
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Figure 16: Identification of treatment biomarker candidates for ketamine’s antidepressant-like mode of action. Biomarker 
candidates for ketamine treatment (cf. figure 15) were compared to re-analyzed data obtained by Webhofer et al432. In this 
study, metabolomics profiling of mice treated with the SSRI antidepressant Paroxetine was performed. The re-analyzed 
metabolomics data from mice treated with Paroxetine was then compared to the FC, VIP-score, and q-values of the 
biomarker candidates obtained in the present study for ketamine treatment. A) FC comparison of treatment biomarkers of 
Paroxetine- and ketamine-treated animals compared to vehicle-treated mice. B) Q-value and VIP-score comparison of 
treatment biomarker candidates of Paroxetine- and ketamine-treated animals. Important metabolites showing VIP-
score≥1.0 for the first three time points and q≤0.1 for at least one time point. N=5 mice per group and time point. *p≤0.05, 
**p≤0.01. P-values were determined by Student’s t-test and SAM. 
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3 out of the 7 biomarker candidates obtained from the present metabolomics profiling study of 
ketamine-treated animals (2-Keto-isovalerate, maleate, and fumarate) showed similar FCs (figure 
16A), VIP-scores, and significant q-values (figure 16B) in the time-dependent metabolomics analyses 
of Paroxetine treatment. The q-values of the biomarkers for ketamine’s antidepressant-like effect are 
small (q≤0.10) for the 2h time point and time-dependently increase with the highest value at the 72h 
time point.  
In contrast, with Paroxetine treatment it takes 2 to 4 weeks for the same biomarker candidates  to 
reach the same effect that are seen within hours for ketamine treatment (figure 16B),  reflecting the 
fast antidepressant-like effect of the latter on the biomolecular level. A VIP-score≥1.0 is observed at 
earlier time points in ketamine-treated animals and decreases over time whereas in Paroxetine-
treated animals it takes weeks of the treatment to see the increase (figure 16B). Taken together, 7 
biomarkers qualify as treatment biomarkers for ketamine’s drug response in the HPC. Out of these 7 
biomarkers, 3 also qualify as treatment biomarkers for the antidepressant-like effect of ketamine. 
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4.3 Time-dependent hippocampal proteome profiling 
In addition to the time-dependent HPC metabolome analyses, I performed quantitative proteome 
profiling analyses 2h and 24h after a single injection of a low dose of ketamine (3 mg kg-1). Five mice 
per time point and treatment group were chosen based on the FST results (cf. section 4.1). 
Membrane-associated (MF) and cytoplasmic (CF) proteins from ketamine- and vehicle-treated mice 
2h and 24h after ketamine treatment were isolated from the HPC and quantified relatively with 15N 
metabolic labelled reference proteins by LC-MS/MS analyses.  
 
 
 
Figure 17: Multivariate partial least squares-discriminant analysis (PLS-DA) of (A) membrane-associated (MF2h) and (B) 
cytoplasmic (CF2h) proteins of the 2h time point and (C) membrane-associated (MF24h) and (D) cytoplasmic (CF24h) 
proteins of the 24h time point after a single injection of a low dose of ketamine (3 mg kg-1) or vehicle using all quantified 
proteins. N=5 mice per group and time point.  
 
After proteomics data processing and missing value imputation (cf. section 4.4), a total of 889 
hippocampal MF and 1173 CF proteins were processed by statistical analyses 2h after a single 
injection of ketamine. 24h after ketamine treatment 1550 MF and 1091 CF relatively quantified 
proteins were used for further statistical analyses (supplemental table 3). The protein profiles 
    MF2h                  CF2h                   
    MF24h                      CF24h                  
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allowed a separation of ketamine- and vehicle-treated mice using multivariate PLS-DA at both time 
points (figure 17A–D). 
 
Table 9: Quality criteria assessment (R2, Q2, and accuracy values) of the multivariate data analyses using PLS-DA for 
membrane-associated (MF2h) and cytoplasmic (CF2h) proteins 2h after ketamine and vehicle treatment. R2, Q2 and 
accuracy values indicate good (MF2h: R2=0.99, Q2=0.60, accuracy=1.00; CF2h: R2=1.00, Q2=0.64, accuracy=1.00) and for 
MF24h and CF24h weak models (MF24h: R2=0.90, Q2=0.43, accuracy=0.90; CF24h: R2=0.99, Q2=0.14, accuracy=0.70). N=5 
mice per group and time point. 
 
 
The quality criteria of PLS-DA models were assessed by accuracy, R2, and Q2 values. They indicate 
good models for the 2h time point in both analyses of MF and CF proteins of ketamine- compared to 
vehicle-treated animals. However, the PLS-DA models were weak for the 24h time point, which might 
therefore result in false-positives (table 9).  
To increase the robustness of the statistical analyses, I additionally combined the VIP-score of the 
PLS-DA with SAM analyses, to obtain a reliable list of proteins for MF and CF at the 2h time point, 
that statistically significant contribute to ketamine’s antidepressant action. 61 MF and 95 CF proteins 
were statistically significant altered at the 2h time point when comparing ketamine- to vehicle-
treated mice (table 10).  
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Table 10: Hippocampal (A) membrane-associated (MF) and (B) cytoplasmic protein (CF) alterations 2h after a single 
injection of a low dose of ketamine (3 mg kg-1) (PLS-DA VIP-score≥1.0, SAM FDR≤0.10 and SAM q≤0.1). N=5 mice per group 
and time point. 
 
 
72 
 
 
 
 
 
73 
 
 
 
 
4.3.1 Ketamine’s effect on the glutamatergic and GABAergic system 
It is assumed that ketamine’s antidepressant activity is the result of the drug’s blocking of the 
NMDAR on GABAergic inhibitory interneurons thereby indirectly resulting in an increased synaptic 
activity of glutamatergic excitatory neurons.  
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Figure 18: Hippocampal protein level and correlation analyses after a single injection of a low dose of ketamine (3 mg kg-1). 
A) Alterations of GABAA receptor α1 (GABAARα1), and AMPA receptor subunits Gria2 and Gria3 protein levels determined 
by quantitative proteomics analyses 2h after ketamine treatment. B) Correlation analyses of GABAARα1, Gria2 and Gria3 
protein intensities with the FST floating time (p p≤0.05). C) Western blots analysing of GABAAR1 and NMDAR1 protein levels 
2h, 14h, 24h, and 72h after a single injection of ketamine. D) CaMKII alpha and PKC gamma protein levels were analyzed by 
Western blots for the 2h, 14h, 24h, and 72h time points. The results from ketamine-treated animals are normalized to the 
ones obtained from vehicle treatment (mean value = 1). N=5 mice per group and time point. #p≤0.10, *p≤0.05, **p≤0.01, 
***p≤0.001. P-values were determined by Student’s t-test and SAM. Error bars represent s.e.m. The correlation coefficient, 
r, was calculated by Pearson. The linear regression line is only shown for significant (p≤0.05) correlation coefficients. 
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Alternatively, ketamine’s antidepressant effect may result from blocking the NMDAR on the 
glutamatergic excitatory neurons directly, which, subsequently, stimulates a homeostatic mechanism 
in the neuronal network trying to keep the original neuronal network activity (cf. chapter 1). In this 
regard it is interesting to observe that ketamine downregulates GABAARα1 and the AMPA receptor 
subunit Gria3 protein levels, while increased AMPA receptor subunit Gria2 protein levels are found 
for the 2h time point (table 10 and figure 18A). Moreover, these proteins also significantly correlated 
with the FST floating time (figure 18B). The results were further validated by Western blots which 
showed decreased but not statistically significant GABAAR1 protein level changes. The observed 
changes on the glutamatergic receptors seem not to affect NMDAR receptors as Western blot 
analysis did not show any changes in NMDAR1 protein levels for all time points (figure 18C). 
Ca2+/Calmodulin-dependent protein Kinase (CaMKII) alpha and Protein Kinase C (PKC) gamma 
mediate AMPA receptor internalization into the synaptic membrane, a mechanism involved in 
synaptic plasticity such as LTP437.  Ketamine statistically significant increased and tended to decrease 
CaMKII alpha protein levels 24h and 72h after ketamine treatment, respectively (figure 18C). PKC 
gamma protein levels tended to increase at the 2h and 14h time points and statistically significant 
decreased 24h after a single injection of ketamine (figure 18D). The observed changes related to the 
AMPARs are contradictory to the decreased GABAAR, altered CaMKII alpha and PKC gamma protein 
levels. They might indicate an induction of synaptic or homeostatic plasticity.  
 
Synaptic plasticity, especially LTP, is promoted by glutamate that is released into the synaptic cleft 
upon neuronal activity. Once released, glutamate for instance binds and activates AMPARs and 
NMDARs. In contrast, GABA release into the synaptic cleft by GABAergic inhibitory interneurons 
inhibits neuronal activity and therefore also synaptic plasticity. Glutamate and GABA are metabolized 
by glutamine (cf. chapter 1). Therefore, I examined the metabolite ratios and levels of glutamate, 
glutamine and GABA. When analyzing neurotransmitter ratios I found the GABA/glutamate ratio to 
be increased 72h after a single injection of ketamine (figure 19A). At 14h the glutamate/glutamine 
and GABA/glutamine metabolite ratios were increased (figure 19A). GABA levels were upregulated at 
72h (figure 19B). For the 14h time point glutamate and glutamine levels were decreased (figure 19B). 
Putrescine and serine levels, two positive modulators of the NMDAR438, 439, were elevated already 2h 
after a single injection of ketamine (figure 19C). Furthermore, GABA, glutamate, glutamine, 
putrescine and serine metabolite intensities statistically significant correlated with the FST floating 
time at the 72h, 14h and 2h time points, respectively (figure 19D). 
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Figure 19: Hippocampal metabolite ratio and metabolite level analyses after a single injection of a low dose of ketamine (3 
mg kg-1). A) Glutamate/GABA, glutamate/glutamine and GABA/glutamine metabolite ratio analyses determined by time-
dependent metabolomics profiling analyses. B) Time-dependent metabolite levels of GABA, glutamate, and glutamine. C) 
Time-dependent metabolite level changes of NMDAR positive modulators putrescine and serine. D) Correlation analyses of 
GABA (72h, p≤0.05), glutamate (14h, p≤0.05), glutamine (14h, p≤0.05), putrescine (2h, p≤0.05) and serine (2h, p≤0.05) 
metabolite intensities with the FST floating time. The results from ketamine-treated animals are normalized to the ones 
obtained from vehicle treatment (mean value = 1). N=5 mice per group and time point. *p≤0.05, **p≤0.01. P-values were 
determined by Student’s t-test and SAM. Error bars represent s.e.m. The correlation coefficient, r, was calculated by 
Pearson. The linear regression line is only shown for significant (p≤0.05) correlation coefficients. 
 
A loss of HPC volume has been observed for a subset of MDD patients. This process can be reversed 
by AD treatment which also results in symptom reduction. The volume decline seems to be caused by 
neuronal atrophy due to weakened and shrunk synaptic connections and seems to be caused by 
stress. The observed reversal of the volume reduction in MDD patients might result from increased 
synaptic plasticity (cf. chapter 1).  
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Figure 20: Hippocampal protein level analyses after a single injection of a low dose of ketamine (3 mg kg-1). Time-
dependent Western blots for MBP (n=5 mice per group and time point) and MOG (2h: ketamine-treated, n=4; vehicle-
treated, n=4; 14h: ketamine-treated, n=5; vehicle-treated, n=5; 24h: ketamine-treated, n=5; vehicle-treated, n=5; 72h: 
ketamine-treated, n=5; vehicle-treated, n=5). The results from ketamine-treated animals are normalized to the ones 
obtained from vehicle treatment (mean value = 1). #p≤0.10, *p≤0.05, **p≤0.01, ***p≤0.001. P-values were determined by 
Student’s t-test. Error bars represent s.e.m. 
 
The myelin sheath is a protective lipid layer around axons, but not the cell body, produced by glial 
cells supporting fast neuronal signaling minimizing a loss of information440. Therefore, a reversal of 
the volume reduction observed in a subset of treated MDD patients caused by synaptic plasticity 
with an outgrowth of synaptic connections should result in an elevated number of myelin proteins. 
On one hand, a low dose of ketamine has previously been shown to induce synaptic plasticity 
apparent by newly formed spines in the PFC of rats (cf. chapter 1). On the other hand, when applied 
at higher doses ketamine is also used as an animal model of schizophrenia where a loss of the myelin 
sheath is discussed254-257. Western blots were conducted for two myelin proteins to gauge their 
response to ketamine. As expected, ketamine treatment increases myelin basic protein (MBP) levels 
already 2h and 24h after a single injection (figure 20). Myelin oligodendrocyte glycoprotein (MOG) 
protein levels tended to be elevated at the 2h and 72h time points (Figure 20). Therefore, I can rule 
out that the low dose of ketamine that was used in this study produces molecular alterations 
characteristic for schizophrenia like decreased myelin proteins441, 442. 
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4.3.2 Ketamine’s impact on the mitochondrial energy metabolism, protein damage and 
quality control system 
Several previous analyses and the present study show an impact of major energy metabolism 
pathways like glycolysis, pyruvate metabolism, citrate cycle and the OXPHOS on psychiatric disorders 
and AD drug action432-434.  
Pathway enrichment analyses for the altered HPC proteins highlight protein processing in 
endoplasmic reticulum, purine, ribosome, fructose, and mannose metabolism, as expected the 
OXPHOS, and proteasome (table 11). Furthermore, the altered proteins and identified pathways are 
in line with the metabolomics profiling results of an affected mitochondrial energy metabolism, 
especially pointing towards an altered OXPHOS (figures 12, 13 and 14 and tables 10 and 11). 
 
Table 11: Pathway enrichment analysis for KEGG pathways of significantly altered hippocampal proteins (PLS-DA VIP-
score≥1.0, SAM FDR≤0.10, and SAM q≤0.10) 2h after a single injection of a low dose of ketamine (3 mg kg-1). N=5 mice per 
group and time point. 
 
 
A low dose of ketamine elevated several OXPHOS protein complexes protein levels including complex 
I NADH dehydrogenase [ubiquinone] flavoprotein 2 (Ndufv2), Cytochrome c1, heme protein (Cyc1), 
and complex I assembly factor (Tmem126B) and lead to decreased levels of NADH dehydrogenase 
[ubiquinone] complex I, assembly factor 7 (Ndufaf7) 2h after a single injection of ketamine (table 10 
and figure 21A). Furthermore, the Ndufv2, Cyc1, Ndufaf7 and Tmem126B protein intensities also 
significantly correlated with the FST floating time (figure 21B). In addition, Western blot analyses 
revealed that the complex II succinate dehydrogenase subunit B (SDHB) and complex III ubiquinol-
cytochrome C reductase core protein II (Uqcrc2) are upregulated 14h and 24h after ketamine 
treatment, respectively. In contrast, NADH dehydrogenase [ubiquinone] 1 beta subcomplex, 8 
(Ndufb8) and ATP synthase, subunit alpha (ATP5a) did not show any differences at the 14h and 24h 
time points (figure 21C). 
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Figure 21: Hippocampal protein level analyses 2h after a single injection of a low dose of ketamine (3 mg kg-1) of (A) the 
OXPHOS protein levels Ndufv2, Cyc1, Ndufaf7, and Tmem126B, determined by quantitative proteomics profiling analyses. 
B) Correlation analyses of Ndufv2, Cyc1, Ndufaf7, and Tmem126B protein intensities with the FST floating time 2h after a 
single injection of ketamine (p≤0.05). C) Western blot analyses of Ndufb8, SDHB, Uqcrc2, and ATP5a protein levels 14h and 
24h after ketamine treatment. The results from ketamine-treated animals are normalized to the ones obtained from vehicle 
treatment (mean value = 1). N=5 mice per group and time point. *p≤0.05, **p≤0.01, ***p≤0.001. P-values were determined 
by t-test and SAM. Error bars represent s.e.m. The correlation coefficient, r, was calculated by Pearson. The linear 
regression line is only shown for significant (p≤0.05) correlation coefficients. 
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I further investigated the consequences of the observed protein level changes related to the OXPHOS 
protein complexes on the associated energy equivalents: ATP, ADP, NADH, NAD, GTP, and GDP. The 
ATP/ADP metabolite ratio tends to be down for both time points (figure 22A). The metabolite levels 
of both ATP and ADP showed no significant differences for the 2h time point, but a statistically 
significant decrease for both metabolite levels 24h after ketamine treatment (figure 22B). Neither 
the NADH/NAD metabolite ratio nor the NADH and NAD metabolite levels are statistically significant 
altered after ketamine treatment (figures 22A and 22B). A single injection of ketamine statistically 
significant increases the GTP/GDP metabolite ratio at 2h, but it tends to decrease at the 24h time 
point (figure 22A). In line with this observation, GTP metabolite levels were statistically significant 
increased 2h and also tend to decrease 24h upon ketamine treatment, whereas the GDP levels do 
not show any significant differences at any time point (figure 22B). Moreover, correlation analyses of 
ATP, ADP and GTP for the respective time points where significant metabolite level alterations were 
found revealed that they significantly correlated with the FST floating time (figure 22C). 
 
 
81 
 
 
Figure 22: Time-dependent hippocampal metabolite ratio and metabolite level analyses. A) ATP/ADP, NADH/NAD, and 
GTP/GDP metabolite ratio analyses of the 2h and 24h time points determined by time-dependent metabolomics profiling 
analyses. B) Time-dependent ATP, ADP, NADH, NAD, GTP, and GDP levels at the 2h and 24h time points. C) Correlation 
analyses of ATP (2h, not significant; 24h, p≤0.05), ADP (2h, not significant; 24h, p≤0.05), GTP (2h and 24h, p≤0.05) and GDP 
(2h and 24h, not significant) with the FST floating time. The results from ketamine-treated animals are normalized to the 
ones obtained from vehicle treatment (mean value = 1). N=5 mice per group and time point. #p≤0.10, *p≤0.05, **p≤0.01. P-
values were determined by Student’s t-test and SAM. Error bars represent s.e.m. The correlation coefficient, r, was 
calculated by Pearson. The linear regression line is only shown for significant (p≤0.05) correlation coefficients. 
 
Synaptic plasticity, especially LTP, is a process of high ATP consumption. AMP activated protein 
Kinase (AMPK) is the major energy status sensor that promotes catabolic pathways to generate ATP 
and inhibits anabolic pathways that consume ATP. AMPK is activated by high AMP and ADP levels 
whereas increased levels of ATP inhibit AMPK443-449. I time-dependently analyzed AMPK protein levels 
as well as the phosphorylation (active state of AMPK) status of the protein kinase (pAMPK) by 
Western blots. The overall AMPK protein levels stay relatively constant at a slightly lowered level, 
however statistically this only reaches trend level at 14 and 24h (figure 23A). PAMPK protein levels 
statistically significant increase at the 24h time point (figure 23A), ultimately leading to an elevated 
ratio of pAMPK/AMPK 24h after a single injection of ketamine (figure 23B). Activation of the AMPK 
leads to the conclusion that ketamine treatment results in an energy deficit that needs to be 
regulated by promoting catabolic pathways443-451. In general, neurons either might cope with higher 
energy demands by increasing mitochondrial proteins as shown by the obtained results (cf. figure 
21), the number of mitochondria, also termed mitochondrial biogenesis and/or by regulating the 
local position of mitochondria to the synapses where energy is needed.   
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Figure 23: Hippocampal protein level analyses after a single injection of a low dose of ketamine (3 mg kg-1). A) Time-
dependent Western blot analysis of AMPK and pAMPK protein levels. B) Ratio of the pAMPK to AMPK protein levels to 
determine the activated related to the non-activated form of the enzyme. The results from ketamine-treated animals are 
normalized to the ones obtained from vehicle treatment (mean value = 1). N=5 mice per group and time point. #p≤0.10, 
*p≤0.05. P-values were determined by Student’s t-test. Error bars represent s.e.m. 
 
Mitochondrial biogenesis is achieved by an elevation of mitochondrial transcription factors ultimately 
resulting in elevated mitochondrial protein levels, especially for the mitochondrial ETC complexes of 
the OXPHOS. Mitochondrial proteins are not only expressed in the nucleus, but also in the 
mitochondria as they contain their own mitochondrial DNA. Nuclear encoded mitochondrial proteins 
are transcribed in the nucleus, the mRNA is then transported and imported into the mitochondria 
where they are finally translated452-454.  I therefore analyzed mitochondrial transcription factors and 
mitochondrial import protein levels by Western blots. The peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC1α) protein levels tended to be decreased in the cytoplasm 
2h after a single injection of ketamine.     
 
 
Figure 24: Hippocampal protein level analyses after a single injection of a low dose of ketamine (3 mg kg-1). A) Time-
dependent Western blot analyses of PGC1α and Tfam protein levels. B) Time-dependent Western blot analysis of TIM23 
protein levels. The results from ketamine-treated animals are normalized to the ones obtained from vehicle treatment 
(mean value = 1). N=5 mice per group and time point. #p≤0.10, *p≤0.05, P-values were determined by Student’s t-test. Error 
bars represent s.e.m. 
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Mitochondrial transcription factor A (Tfam) protein levels were statistically significant reduced at the 
72h time point (figure 24A). No protein level changes were observed for the mitochondrial import 
protein translocase of inner membrane 23 (TIM23) (figure 24B).  
Oxidative stress describes an imbalance in the amount of reactive oxygen species (ROS) and the 
cellular defense system including molecules like antioxidants and enzymes such as Peroxiredoxins 
(Prdxs). Both, the antioxidants and the Prdxs have an antioxidant capacity and counteract ROS455-459.  
Therefore, I next analyzed the effects of the altered OXPHOS protein levels on oxidative stress.  I 
performed Western Blots of cytoplasmic Prdx1 and mitochondrial Prdx3 and analyzed the total 
antioxidant capacity (TAC) 2h, 14h, 24h, and 72h after a single injection of a low dose of ketamine (3 
mg kg-1). Cytoplasmic Prdx1 protein levels were statistically significant downregulated at the 2h time 
point. Furthermore, the mitochondrial Prdx3 protein levels were reduced 72h after ketamine 
treatment (figure 25A). Ketamine not only downregulated levels of enzymes combating ROS, but also 
decreases the TAC 72h after a single injection (figure 25B). 
Oxidative stress can lead to cellular damage as ROS radicals react with DNA, RNA, lipids, and also 
proteins460. Therefore, I continued to analyze ROS mediated damaged (carbonylated) protein levels 
by OxyBlot. Protein carbonylation can be caused by abatement in the antioxidant defense system, 
increased production of ROS during standard metabolic processes, failure to remove oxidized 
proteins e.g. by the proteasome, or an increased vulnerability to oxidative attack461, 462. The results 
indicate that ketamine has an influence on protein carbonylation leading to statistically significant 
level reductions 72h after ketamine treatment (figure 25C)463.  
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Figure 25: Hippocampal protein level analyses after a single injection of a low dose of ketamine (3 mg kg-1). A) Time-
dependent Western blot analysis of Prdx1 and Prdx3. N=5 mice per group and time point. B) TAC analyses to determine the 
antioxidant capacity of the HPC. N=5 mice per group and time point. C) OxyBlot analysis of the time-dependent protein 
damage by protein carbonylation in the HPC after ketamine treatment. N=4 mice per group and time point463. The results 
from ketamine-treated animals are normalized to the ones obtained from vehicle treatment (mean value = 1). *p≤0.05, 
**p≤0.01. P-values were determined by Student’s t-test. Error bars represent s.e.m. 
 
The pathway enrichment analyses also revealed an involvement of the proteasome at the 72h time 
point (table 11). The proteasome is a multicatalytic proteinase complex which is characterized by its 
ability to cleave unneeded or damaged proteins. The addition of ubiquitin to a substrate protein is 
called ubiquitination or ubiquitylation. Ubiquitination can affect proteins in many ways: it can signal 
for their degradation via the proteasome, alter their cellular location, affect their activity, or promote 
or prevent protein interactions461, 462. 
The quantitative proteomics profiling analyses revealed that ketamine statistically significant 
decreased Ubiquitin carboxyl-terminal hydrolase 8 (Otub1), Ubiquitin-conjugating enzyme E2 H 
(Ube2h) and Ubiquitin carboxyl-terminal hydrolase isozyme (Uchl3) as well as 26S proteasome 
subunit beta type-7 (Psmb7) protein levels at the 2h time point (figure 26A and 26B).    
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Figure 26: Hippocampal protein level analyses of the ubiquitin and proteasome systems determined by quantitative 
proteomics profiling analyses 2h after a single injection of a low dose of ketamine (3 mg kg-1) of (A) Ubiquitin carboxyl-
terminal hydrolase 8 (Otub1), Ubiquitin-conjugating enzyme E2 H (Ube2h), Ubiquitin carboxyl-terminal hydrolase isozyme 
(Uchl3), (B) 26S proteasome non-ATPase regulatory subunit 1 (Psmd1), 26S proteasome non-ATPase regulatory subunit 6 
(Psmd6), 26S proteasome non-ATPase regulatory subunit 8 (Psmd8) and 26S proteasome subunit beta type-7 (Psmb7) 
protein levels. C) Correlation analyses of Otub1, Ube2h, Uchl3, Psmd1, Psmd8 and Psmb7 protein intensities with the FST 
floating time 2h after a single injection of ketamine (p≤0.05). The results from ketamine-treated animals are normalized to 
the ones obtained from vehicle treatment (mean value = 1). N=5 mice per group and time point. ***p≤0.001. P-values were 
determined by Student’s t-test and SAM. Error bars represent s.e.m. The correlation coefficient, r, was calculated by 
Pearson. The linear regression line is only shown for significant (p≤0.05) correlation coefficients. 
 
In contrast, the 26S proteasome non-ATPase regulatory subunit 1 (Psmd1), 26S proteasome non-
ATPase regulatory subunit 6 (Psmd6) and 26S proteasome non-ATPase regulatory subunit 8 (Psmd8) 
protein levels are statistically significant up-regulated 2h after a single injection of ketamine (table 10 
and figure 26B). Furthermore, Otub1, Ube2h, Uchl3, Psmd1, Psmd6, Psmd8 and Psmb7 protein 
intensities significantly correlated with the antidepressant-like FST floating behavior (figure 26C). 
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Otub1 is a hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an 
important regulatory role at the level of protein turnover by preventing degradation464. Ube2h 
accepts ubiquitin and catalyzes its covalent attachment to other proteins465. Uchl3 is a 
deubiquitinating enzyme that controls levels of cellular ubiquitin through processing of ubiquitin 
precursors and ubiquitinated proteins466, 467. Psmb7 of the proteasome has an ATP-dependent 
proteolytic activity. This unit is responsible for the trypsin-like activity of the proteasome. Psmd1, 
Psmd6, and Psmd8 are regulatory subunits of the proteasome468-473.  
 
 
4.3.3 A potential signaling cascade for ketamine drug action  
Next I focused on ketamine’s cellular signaling cascade with regard to its effects on mitochondria. 
The Protein Kinase A (PKA) gets only activated in the presence of cyclic adenosine 
3′,5′monophosphate (cAMP).  
 
 
Figure 27: Hippocampal protein and metabolite level as well as metabolite ratio analyses 2h and 24h after a single injection 
of a low dose of ketamine (3 mg kg-1). A) PKA and AKAP1 protein level alterations were determined by quantitative 
proteomics analyses. B) cAMP/ATP metabolite ratio analyses. C) cAMP and ATP metabolite level analyses. D) Correlation 
analyses of Prkar2a (2h, p≤0.05), Akap1 (2h, p≤0.05), cAMP (2h, p≤0.05) and ATP (24h, p≤0.05) protein and metabolite 
intensities with the antidepressant-like FST floating behaviour. The results from ketamine-treated animals are normalized 
to the ones obtained from vehicle treatment (mean value = 1). N=5 mice per group and time point. #p≤0.10, *p≤0.05, 
**p≤0.01, ***p≤0.001. P-values were determined by Student’s t-test and SAM. Error bars represent s.e.m. The correlation 
coefficient, r, was calculated by Pearson. The linear regression line is only shown for significant (p≤0.05) correlation 
coefficients. 
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Both have previously been described to play a role in MDD pathobiology. cAMP is catalyzed by 
Adenylyl cyclases converting ATP to cAMP112, 474. The regulatory subunit II of PKA (Prkar2a) binds to A-
kinase anchor protein 1 (AKAP1) that tethers the PKA to mitochondria. Thereby AKAP1 allows to 
specifically targets substrates regulated by PKA phosphorylation to the mitochondria475-477. The 
proteomics data showed that Prkar2a and AKPAP1 are statistically significant upregulated and 
correlated with the antidepressant-like FST floating behavior 2h after a single injection of ketamine 
(figure 27A and 27D). I further analyzed the metabolite ratios and levels connected to PKA activity. 
Ketamine treatment statistically significant elevates or tends to increase cAMP/ATP metabolite ratios 
at the 2h and 24h time points, respectively (table 10 and figure 27B). cAMP metabolite levels were 
statistically up-regulated and correlated  with the FST floating time at the 2h time point, whereas ATP 
metabolite levels were downregulated and also correlated with the FST floating time 24h after 
ketamine injection (figure 27C and 27D).  
 
 
4.4 Analyses of mitochondrial OXPHOS protein complexes with blue native-polyacrylamide 
gel electrophoresis (BN-PAGE) 
The metabolome and proteome profiling analyses revealed that ketamine has an impact on 
mitochondrial energy metabolism pathways including glycolysis, citrate cycle, and the OXPHOS. A 
time-dependent increase of the mitochondrial OXPHOS protein complexes I and II were observed. 
Ketamine might time-dependently increase the enzymatic activity of the OXPHOS protein complexes 
in order to cope with a possible higher energy demand at activated synapses. In order to test this 
hypothesis several methods first had to be established: 
 Enrichment and isolation of mitochondria and solubilization of native mitochondrial 
membrane protein complexes 
 Separation of native mitochondrial membrane protein complexes with BN-PAGE 
 In-gel enzymatic activity measurement of the OXPHOS protein complexes 
 
 
4.4.1 Isolation of mitochondria 
Mitochondria from brain tissue were enriched in order to analyze the enzymatic activity of the 
OXPHOS protein complexes. Mitochondria were then fractionated and isolated through gradient 
centrifugation containing 20%, 36%, and 50% sucrose. After the centrifugation 3 fractions were 
visible with the third expected to contain mitochondria (figure 28A). The fractions were collected, 
resolved and a Western blot was performed to verify the mitochondrial fraction. All obtained 
fractions from the sucrose gradient centrifugation as well as a cytoplasmic protein fraction as a 
control were analyzed with antibodies against a mitochondrial membrane marker (porin), a 
mitochondrial matrix marker (Prdx3), and a cytoplasmic marker (β-actin). The results of the Western 
blots revealed that fraction 1 and the cytoplasmic protein fraction contain β-Actin but almost no 
mitochondrial proteins. Fraction 2 contains mitochondrial proteins, but also β-Actin. Fraction 3 
contains almost no β-Actin, but shows the highest concentration of the mitochondrial marker 
proteins (figure 28B). Therefore, fraction 3 was used for further analyses478.  
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Figure 28: Isolation of mitochondria. A) Fractionation of enriched mitochondria through gradient centrifugation with 20%, 
36% and 50% sucrose. Schematic and original picture of the three fractions revealed by sucrose gradient centrifugation. B) 
Western blot determination of the different fractions from the sucrose gradient centrifugation as well as from the 
cytoplasmic fraction as a control with antibodies against a mitochondrial membrane marker (Anti-porin), mitochondrial 
matrix marker (Anti-Prdx3), and a cytoplasmic marker (Anti-β-actin)478. 
 
 
4.4.2 Separation and identification of the OXPHOS protein complexes with BN-PAGE and 
LC-MS/MS analyses 
OXPHOS protein complexes can be separated with BN-PAGE. This method allows a separation of 
protein complexes in their native and functional form.  
 
 
Figure 29: BN-PAGE separating mitochondrial membrane protein complexes solubilized with Digitonine, DDM and TX-100. 
A) Separation of mitochondrial membrane protein complexes that were previously solubilized with Digitonine, DDM or TX-
100. OXPHOS protein complexes were identified by LC-MS/MS analyses. Bold: Protein complex with most of the subunits 
identified. Grey: ~8 subunits of a complex were identified. In parentheses: ≤5 subunits of a complex identified. B) OXPHOS 
protein complexes and bands used for further enzymatic in-gel activity measurements and comparison with already 
published BN-PAGE from Wittig et al478, 479. 
 
However, mitochondrial protein complexes first have to be solubilized from the membrane. 
Therefore, three different mild detergents were tested: Digitonine, Dodecylmaltoside (DDM), and 
Triton-x-100. The solubilized mitochondrial membrane protein complexes were then separated by 
BN-PAGE and mitochondrial OXPHOS protein complexes identified with LC-MS/MS-analyses (figure 
29A). DDM and Triton-x-100 showed a very similar band pattern in contrast to the milder detergent 
Digitonine (figure 29A). There is a very clear separation and no double bands are visible with 
digitonine solubilization compared to DDM and Triton-x-100 (figure 29A). 
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The OXPHOS protein complexes were identified by LC-MS/MS-analyses and showed very similar 
results when comparing the bands from the three solubilizations. Furthermore, the band pattern is 
similar to the one published by Wittig and colleagues (figure 29B)478 479.  
Every band contained subunits of different mitochondrial OXPHOS protein complexes. However, the 
more subunits were identified the more abundant the protein complex. The upper bands 1–3, 4, 12, 
13/14 mainly contained subunits of complex I and V. Bands 5, 15, 23 and 24 mainly consist of 
complex V subunits, but also complexes III and IV subunits and less of complex I and II. Bands 6 and 
16/17 had subunits of complexes III, IV and V. Bands 7 and 18 mainly contained complex V subunits 
and bands 8, 19 and 25/26 mainly complexes IV subunits and less complex V subunits. Furthermore, 
they also contained complex II subunits. The other bands (9, 20, 27, 10, and 21/22) mainly consist of 
subunits of the complex II and V (figure 29A).  
The identification of different subunits of OXPHOS complexes might be due to the formation of so-
called supercomplexes, a complex formation made up of different OXPHOS complexes. However, 
only the individual OXPHOS complexes and not the supercomplexes are of interest and, therefore, 
considered for further enzymatic OXPHOS protein complex in-gel activity measurements. The 
mitochondrial membrane OXPHOS protein complexes were solubilized with DDM for further 
enzymatic in-gel activity measurements. The bands with the most subunits of a specific complex 
were chosen for the in-gel enzymatic activity analyses. The related bands were cut out of the gel 
after BN-gel electrophoresis and the activity of the related OXPHOS complex was measured478.  
 
 
4.4.3 OXPHOS protein complex in-gel-enzymatic activity measurement 
The goal was to analyze the mitochondrial OXPHOS protein complex activity in ketamine- compared 
to vehicle-treated mice. However, the method first needed to be established. Different protein 
amounts of solubilized mitochondrial membrane protein complexes were separated by BN-PAGE and 
the enzymatic activity of each OXPHOS complex was measured inside the gel. Linearity of protein 
amount with Coomassie staining in the BN-gel and OXPHOS protein complex enzymatic activity was 
then determined with colored chemical substrate reaction (cf. chapter 3). 
The optimal fitting curves to all measurements were linear, except for complex V (F1) where an 
exponential fit was used. The regression R2  values all indicate very good fits with values ranging from 
0.95 to 0.98 for the Coomassie-stained proteins of the BN-gel and from 0.91 to 0.97 for the 
enzymatic activity measurements of the ETC complexes, with the  exception of the ETC complex 
activity of the F1F0 holo-enzyme (figure 30) where only R2=0.62 was reached. The enzymatic activity 
of complex II could not be determined478. 
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Figure 30: Linearity analyses of the OXPHOS protein complex enzymatic activity measurements. Different amounts of 
mitochondrial membrane protein complexes were separated with BN-PAGE and the enzymatic activity of each OXPHOS 
protein complex was measured. The protein amount of the OXPHOS complexes I to V (F0F1 and F1) and their enzymatic 
activity were determined by the Coomassie-stained proteins and chemical reactions, respectively, as described in chapter 3. 
The R2 of the regression was calculated for all analyses478. 
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Next, the OXPHOS complex enzymatic activity of ketamine- and vehicle-treated mouse brains was 
measured using 12µg of mitochondrial proteins. There were no statistically significant differences in 
OXPHOS protein complex activity comparing ketamine- with vehicle-treated mice (figure 31)478.         
 
 
Figure 31: In-gel enzymatic activity measurements of the mitochondrial OXPHOS protein complexes by BN-PAGE. The 
enzymatic activity of the complexes I–V (except complex II) were analyzed comparing ketamine- (3 mg kg-1, n=3) and 
vehicle-treated (n=4) mice478.  
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5.0 Discussion 
MDD is a devastating psychiatric disorder with approximately 350 million people suffering 
worldwide. Conventional treatment options include ADs that take 2 to 4 weeks until a therapeutic 
effect becomes apparent8. Unfortunately, approximately one third of the patients does not respond 
to conventional AD treatment and thus suffer from TRD. To date, ketamine is the only fast-acting 
medication used in the clinic being effective between 2h and 4h – especially for patients suffering 
from TRD (cf. chapter 1). Research on biomolecular mechanisms involved in ketamine’s fast 
antidepressant effect mainly focuses on synaptic plasticity, which seems to be induced through 
mTORC1 and BNDF (cf. chapter 1). However, the exact mechanisms still remain elusive.  In order to 
understand the biomolecular pathways and cellular mechanism underlying ketamine’s mode of 
action as well as to aid at developing fast acting ADs, time-dependent metabolomics and proteomics 
profiling analyses and treatment response biomarker discovery were performed. Furthermore, I 
focused on several pathways that were significantly enriched in my –omics data, especially 
mitochondrial energy metabolism. To the best of my knowledge, this is the first study that identifies 
metabolome and proteome alterations, affected pathways and biomarker candidates for the 
ketamine treatment response in mice. 
In humans, ketamine is used as an antidepressant by injecting 0.5 mg kg-1, whereas anesthesia is 
already introduced by 1-5 mg kg-1 251, 480, 481. In contrast, mice are anaesthetized with doses of 50-200 
mg kg-1 of ketamine482, 483. In addition, ketamine is not only used to study the fast antidepressant-like 
effects in mice, but also as an animal model for schizophrenia thereby already analyzing the effects 
of 6 mg kg-1 of ketamine254-257. In the present study, a low dose of 3 mg kg-1 of ketamine was used as 
described in Autry et al., in contrast to other researchers mostly treating mice with 10 mg kg-1 of 
ketamine (cf. chapter 1).  
 
 
5.1 Ketamine’s fast antidepressant-like effects 
The first part of the thesis is focused on the time-dependent antidepressant-like effect of a low-dose 
of ketamine (3 mg kg-1). The FST revealed time-dependent antidepressant-like effects, starting 
already after 2h and lasting up to 72h, thereby reflecting the fast antidepressant-like effect of the 
drug. The FST is the most widely used behavioral test and highly reliable for predicting the 
therapeutic potential of a compound. No other behavioral assays were performed since they might 
affect the animals' metabolome and proteome and skew the data. However, repeating this study 
with an animal model of depression would add further relevance to the human situation. For further 
–omics and validation analyses 3 to 5 mice were chosen around the FST mean behavior, especially 
not considering behavioral extremes in order to analyze ketamine’s general biomolecular effects in 
mice.  
 
 
5.2 A comparative metabolomics profiling analyses 
The second part of my thesis focused on metabolomics profiling analyses of different mouse tissues, 
BP and PHN. Metabolomics provides an analytical tool for the identification of pathway alterations 
and drug targets.  
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Ketamine had a statistically significant metabolomic effect on the liver, PHNs and the HPC, but not 
the CRBL, BP and most surprisingly not the PFC. In addition, the results obtained from the profiling 
analyses of the liver and the CRBL can also be considered as an evidence for the methodical validity 
of metabolomics study. Ketamine is degraded in the liver. Therefore, metabolite changes were to be 
expected. In contrast, and in line with the results obtained in this present study, no drug effects were 
expected in the CRBL as this brain region does not seem to play a significant role in MDD.   
Biomarkers are useful in drug development efforts by providing information of a biological state or 
drug effect. Drug development would benefit from biomarkers or a biosignature of ketamine to 
predict a treatment effect for newly developed ADs. Biomarker discovery favors BP as it is easy to 
obtain. Unfortunately, my metabolomics profiling analyses did not reveal any statistical significant 
alterations in the BP. Repeating this study with a mouse model of depression would probably be 
more effective for a biomarker discovery in the BP. Stress per se already causes many biomolecular 
alterations that are reflected in the blood and could be reversed by AD treatment (cf. chapter 1) and 
thus might also generate biomarkers for ketamine’s antidepressant-like effects.  
Mouse PHN also showed significant metabolome alterations. In order to verify the best ketamine 
concentration used for PHN treatment and subsequent metabolomics profiling analysis, different 
ketamine concentrations were first tested by the MTT assay. This assay is a toxicity test measuring 
the metabolic activity of the cells and therefore indirectly cellular viability. In general, ketamine 
treatment in PHNs exhibits three different stages with increasing concentrations of the drug. At first, 
the metabolic activity drops, then increases again and finally drops again until nearly all cells show no 
cellular activity. Ketamine’s mode of action is dose-dependent at high doses resulting in apoptosis. 
Metabolomics results obtained from ketamine treatment of PHN were in line with findings observed 
in the HPC that will be described below. In both analyses – the PHN and HPC metabolomics profiling 
– the alanine, aspartate and glutamate metabolism was overrepresented. However, 
carbamoylphosphate and deoxyglucose-6 phosphate which were significantly altered in PHN and HPC 
showed different FCs. This difference could be explained due to the fact that ketamine might also 
affect NMDARs at glial cells including astrocytes, oligodendrocytes and microglia484. In addition, 
ketamine’s drug effect might also be dependent on the presence of a complete neuronal network as 
present in the brain.   
The PFC is discussed to play a significant role in MDD development, conventional AD treatment 
effects and also ketamine’s fast antidepressant mode of action (cf. chapter 1). Several reasons might 
explain why in this study ketamine did not show significant PFC metabolomics alterations: The PFC is 
a brain region responsible for goal-directed behavior which involves action planning and executive 
functions. The amygdala plays a primary role in the processing of memory, decision-making, and 
emotional reactions, which is believed to be important for MDD development. The PFC regulates the 
emotional reactions of the amygdala, a process which is perturbed in patients suffering from MDD. 
Several lines of evidence points to a PFC, HPC volume decline and amygdala volume increase in a 
subset of depressed patients due to stressful life events. In rodents, stress leads to neuronal atrophy 
of the PFC and HPC, whereas the amygdala shows an increase in synaptic plasticity24, 25, 30, 35-45, 208, 485, 
486. Therefore, the PFC’s regulatory role over the amygdala’s emotional reactions is inhibited, most 
probably leading to the MDD symptoms in humans. ADs as well as ketamine seem to reverse 
neuronal atrophy (cf. chapter 1). In the present thesis, non-stressed mice were treated with 
ketamine. Therefore, no dysregulation of the PFC or amygdala was caused by stress and could be 
reversed by the drug. Although ketamine should also block NMDARs in the PFC and therefore 
observable biomolecular alterations might have occurred in less than 2h after ketamine treatment179. 
This could also be a reason why no statistically significant metabolome changes were found. 
94 
 
5.3 Time-dependent hippocampal metabolomics and proteomics profiling analyses 
The most interesting results were obtained by the time-dependent metabolomics and proteomics 
profiling analyses of the HPC. The following discussion will focus on the results obtained from the 
HPC analyses. They not only showed a very good time-dependent separation of ketamine- and 
vehicle-treated mice with a good quality assessment of the PLS-DA, but also many statistically 
significant metabolite and protein level and metabolite ratio alterations as well as overrepresented 
pathways. In addition, PLS-DA and VIP-score analyses obtained by the metabolomics analyses 
revealed that 2-Keto-isovalerate, maleate and fumarate qualified as antidepressant treatment 
response biomarkers. They could be used for the development of alternative faster acting ADs with a 
similar mode of action as ketamine, however, with fewer side effects. 
 
 
5.3.1 Ketamine’s impact on the mitochondrial energy metabolism  
The HPC metabolomics profiling analyses indicate statistically significant metabolite level and 
metabolite ratio changes that are part of several pathways including citrate cycle and glycolysis. 
Mitochondrial abnormalities including alterations in energy metabolism have previously been 
implicated in the pathobiology of affective disorders432-434. Several metabolite level and metabolite 
ratio changes of the citrate cycle and glycolysis were observed already 2h and 14h after ketamine 
treatment, thereby reflecting the fast antidepressant-like effect of the drug. Moreover, it is 
interesting to note, that the citrate cycle and glycolysis are connected pathways ultimately producing 
energy in form of ATP through the OXPHOS. Glycolysis is a major catabolic cytoplasmic pathway 
where glucose is degraded to pyruvate, which is further metabolized by pyruvate dehydrogenase 
complex to Acetyl-CoA that enters the citrate cycle. The latter is a mitochondrial matrix pathway that 
is coupled to the mitochondrial OXPHOS435. Almost all metabolites of the glycolytic pathway showed 
lower levels 14h after ketamine injection, with the exception of 3-phosphoglycerate and 
phosphoenolpyruvate that were upregulated at the 2h time point. The observed changes might be 
caused by an inhibitory feedback mechanism of the citrate cycle probably observable by the 
metabolite ratio changes of the citrate cycle and glycolysis pathway thereby indicating altered 
enzyme activities or protein expression435. Whereas in the present study reduced metabolite levels of 
the glycolysis pathway after ketamine treatment were found, a previous study has shown an 
elevation of glycolytic metabolites following SSRI treatment, suggesting that the two drug types have 
very different modes of action432. In line with this hypothesis is the observation that neither 
conventional ADs such as imipramine and fluoxetine acutely or chronically administered nor 
electroconvulsive shock activate mTORC1. Moreover, it was observed that the SSRI sertraline inhibits 
mTORC1179. All these findings might explain the delayed onset of conventional ADs and the opposite 
findings with regard to pathway activity between conventional ADs and ketamine.  
The connecting metabolites of the citrate cycle to the OXPHOS, succinate and fumarate, as well as 
the metabolite ratio of succinate/fumarate showed statistically significant differences and the 
metabolites strongly correlated with the antidepressant-like FST floating behavior. Metabolite ratio 
changes might indicate protein level changes of the OXPHOS enzymatic subunit SDHA of the complex 
II transforming these metabolites436. As expected SDHA protein levels were indeed upregulated 14h 
and 24h after a single injection of ketamine. In addition, the correlated metabolites, succinate and 
fumarate, as well as the observed upregulated SDHA protein levels led to the hypothesis that the 
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mitochondrial energy metabolism plays an important role in transducing the antidepressant-like 
effect of ketamine.  
The energy equivalents GTP and NADH are produced through the citrate cycle and ATP via the 
connected OXPHOS pathway. GTP is generated during the transformation of succinate-CoA to 
succinate435. Statistically significant higher levels of succinate were observed after ketamine 
treatment possibly resulting in the observed elevated GTP levels at the same time point which are 
also well correlated with the FST floating time. Mitochondria are usually bound to microtubules of 
axons and dendrites. Ca2+ rises after synaptic activation at excitatory glutamatergic neurons and 
separates the mitochondria from the microtubule. The mitochondrial separation from microtubules 
is required to enrich these organelles in the synaptic density in order to increase ATP levels at the 
activated synapses. Furthermore, pyruvate dehydrogenase, isocitrate dehydrogenase, a citrate cycle 
enzyme, and the complex II of the OXPHOS are also regulated by Ca2+ 453, 475, 487, 488. Ketamine’s 
increased influx of Ca2+ at activated synapses also results in an uptake into the mitochondria, which 
ultimately could be the cause for the here observed metabolite level, metabolite ratio and protein 
level alterations. Decreased isocitrate/alpha-Ketoglutarate and succinate/fumarate ratios as well as 
increased OXPHOS complex II SDHA and SDHB protein levels further support this hypothesis. In 
addition, the correlation of succinate, fumarate and GTP with the behavioral effects measured by the 
FST sets the observed metabolite changes in a relation with ketamine’s antidepressant-like effects. 
Ketamine was shown to phosphorylate and therefore activate mTORC1 which not only leads to 
increased synthesis of synaptic proteins, but also increased mitochondrial metabolism176, 177, 179. This 
study describes an involvement of the mitochondrial energy metabolism, especially the OXPHOS that 
is most probably upregulated in order to generate energy in form of ATP to compensate for the 
higher energy demand at activated synapses. My metabolomics and proteomics profiling as well as 
further Western blot analyses results support this assumption. Ketamine treatment affects the 
OXPHOS pathway and several ETC complex protein levels including complex I Ndufv2, Cyc1 and 
Tmem126B were time-dependently altered and also correlated with the FST floating time. Further 
Western Blot analyses revealed that complex II SDHA and SDHB and complex III Uqcrc2 are time-
dependently upregulated, too. In addition, also ADP levels were downregulated and significantly 
correlated with the FST behavior 24h after a single injection of ketamine as well as the ATP/ADP ratio 
tended to be lower at the 2h and 24h time points. Presumably more ATP is consumed than can be 
produced from ADP at the OXPHOS complex V, most probably because of the high energy demand at 
activated synapses. An increase of OXPHOS complex protein levels should result in increased ATP 
levels and indeed the at first lowered ATP levels turned back to the same FC observed for vehicle-
treated animals at the 72h time point.  
Furthermore, results from previous studies have shown that treatment with ADs alters ATP levels. 
Phosphorous-31 magnetic resonance spectroscopy data have shown decreased NPT levels (mainly 
ATP) in the brain of depressed patients. Another magnetic resonance spectroscopy study could 
demonstrate lower NPT levels (mainly ATP) in fluoxetine responders compared with non-
responders489, 490. These inconsistent findings make it difficult to know whether the observations of 
decreased ATP levels contribute to the ketamine antidepressant-like effect. However, the correlation 
analyses of ATP and ADP also create a relation of the drug treatment and the herein before 
mentioned observed antidepressant-like effects of ketamine. 
A low ATP/ADP ratio activates and phosphorylates the AMPK (pAMPK), the major energy sensor of 
the cell. pAMPK decreases and increases the activity of pathways that consume a lot of energy 
(anabolic pathways) and produce energy (catabolic pathways), respectively443-449. Previous data from 
a study in rats suggested that ketamine’s antidepressant-like effects are mediated by an increased 
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anabolic rate, thereby inducing cell growth and differentiation179. An elevated anabolism seems to 
come along with a higher energy demand, which I assume is the case during the first 24h after 
ketamine treatment. As expected, the pAMPK/AMPK ratio is elevated while ATP levels and ATP/ADP 
ratio are lower at the 24h time point. pAMPK activates mitochondrial biogenesis through PGC1α, 
inhibits mTORC1 and thereby decreases mitochondrial metabolism, promotes autophagy and glucose 
uptake174, 491-495. As expected, no mitochondrial changes apparent by altered metabolite levels, ratios 
and protein levels are observed 72h after a single injection of ketamine. Furthermore, the PLS-DA 
quality criteria for the 72h time point indicated a weak model and all changes observed related to 
glycolysis, citrate cycle and OXPHOS returned to normal levels. I conclude that the first 24h after 
ketamine treatment is an important time window that is critical for the fast antidepressant-like 
effects. However, ketamine’s behavioral effect during the FST is still present at the 72h time point. In 
this regard Autry et al. showed antidepressant-like effects lasting up to 1 week after a single injection 
of ketamine243. Therefore, I would propose that ketamine’s mode of action could probably be divided 
into an acute and a more sustained effect inducing and stabilizing synaptic plasticity, respectively. 
The acute effect might be dependent on the activation of mTORC1, BDNF, synaptic protein synthesis 
and mitochondrial energy metabolism.    
An increase of the pAMPK/AMPK ratio led to the assumption that mitochondrial biogenesis is 
induced by PGC1α activation. Tfam, a mitochondrial transcription factor, is translated upon PGC1α 
activation. Further nuclear encoded mitochondrial proteins are then imported into the mitochondria 
by import proteins including TIM23. Activation of mTORC1, but also AMPK, results in the relocation 
of PGC1α from the cytoplasm into the nucleus173, 174, 495. Ketamine activates mTORC1 within the first 
30min of treatment179 whereas my results show an activation of AMPK at the 24h time point. 
Therefore, and as expected, Western blot analyses showed alterations of PGC1α protein levels at the 
2h and 24h time points. However, the method used in the present study only isolates cytoplasmic 
proteins and not proteins from the nucleus (cf. chapter 3). This could explain the decreased PGC1α 
protein levels. Ketamine might lead to the translocation of PGC1α into the nucleus. Further studies 
analyzing the nuclear protein fraction upon ketamine treatment for PGC1α would elucidate this 
research question. Tfam protein levels were decreased at the 72h time point after a single injection 
of ketamine.  
Probably, earlier measurements as in this study as well as during the 24h and 72h time point would 
result in a more detailed understanding of ketamine’s biomolecular effects at the mitochondrial 
biogenesis and metabolism regulation. Western blot analyses of TIM23 did not show any significant 
differences. Ketamine’s effects on mitochondrial biogenesis, especially the transcription and import 
require further analyses at different time points. 
 
 
5.3.2 Ketamine’s effects on the antioxidant defense and quality control system 
An increased protein expression and elevated activity of OXPHOS protein complexes may also lead to 
an elevated production of ROS. These radicals when at high levels may damage proteins, DNA and 
lipids and therefore result in oxidative stress. ROS are difficult to measure since oxygen radicals are 
highly reactive towards other molecules. One of the most popular indirect ROS assessments is 
protein damage, specifically the analysis of carbonylated (damaged) proteins (cf. chapter 3)455. 
Protein damage time-dependently decreases and is statistically significant reduced at the 72h time 
point. Either ROS levels decrease over time or the cellular defense system is activated. The cellular 
defense system includes antioxidant molecules and enzymes such as Prdxs that combat ROS. In 
97 
 
addition, a protein quality control system that degrades damaged proteins counteracts oxidative 
stress. The main function of the proteasome is to degrade damaged or unneeded proteins that are 
tagged for proteolysis by ubiquitin456-459, 462, 470. The TAC and cytoplasmic Prdx1 levels were decreased 
at the 2h and 72h time points and mitochondrial Prdx3 levels 72h after a single injection of ketamine. 
Therefore, the antioxidant defense system might not be needed suggesting that ROS levels were not 
increased at any time point. However, the downregulated carbonylated protein levels might also be 
indicative of an increased activity of the protein quality control system. The proteomics profiling 
analyses revealed that the proteasome pathway was overrepresented 2h after ketamine treatment. 
However, the results are somewhat contradictory. Ketamine treatment significantly decreased 
Otub1, a hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an 
important regulatory role at the level of protein turnover by preventing proteasomal degradation. 
Uchl3, a deubiquitinating enzyme that controls cellular ubiquitin levels through processing of 
ubiquitin precursors and ubiquitinated proteins is also decreased upon ketamine treatment. 
Furthermore, the 26S proteasome non-ATPase regulatory subunits Psmd1, Psmd6 and Psmd8 protein 
levels are significantly upregulated 2h after a single injection of ketamine. In contrast, Ube2h, that 
accepts ubiquitin and catalyzes its covalent attachment to proteins, as well as the proteasomal 
subunit Psmb7 protein levels were decreased at the 2h time point464-473. Moreover, these proteins 
showed a significant correlation with the FST floating time. The antioxidant defense system might not 
get activated since ROS levels were not elevated at any time point of ketamine treatment. In 
conclusion, ketamine treatment might lead to an increased degradation of damaged proteins and 
therefore in a decrease in protein damage, TAC as well as antioxidant Prdx1 and Prdx3 protein levels 
eventually resulting in an homeostatic redox adjustment which promotes the antidepressant-like 
effects of ketamine.  
 
 
5.3.3 A potential novel signaling cascade for ketamine’s antidepressant-like effects 
The present study results suggest a mitochondrial impact of ketamine’s mode of action. However, 
the downstream effect promoting mitochondrial metabolism might not only be through an activation 
of mTORC1, but also involves the regulatory subunit of PKA and Akap1. PKA has previously been 
shown to play a role in MDD and is required for hippocampal memory formation mediated by LTP. 
Multiple chemical neurotransmitters, hormones, and other signaling substances use cAMP as an 
intracellular second messenger through activation of G protein coupled receptors. The cAMP/PKA 
signaling pathway critically regulates molecular components underlying LTP and long-term memory. 
In the postsynaptic neuron PKA targets include NMDARs and AMPARs and the transcription factor 
CREB that has been implicated in BDNF synthesis496. PKA binds with its regulatory subunits to AKAPs 
and phosphorylates target proteins. The regulatory subunit Prkar2a of PKA binds to AKAP1, a protein 
that is found on the outer mitochondrial membrane238, 475, 476, 497-499. Prkar2a and AKPA1 as well as 
cAMP/ATP ratio levels were elevated suggesting an increased activation of the PKA. Furthermore, 
Prkar2a, AKAP1, cAMP and ATP significantly correlated with the FST floating time. AKAP1 not only 
recruits PKA, but also mRNA, suggesting a role in supporting mitochondrial biosynthesis. Results from 
a previous study showed that overexpression of wild-type AKAP1 increased mitochondrial membrane 
potential, while expression of AKAP1ΔPKA reduced mitochondrial membrane potential below control 
levels. In conclusion, AKAP1/PKA play an important role in ATP synthesis as this process is dependent 
on a high mitochondrial membrane potential. PKA-dependent substrate phosphorylation due to 
increased cAMP levels can result in mitochondrial elongation as well as more efficient ATP 
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production. In addition, the AKAP1/PKA response protects mitochondria from degradation and 
support mitochondrial network integrity and neuronal survival475, 476, 500. Therefore, I propose that 
during LTP, PKA not only targets NMDARs, AMPARs and CREB, but also mitochondria, thereby 
supporting energy supply resulting in the herein before mentioned antidepressant-like effects.  
Besides PKA, CamKII and PKC are promoting downstream effects upon LTP and both proteins are 
activated by Ca2+ 144, 437. In addition, CaMKII and PKC are involved in the insertion of additional 
AMPARs into the postsynaptic membrane. CaMKII alpha protein levels were slightly increased and 
tended to be decreased 24h and 72h after ketamine treatment. PKC protein levels tended to be 
increased at the 2h and 14h time points, whereas decreased levels were observed at 24h. Future 
studies should analyze the phosphorylation status of these proteins as they indicate their enzymatic 
activity.  
 
 
5.3.4 Ketamine’s effects on the glutamatergic and GABAergic system 
Ketamine decreases GABAAR1 levels and AMPAR subunit Gria3 and elevates AMPAR subunit Gria2 
protein levels, changing AMPAR composition in favor of Gria2. Furthermore, the observed protein 
intensities also significantly correlated with the FST floating behavior. In the mammalian central 
nervous system, AMPA-type glutamate receptors mediate the vast majority of fast excitatory 
synaptic transmission. The AMPAR Gria2 subunit dictates the critical biophysical properties of the 
receptor, strongly influences receptor assembly and trafficking, and plays pivotal roles in a number of 
forms of long-term synaptic plasticity. Gria2 is a critical subunit for determining mammalian AMPAR 
function501.  
Homeostatic synaptic plasticity is distinct from input-specific Hebbian forms of synaptic plasticity 
such as LTP, and is most readily induced by chronically blocking neuronal activity or glutamatergic 
transmission in cultured neurons502-504. An increase in Gria1, but not Gria2, protein expression is 
observed in response to NMDAR activity blockade, and this appears to be primarily due to a selective 
increase in dendritic protein synthesis of the Gria1 subunit. 10 mg kg-1 of ketamine also increased 
Gria1 as wells as further synaptic protein levels, induced LTP and increased the spine number in the 
PFC of rats; thereby supporting the hypothesis that ketamine might be the cause of a homeostatic 
plasticity mechanism179. On the other hand, Zanos et al. recently has shown that 10 mg kg-1 of 
ketamine increased Gria1 and Gria2 protein levels in the HPC, but not in the PFC262. The results of the 
present study in which an even lower dose of ketamine (3 mg kg-1) was used, showed an elevation of 
AMPAR Gria2 subunit protein levels, thereby favoring the most popular hypothesis of ketamine drug 
action, the input-specific Hebbian forms of plasticity such as LTP.  
In summary, it seems that a low dose of 3 mg kg-1 of ketamine more likely blocks NMDARs on 
GABAergic inhibitory neurons thereby resulting in an increased activation of glutamatergic excitatory 
neurons promoting LTP (cf. chapter 1). In addition, the lower GABAAR1 protein levels might thereby 
further decrease the inhibitory function of GABAergic interneurons and the increase of AMPAR Gria2 
subunit protein levels ultimately promote an increased activity at excitatory glutamatergic synapses. 
This increased synaptic plasticity ought to be observable by changes of the neurotransmitter GABA 
and glutamate transducing the inhibitory and excitatory effects, respectively (cf. chapter 1).  
Glutamate and GABA metabolite levels were decreased and increased in the 14h and 72h time 
points, respectively. The latter result might be a false positive as the PLS-DA quality assessment 
indicated a weak model for this time point. However, the GABA as well as glutamate levels correlated 
very well with the antidepressant-like effects measured by the FST. Glutamate and GABA are 
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metabolized by glutamine and recycled in the respective glutamate/glutamine and GABA/glutamine 
cycle (cf. chapter 1). Glutamine metabolite levels are decreased and the glutamate/glutamine and 
GABA/glutamine ratios were increased 14h after ketamine treatment. In addition, glutamine levels 
also significantly correlated with the FST floating time. In conclusion, the results obtained from the 
present study appear contradictory to previous analyses showing an increased glutamate outflow in 
the PFC (cf. chapter 1). Therefore, opposite neurotransmitter levels of glutamate and GABA would be 
more likely to be expected in this study. A blockage of NMDARs present at inhibitory GABAergic 
neurons would lead to increased and lowered levels of glutamate and GABA levels in the synaptic 
cleft, respectively. In addition, my results indicate disturbances in the glutamate/glutamine and 
GABA/glutamine cycles. However, the GABA/glutamate ratio was only decreased at the 72h time 
point. Despite from the at first site appearing contradictory results of the present study, it is more 
likely that glutamate and GABA release will be different depending on the activity of inhibitory and 
excitatory neurons. The observed neurotransmitter changes only represent the total pool of 
glutamate, GABA and glutamine and not the released neurotransmitter levels. Therefore, 
microdialysate measurements are more suitable and should be used in future experiments thereby 
revealing the actual released pool of glutamate and GABA into the synaptic cleft by neuronal 
activation and inhibition.  
Two positive modulators of the NMDAR, serine and putrescine, are elevated and significantly 
correlated with the FST floating time 2h after a single injection of ketamine. The fast antidepressant-
like effects of ketamine might be even more pronounced by an augmentation therapy with these 
NMDAR modulators. In this regard putrescine has already been shown to exhibit a fast 
antidepressant effect in the FST439.  
 
Ketamine treatment causes LTP with synaptic spine outgrowth, which further support the hypothesis 
that the observed HPC and PFC volume reductions in a subset of MDD patients is rescued by synaptic 
plasticity (cf. chapter 1)43. The myelin sheath is an isolating lipid layer around axons in order to 
preserve fast neuronal signaling and minimizing information loss440. Therefore, a reversal of the 
volume reduction observed in a subset of treated MDD patients caused by synaptic plasticity with an 
outgrowth of synaptic connections should result in an elevated number of myelin proteins. As 
expected, ketamine treatment at low doses (3 mg kg-1) also results in increased MBP protein levels at 
the 2h and 24h time points and tended to elevate MOG protein levels at 2h and 72h time points. In 
contrast, when applied at higher, but still subanaesthetic doses, ketamine (6 mg kg-1) is also used as 
an animal model of schizophrenia, where a loss of the myelin sheath is discussed254-257. Therefore, I 
can also rule out that a low dose of ketamine as used in this study produces molecular alterations 
characteristic for schizophrenia like decreased myelin proteins441, 442. 
A possible explanation for the different ketamine treatment effects observed for an acute, chronic, 
low and high dosage might be the involvement of different receptor types as well as the fact that 
ketamine at higher doses might block NMDARs universally and not only at inhibitory interneurons. 
Acute low doses of ketamine treatment has been reported to only block NMDARs on GABAergic 
interneurons, whereas chronic treatment with high doses not only blocks NMDARs universally but 
also nicotinic acetylcholine receptors (cf. chapter 1)255.  
Alterations in metabolite, transcript and protein levels in post-mortem tissue from schizophrenic 
patients have been reported for glycolysis, citrate cycle and OXPHOS, the same pathways observed 
to be affected in the present study505-507. As ketamine at higher doses can induce schizophrenia-like 
symptoms, it is conceivable that certain molecular pathways are shared between the antidepressant 
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and psychotic effects. At the same time there must be differences in other affected pathways 
responsible for the opposite effects of the drug.  
 
 
5.4 An additional and novel model for Ketamine’s antidepressant effect 
Taken together, my results do not provide an ultimate answer to the question, which of the 
previously described hypotheses for ketamine drug action are the correct one albeit there are some 
hints that rather promote the LTP-like process. In fact, the obtained results fit to the indirect as well 
as the direct hypothesis of ketamine’s antidepressant-like drug action either leading to a synaptic 
LTP-like process or homeostatic synaptic mechanism, respectively (cf. chapter 1). In addition, to the 
best of my knowledge the results of the present study are the first to connect the antidepressant-like 
effects observed for ketamine with the mitochondrial energy metabolism. In order to link the 
previously stated hypotheses with the obtained results of the present thesis, I especially considered 
the findings obtained pointing towards an altered mitochondrial energy metabolism: Thus, I 
postulate an additional and novel model for ketamine’s antidepressant effect with an important 
impact of the mitochondrial energy metabolism. The proposed model suggests that ketamine 
increases synaptic plasticity as it also increases synaptic activity.  
 
 
Figure 32: Schematic representation of a novel and additional model of the antidepressant LTP-like process mediated by 
ketamine drug action on excitatory glutamatergic and inhibitory GABAergic interneurons. Previous studies showed that 
pharmacological treatment with ketamine results in a glutamate burst, increased BDNF levels, TrkB receptor and mTORC1 
activation (pmTORC1), elevated synaptic protein synthesis and integration of AMPARs into the synaptic membrane. These 
processes strengthen glutamatergic synapses resulting in synaptogenesis (cf. chapter 1). A) Synapses without ketamine 
treatment. Glutamatergic neurons are inhibited by active GABAergic inhibitory neurons. B) Ketamine’s indirect inhibition of 
excitatory pyramidal neurons inhibiting NMDARs at GABAergic inhibitory interneurons, thereby resulting in an LTP-like 
process. The novel finding for ketamine’s antidepressant-like effect implicates an impact of the mitochondrial energy 
metabolism, especially mitochondrial enrichment in synaptic compartments as well as increased synthesis of OXPHOS 
protein complexes. The proposed novel model describes that an elevation of synaptic Ca2+ leads to mitochondrial 
enrichment of mitochondria into the active synaptic compartment. Furthermore, pmTORC1 induces mitochondrial 
metabolism and promotes ATP production to cope for the high energy demand in activated synapses.   
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Therefore, an elevation of synaptic Ca2+ firstly leads to a mitochondrial enrichment into the active 
synaptic compartment, secondly, to an activation and increased protein expression of mitochondrial 
enzymes including OXPHOS complex II SDHA and SDHB.  
In addition, pmTORC1 and pAMPK induce mitochondrial metabolism and promote ATP production to 
cope for the high energy demand in activated synapses. Overall, ketamine might especially promote 
its antidepressant effect by an increased mitochondrial energy metabolism in synaptic 
compartments, increased synthesis of OXPHOS protein complexes as well as synaptogenesis (figure 
32B and 33B). The results obtained by the present study also provide novel drug targets – besides the 
NMDAR – for faster acting antidepressants with a similar mode of action as ketamine, like 
mitochondria and related enzymes of the energy metabolism. 
 
Figure 33: Schematic representation of a novel and additional model of the antidepressant drug effect mediated by a 
synaptic homeostatic plasticity mechanism of the excitatory glutamatergic neurons induced by ketamine. Previous studies 
showed that pharmacological treatment with ketamine results in a glutamate burst, increased BDNF levels, TrkB receptor 
and mTORC1 activation (pmTORC1), elevated synaptic protein synthesis and integration of AMPARs into the synaptic 
membrane. These processes strengthen glutamatergic synapses resulting in synaptogenesis (cf. chapter 1). A) Ketamine 
blocks NMDARs at excitatory glutamatergic neurons thereby inducing a homeostatic synaptic plasticity mechanism. B) The 
direct inhibition of NMDARs and the induced homeostatic synaptic plasticity results after the degradation of ketamine to an 
increased activity of glutamatergic excitatory neurons. The novel finding for ketamine’s antidepressant-like effect implicates 
an impact of the mitochondrial energy metabolism, especially mitochondrial enrichment in synaptic compartments as well 
as increased synthesis of OXPHOS protein complexes. The proposed novel model describes that an elevation of synaptic 
Ca2+ leads to mitochondrial enrichment of mitochondria into the active synaptic compartment. Furthermore, pmTORC1 
induces mitochondrial metabolism and promotes ATP production to cope for the high energy demand in activated 
synapses.   
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5.4 Clinical relevance 
Several previous studies have shown an involvement of mitochondria in MDD pathobiology432, 487, 508. 
In addition, mitochondrial respiration in peripheral blood mononuclear cells from depressed patients 
was lower compared to control subjects and correlated with depressive symptom severity509. In 
addition, patients with mitochondrial disorders are very often co-morbid for psychiatric illnesses 
including MDD. These patients suffer from primary impairment of mitochondrial functioning through 
either nuclear or mitochondrial DNA mutations of the mitochondrial genome. Mitochondrial 
impairment mostly affects high energy consuming organs like muscles and the brain. MDD symptoms 
and molecular findings are apparent by depressed mood, fatigue, cognitive decline, elevated blood 
lactate levels and atrophy, most of them explainable by mitochondrial dysfunction. Patients are 
mostly first diagnosed with MDD and the mitochondrial disorder is only recognized later in life. 
Conventional ADs are mostly not effective and these patients suffer from TRD. Moreover, traditional 
ADs seem to worsen the effects as SSRIs and TCAs inhibit mitochondrial OXPHOS ETC protein 
complexes510, 511. Ketamine is especially effective in MDD patients suffering from TRD and my results 
indicate an increase of the mitochondrial energy metabolism after a single injection of a low dose of 
ketamine. For all these reasons I submit that mitochondria play a critical role in the development of 
MDD as well as AD treatment response, at least in a subset of patients with a defined 
symptomatology.  
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Weckmann K et al., Time-dependent metabolomics profiling of Ketamine drug action reveals 
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2015 Mifek-Kirschner award, Max Planck Institute of Psychiatry, Munich 
 
2015 Travel grant for the 11th International Conference of the Metabolomics 
Society in San Fransisco, USA 
 
2015 Travel grant for the NPC progress meeting in Utrecht, The Netherlands 
 
2013  PRIME-XS, a European Union funded access to an infrastructure of state-
of-the-art proteomics technology. Collaboration with the PRIME-XS access 
site of Cambridge Centre for Proteomics, Cambridge, UK 
 
Ph.D. fellowship 
2012 to 2016 International Max Planck Research School for Molecular and Cellular Life 
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Supervision 
May to Sep 2013 B.Sc. student 
 
Advanced and specialized methods training 
Project management skills 
 Time and project management 
 
Communication and soft skills 
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 Power point presentation 
 Poster Design 
 Career Mentoring & Management 
 Conflict Management 
 
Methods training 
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 Ph.D. representative of the Max Planck Institute of Psychiatry, Munich, Germany  
 Co-founder of the Window of Life foundation in Germany. The foundation supports a local 
organization in Uganda that runs a Babies home and finances the education of talented 
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Referees 
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